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Summary 
The work discussed in this thesis adds further knowledge regarding the survival 
of embryonic dopaminergic grafts, derived from the rat ventral mesencephalon, in the 
rat model of Parkinson’s disease, in terms of the populations of cells involved, their 
distribution within the grafts, and how these are affected by the donor age and the host 
environment in to which they are implanted. 
The current data further reinforce the notion that harvesting ventral 
mesencephalic tissue at embryonic day 12 (E12) before the peak of dopamine 
neurogenesis yields more dopamine cells in the grafts and, more importantly, also yields 
more nigral A9 type dopamine neurons, which are an important determinant for 
functional recovery. 
Following on from this, commitment of dopamine neural precursor cells to the 
two dopamine neuron phenotypes, and how this is affected by the host environment was 
investigated, by grafting rat E12 and E14 ventral mesencephalon tissue into different 
cerebral targets. Brain regions were chosen that receive either the nigral A9 type 
dopamine, ventral tegmental A10 type dopamine or noradrenaline innervation. The 
yield of A9 type dopamine neurons was found to be influenced both by the environment 
within the graft and by the host environment in the transplantation site to a higher extent 
than the yield of A10 type dopamine neurons.  
Dopaminergic progenitors procured from rat embryos at E12 were shown to 
have a greater potential to proliferate post-grafting and differentiate into mature 
dopamine neurons as compared to embryos at E14. In vivo proliferation of younger 
precursor cells significantly contributed to the higher yields of the A9 type dopamine 
neurons in the grafts. If this improved yield of the A9 type dopamine neurons could be 
reproduced in human trials, fewer human donors might suffice to produce functional 
grafts in Parkinson’s disease patients. 
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1.1 Mesencephalic dopamine neuron system in the brain 
1.1.1 Anatomy of the ventral mesencephalon 
The study of dopamine (DA) neurons and their axonal projections in the brain 
goes back to the early 1960s and it is now one of the best known neurotransmitter 
systems. Catecholamine (CA) DA neurons together with noradrenaline (NA) neurons 
were first identified in discrete neuronal systems in the brain using formaldehyde 
histofluorescence method (Carlsson et al., 1962, Falck et al., 1962). 
Immunohistochemistry (IHC) for tyrosine hydroxylase (TH), a rate-limiting DA-
synthesizing enzyme, was introduced in the 1970s and allowed mapping of CA systems 
more accurately and distinction of different CA neuron types. Whilst the use of TH IHC 
has confirmed the original anatomical organisation and projection patterns of DA 
systems, it has also revealed large numbers of cells labelled with TH that were negative 
for DA or NA in striatal and cortical areas in primates and humans (Kohler et al., 1983, 
Gaspar et al., 1985, Gaspar et al., 1987). Even though TH expression is not exclusive to 
DA neurons throughout the whole brain, TH IHC accurately identifies DA neurons in 
the ventral mesencephalon (VM) and because there are no NA neurons in this structure 
all TH-immunoreactive (TH-ir) cells in the VM can be safely considered to be DA-
producing neurons.  
In the rat VM, between 21,000 – 25,000 DA neurons (bilaterally) are located in 
the substantia nigra pars compacta (SNpc), around the same number of DA neurons 
make up the ventral tegmental area (VTA) and approximately 2,600 – 6,100 DA 
neurons reside in the retrorubral field [RRF; (German and Manaye, 1993, Nair-Roberts 
et al., 2008)]. Each DA neuron of the SNpc makes thousands of synaptic connections 
with striatal neurons. The proportions of DA cell populations in the VM differ between 
species, e.g. the total number of DA neurons in the VM is between 160,000 – 320,000 
in rhesus monkeys and 400,000 – 600,000 in humans, with >70% of the neurons making 
up the SNpc (Emborg et al., 1998, Chu et al., 2002). This phylogenetic increase in the 
total number of DA neurons and the proportion of SNpc DA neurons follows the 
expansion of the DA innervated neocortex, which receives many more ascending DA 
projections in humans than rodents. 
Out of nine DA neuron cell groups in the brain three are present in the 
mammalian VM, namely the A8 type DA neuron population in the RRF, the A9 type in 
the SNpc and the A10 type in the VTA (Dahlstrom and Fuxe, 1964). In a very 
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simplified model, the A9 type DA neurons in the SNpc and their ascending axonal 
projections to the dorsolateral striatum comprise the nigrostriatal pathway while the 
A10 type DA neurons in the VTA extend their axons to the limbic and cortical areas 
along the mesolimbic and mesocortical pathways, respectively. However, a number of 
studies have shown that different populations of DA neurons are intermixed within the 
VM regions but their ascending axonal projections rarely (1-5% of cases) deviate from 
their primary pathway (Fallon and Loughlin, 1982, Loughlin and Fallon, 1984). Cells 
located in the ventral tier of the SNpc as well as the ventrolateral region of the VTA and 
the A8 cell group innervate the dorsolateral striatum (Gerfen et al., 1987, Prensa and 
Parent, 2001). These DA neurons are angular in shape, most express G-protein-activated 
inward-rectifier potassium channel 2 (Girk2) and high levels of DA transporter (DAT) 
and comprise the nigrostriatal pathway (Hurd et al., 1994, Thompson et al., 2005, Reyes 
et al., 2012). The VTA and the dorsal tier of the SNpc contain DA neurons which 
together with A8 type DA neurons project to the more central and ventral striatum and 
prefrontal cortex (PFC) as well as to the matrix compartment of the dorsal striatum 
(Gerfen et al., 1987, Lyndbalta and Haber, 1994, Williams and Goldman-Rakic, 1998). 
These cells are relatively round in shape, mostly expressing calcium binding protein, 
calbindin, and low levels of DAT (Hurd et al., 1994, Thompson et al., 2005, Reyes et 
al., 2012) and are the key players in the mesolimbic and mesocortical pathways that are 
implicated in reward and reinforcement behaviours, and cognitive behaviours (reviewed 
in Schultz, 2007). However, recent studies suggest that strong levels of Girk2 protein 
are also detected in DA neurons in the dorsal tier of the SNpc in mice and humans 
(Reyes et al., 2012). Interestingly, although the A9 type and A10 type DA neurons are 
very different both functionally and morphologically, they share up to 97% of their 
genetic profile (Grimm et al., 2004, Chung et al., 2005, Greene et al., 2005).  
1.1.2 Regulation of movement via nigrostriatal dopamine  neurotransmission 
The basal ganglia and the frontal cortex operate together to orchestrate and 
execute planned, motivated behaviours involving motor, cognitive and limbic circuits. 
The subcortical nuclei of the basal ganglia include the caudate nucleus and the putamen 
(together they form striatum in primates), the external and internal (entopeduncular 
nucleus in rodents) segments of the globus pallidus (GPe and GPi, respectively), and 
three closely related structures, the subthalamic nucleus (STN), VTA, and the SN [both 
SNpc and SN pars reticulata (SNpr)]. The A9 type DA neurons in the SNpc project and 
release DA in the caudate nucleus and the putamen regulating the coordination of 
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movement via modulation of the cortical and thalamic inputs (Carlsson and Carlsson, 
1989, Brotchie et al., 1991). 
The most authenticated working model of the basal ganglia is the direct and 
indirect pathway model first described in the 80s (Ilinsky et al., 1982, Deniau and 
Chevalier, 1985). According to this model, the striatum is the main input structure to the 
basal ganglia. It receives all glutamatergic cortical signals and relays them to the output 
nuclei of the basal ganglia, GPi and SNpr, via two distinct pathways, enroute to the 
thalamus which provides glutamatergic input back to the cortex. The monosynaptic 
connection of the striatum to the GPi is called the “direct pathway” while the 
polysynaptic connection of the striatum to the GPi/SNpr via the GPe and then STN is 
referred to as the “indirect pathway”. In the direct pathway, the DA input from the SNpc 
to the putamen activates a population of striatal -amino butyric acid (GABA)-ergic 
medium spiny neurons, that express dynorphin and substance P, via DA binding to the 
D1-family receptors (Gerfen et al., 1990). These GABA-ergic neurons in the putamen 
provide an inhibitory input to the GPi, which in turn projects GABA-ergic fibres to the 
thalamus. Thus, activation of the direct pathway results in the reduced inhibition of the 
thalamus. In the indirect pathway, release of DA in the striatum inhibits a population of 
GABA-ergic neurons, that express enkephalin, via DA binding to the D2-family 
receptors (Gerfen et al., 1990). This leads to a reduced inhibition of the GPe and 
increases a GABA-ergic output from the GPe to the STN, which provides an excitatory 
input to the GPi and SNpr. Reduced activity of the STN causes lower excitation of the 
GPi/SNpr and, in turn, leads to the reduced GABA-ergic input to the thalamus. Thus, 
normal basal ganglia functions are achieved when coordinated balance in the cortical 
and thalamic excitation from the direct and indirect pathway is modulated via DA 
neurotransmission. This oversimplified basal ganglia model has been updated with the 
inclusion of reciprocal connections between functionally related regions and non-
reciprocal pathways between functionally different regions of the basal ganglia, and 
reviewed in details elsewhere (Haber, 2003).  
Hypokinetic (e.g. Parkinson’s disease) and hyperkinetic (e.g. Huntington’s 
disease) movement disorders of basal ganglia origin are thought to result from the 
imbalance in the activity of the two pathways (Reiner et al., 1988, Waters et al., 1988, 
Albin et al., 1989). Failure of the nigrostriatal DA neurotransmission in Parkinson’s 
disease and its restoration are discussed in-depth in the following sections.  
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1.2 Parkinson’s disease 
Parkinson’s disease (PD) is the most common neurodegenerative movement 
disorder that presents in the second half of the 6
th
 decade of life in majority of patients. 
The incidence of the disease rises steeply with age, from 1% of the population at 65 
years of age suffering from PD to up to 9% of people being affected by the age of 80, 
with a lifetime risk of developing the disease of 1-5% (deRijk et al., 1995, Lang and 
Lozano, 1998, Bower et al., 1999). However, one in five affected persons develops the 
disease before they are 50 years old, a case of “early-onset PD”.  The mean lifespan of 
PD patients is 15-20 years from the time of diagnosis, depending on the age at onset, 
with a mortality rate 1.5 times higher than in unaffected individuals of the same age 
(Katzenschlager et al., 2008, Fahn, 2009). The cause of death is usually a concurrent 
unrelated illness or a condition, which develops due to the effects of decreased mobility, 
increased falling with subsequent trauma or respiratory disturbances. For instance, 
pneumonia has been identified as independent predictor of mortality among PD patients 
in nursing homes (Fernandez and Lapane, 2002). A number of studies have identified 
gender as a risk factor with men being 1.5 times more likely to develop PD than 
women, however these findings appear to be restricted to western populations over the 
age of 70 (Twelves et al., 2003, Wooten et al., 2004).  
In 1817, the first formal complete description of what later became known as PD 
was published by the English physician James Parkinson in a slim monograph entitled 
“An Essay on the Shaking Palsy”, in which he described 6 patients presenting with 
“Involuntary tremulous motion with lessened muscular power, in parts not in action and 
even when supported: with a propensity to bend the trunk forwards and to pass from a 
walking to a running pace: the senses and intellect being uninjured” (reprinted: 
Parkinson, 2002). In recognition of his clear description of the unrecognized disorder, 
the syndrome was named after James Parkinson in 1877 by Jean Martin Charcot, the 
“father of neurology”, who referred to the condition as “maladie de Parkinson” 
(Parkinson’s disease). Although physicians have found fragmentary descriptions of PD 
in Sanskrit texts, Egyptian hieroglyphics, the Ayurvedic and biblical texts (Stern, 1989), 
none were as complete and satisfying as that provided by Parkinson. Numerous 
accounts of PD incidents made by different civilisations over the centuries make it 
highly unlikely for race, creed or historic events, such as industrial revolution, to be 
related to the causes of the disease (Lees et al., 2009). Indeed, although important 
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genetic and environmental clues have been identified, the exact causes of PD remain 
unknown. 
1.2.1 Symptoms and diagnosis 
Currently, the diagnosis of PD relies on clinical criteria; no definitive test for PD 
has yet been developed. An accurate diagnosis in early stages of the disease remains an 
extremely challenging task because a number of other neurological disorders such as 
multiple system atrophy, diffuse Lewy body disease, vascular parkinsonism and 
progressive supranuclear palsy, collectively called Parkinsonian syndromes, may 
present with similar symptoms (Wenning et al., 1995, Zijlmans et al., 2004, Williams 
and Lees, 2005). Therefore, initial diagnosis of PD is based on the assessment of the 
cardinal motor symptoms that were described by James Parkinson, associated and 
exclusionary symptoms, and is later confirmed by a substantial (70-100%) clinical 
response to levodopa therapy (Gelb et al., 1999, Lees et al., 2009). Although PD affects 
both sides of the body, it always presents with an asymmetrical onset of symptoms and 
this criterion is one of the associated symptoms used to confirm the diagnosis. However, 
only post-mortem histopathological examination of the brain can provide definitive 
proof of the disease.  
PD is diagnosed when a combination of at least two cardinal motor deficits is 
present: unequivocal bradykinesia with either tremor at rest, muscle rigidity or loss of 
postural reflexes. Bradykinesia is the most characteristic clinical feature of PD and 
refers to slowness of spontaneous movements and gesturing (Berardelli et al., 2001), 
reduced reaction times (Cooper et al., 1994), loss of facial expression, decreased 
blinking, impaired swallowing (Bagheri et al., 1999), and reduced arm swing while 
walking. PD is also characterised by a slow 4-6 Hz tremor of the hands during rest that 
disappears when the hand is engaged in a task or during sleep (Jankovic, 2008). Lower 
limbs are often affected by the resting tremor in early-onset PD patients while older 
patients might develop facial tremors of the jaw, chin, lips and tongue (Lees et al., 
2009). Previous findings suggest that resting tremor presents in 69% of patients at 
disease onset (Hughes et al., 1993) and post-mortem clinical analysis of 65 patients 
revealed that all confirmed PD patients had tremor at some point (Rajput et al., 1991). 
One of the earliest manifestations of PD is muscle rigidity, which causes increased 
resistance to flexion, extension or rotation of a limb about a joint. However, it often 
presents 0-2 years before the onset of other cardinal PD motor symptoms and might 
easily be misdiagnosed as arthritis (Riley et al., 1989). Loss of postural reflexes occurs 
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in the late stages of the disease after manifestation of other clinical features. Freezing of 
gait is also very common in PD and presents in 50% of cases, affecting women less than 
men and manifesting less frequently in patients whose main symptom is tremor (Macht 
et al., 2007). Together with postural instability they are the main cause of falls in PD 
patients and, hence, the most disabling symptoms of the disease (Giladi et al., 2001, 
Williams et al., 2006). PD patients also develop a number of secondary motor 
abnormalities, including re-emergence of the primitive glabellar and palmomental 
reflexes (Brodsky et al., 2004), micrographia (Rao et al., 2003) and mirror movements 
of the limbs (Li et al., 2007). However, these symptoms are not specific for PD; they 
also manifest in other Parkinsonian syndromes and therefore are not used in the 
diagnosis of PD.   
Although traditionally PD has been primarily regarded as a motor disorder, 
clinical observations and scientific research have uncovered a wide range of cognitive 
and psychiatric symptoms in PD patients in the last 8-10 years and have shifted this 
view towards a more widespread disruption of multiple brain systems caused by the 
disease. PD patients develop the following non-motor symptoms: cognitive impairments 
in different aspects of executive function (Hely et al., 2005), autonomic sexual and 
sweating dysfunctions (Pursiainen et al., 2007, Kotkova and Weiss, 2013), sleep 
disorders (Schenck et al., 2013), hyposmia (Wenning et al., 1995, Ponsen et al., 2004), 
depression (Aarsland et al., 2007), visual hallucinations (Williams and Lees, 2005, 
Aarsland et al., 2007). However, a detailed discussion of these symptoms is beyond the 
scope of this thesis and the reader is referred to some recent reviews of this topic 
(Chaudhuri and Schapira, 2009, Chaudhuri et al., 2011, Lima et al., 2012).  Early onset 
hyposmia (Wenning et al., 1995) and late onset of visual hallucinations (Williams and 
Lees, 2005) might aid the initial diagnosis of PD and help rule out alternative 
Parkinsonian syndromes, respectively. Also, hyposmia (Ponsen et al., 2004) and rapid 
eye movement sleep behaviour disorder (Borek et al., 2007, Schenck et al., 2013) have 
been reported to manifest before the first motor symptoms of the disease appear and 
might serve as predictors for PD. However, none of the predictive tests have yet been 
developed into a clinical tool more effective than motor-based assessment.    
1.2.2 Neurobiology of Parkinson’s disease 
PD is a progressive disorder characterised by a substantial loss of the melanised 
A9 type DA neurons in SNpc and subsequent failure to supply DA to the dorsal striatum 
(Kish et al., 1988). The putamen is severely affected by the loss of midbrain DA 
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neurons in the initial stages of the disease. Before any symptoms appear, compensatory 
upregulation of dopamine receptors occurs in the depleted striatum as revealed by 
animal studies and post-mortem studies of PD patients. The postsynaptic GABA-ergic 
neurons become hypersensitive and increase the number of DA receptors (Ungerstedt, 
1971b, Heikkila et al., 1981). Simultaneously, the number of TH-positive neurons in the 
striatum increases several-fold as observed in parkinsonian monkeys (Betarbet et al., 
1997, Palfi et al., 2002) and PD patients (Porritt et al., 2000, Porritt et al., 2006). This 
increase in TH-positive neurons is not due to neurogenesis of DA neurons in the 
striatum but is likely due to an upregulation of TH in GABA-ergic interneurons that are 
already present (Mao et al., 2001, Tande et al., 2006). This compensatory mechanism 
has only a transient beneficial effect and eventually chronic DA depletion causes 
degeneration of the spines of striatal projection neurons involved in the indirect 
pathway of the basal ganglia (Day et al., 2006). At the same time, the reduced nigral 
output to the striatum affects both the direct and indirect pathways resulting in the 
hyperactivity of the GPi and SNpr nuclei and causing strong inhibition of the thalamus 
and severely decreased excitatory output to the cortex and an overall decrease in motor 
behaviour (Gerfen et al., 1990). Thus, by the time patients present with clinically 
assessable motor symptoms, SNpc is already severely degenerated with up to 60% DA 
neuronal loss and 80% reduction in DA release in the striatum (Kish et al., 1988, Waters 
et al., 1988).  
Neurodegeneration also occurs in other regions of the VM. The loss of the A8 
type DA neurons in the RRF has been observed in PD patients with prominent tremor 
while this area was intact in patients without tremor (Rajput et al., 1991, Hughes et al., 
1993). Degeneration of acetylcholine projections from the pedunculopontine nuclei has 
been observed in patients with gait and posture problems (Hirsch et al., 1987). NA 
neurons in the locus coeruleus (LC) degenerate in the later stages of the disease leading 
to a decreased NA levels in the hypothalamus, hippocampus and the cortex (Mann and 
Yates, 1983, Braak et al., 2003). Also, reductions in capacity for function have been 
reported in dorsal motor vagus nucleus, raphe nuclei and the nucleus basalis of Meynert 
and together with cell loss in LC have been associated with mental impairment in PD 
patients (Mann and Yates, 1983). Due to lesions in raphe nuclei, serotonergic (5-HT) 
input to the caudate putamen, frontal cortex and the hypothalamus is greatly reduced. 
Although neuron loss mainly occurs in the SNpc, widespread neurodegeneration of 
multiple cell populations in different regions of the brain and their association with 
manifestation of different symptoms in patients highlight the important fact that PD is a 
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heterogeneous disease. This has significant implications for the treatment of disorder 
which will be discussed further in this chapter. 
1.2.3 Lewy bodies 
Intracellular Lewy body (LB) formation has been associated with a number of 
neurodegenerative diseases including PD, Parkinsonian syndromes, depression and 
Alzheimer’s disease (Spillantini et al., 1997, Arima et al., 1998, Baba et al., 1998, 
Masliah et al., 2001, Braak et al., 2003). However, the composition of LBs differs 
between the diseases. Post-mortem studies of patients with PD revealed that 
intracellular inclusions in the tissue contained aggregates of phosphorylated filamentous 
proteins mainly consisting of α-synuclein protein, and to a lesser extent of ubiquitin 
protein (Lowe et al., 1988, Gibb and Lees, 1989, Spillantini et al., 1997, Baba et al., 
1998, Braak et al., 2003, Kuusisto et al., 2003). The diagnosis of PD is confirmed post-
mortem if, in addition to extensive DA neuron loss in the SNpc, there are LBs present in 
the brain. Intracellular inclusions are found in all major regions of the brain affected 
with PD including the SNpc, LC and the cortex. The exact role of LB in aetiology of 
PD, however, remains unknown because they are also sparsely distributed throughout a 
normal aged brain (Parkkinen et al., 2001, Bloch et al., 2006). LB formation has been 
observed in the autonomic nuclei of the spinal cord, peripheral autonomic nervous 
system and the olfactory nerves in neurologically unimpaired elderly subjects (Bloch et 
al., 2006). Autonomic failure has been reported as a pre-motor symptom of PD which 
suggests that neurodegeneration might first occur outside the central nervous system in 
autonomic postganglionic neurons (Kaufman et al., 1983). Also, the appearance of LBs 
seems to follow the onset of symptoms with the first intracellular inclusions appearing 
in the dorsal efferent motor nucleus of the vagus nerve and in the anterior olfactory 
nucleus (Braak et al., 2003). Thus, early LB formation in these areas might contribute to 
the initial non-motor symptoms of the PD including loss of smell, constipation and 
other autonomic dysfunctions. LBs then spread through the brainstem and the basal 
forebrain in the ascending pattern [raphe nuclei – LC – amygdala – SNpc (which 
corroborates the manifestation of motor symptoms)] before propagating to the 
anteromedial temporal mesocortex, the higher order sensory association neocortex, the 
PFC and eventually reaching the primary sensory and motor cortical areas (Braak et al., 
2003). While the propagation of LBs seems to generally correspond to the onset of 
symptoms as PD progresses, LB density does not appear to correlate with the neuronal 
loss, the severity of clinical symptoms or the disease duration (Galvin et al., 2006, 
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Libow et al., 2009, Greffard et al., 2010). A recent study revealed that most of the α-
synuclein aggregates, much smaller than LBs, were located at the presynapses of 
neurons and, while the presynapses were relatively preserved, dendritic spines were 
retracted suggesting a neurotransmitter deprivation (Kramer and Schulz-Schaeffer, 
2007). This raises an alternative hypothesis that smaller aggregates of proteins, not LBs, 
play a role in neurodegeneration via modulation of neurotransmitter release (Lundblad 
et al., 2012).  
1.2.4 Aetiology of Parkinson’s disease 
Although several environmental and genetic risk factors have been identified, 
the cause of PD is still as elusive now as it was in 1817 when the condition was first 
described. The majority of PD cases are sporadic (idiopathic) and only 15 to 20% of PD 
patients have an affected first-degree relative (Samii et al., 2004, McDonnell et al., 
2006). Therefore, most PD patients are believed to have a complex aetiology due to an 
interaction of genetic and environmental factors.  
1.2.4.1 Genetic risk factors 
To date, molecular genetic analyses of familial cases of PD have improved 
understanding of the disease mechanisms underlying PD pathology and identified 
mutations in seven disease associated genes: α-synuclein (Polymeropoulos et al., 1997), 
leucine-rich repeat kinase 2 [LRRK2, (Funayama et al., 2002, Zimprich et al., 2004)], 
parkin [PARK2, (Kitada et al., 1998)], phosphatase and tensine homolog (P-TEN)-
induced putative kinase 1 [PINK1, (Valente et al., 2004)], DJ-1 (Bonifati et al., 2003), 
eukaryotic translation initiation factor 4 gamma 1 [EIF4G1, (Chartier-Harlin et al., 
2011) ], and vacuolar protein sorting 35 [VPS35, (Vilarino-Gueell et al., 2011, Zimprich 
et al., 2011)]. Mutations in the α-synuclein, LRRK2, EIF4G1 and VPS35 genes are 
implicated in the autosomal dominant late-onset forms of PD while mutations in the 
PARK2, PINK1 and DJ-1 genes are associated with the autosomal recessive early-onset 
PD. Familial cases of PD follow a Mendelian distribution. Mutations in several genes 
have been implicated in sporadic forms of PD such as α-synuclein muations (Michell et 
al., 2005, Kay et al., 2008),  LRRK2 mutations (Puschmann et al., 2012), and PINK1 
mutations (Valente et al., 2004). Also, LRRK2 mutations are the most common genetic 
risk factors for PD due to their location within a common haplotype (Di Fonzo et al., 
2005, Lesage et al., 2006). 
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Overexpressed α-synuclein is misfolded and aggregated to form LBs 
predominantly in neurons and to some extent in glial cells, as revealed by post-mortem 
studies of PD patients (Spillantini et al., 1997, Braak et al., 2003). Additionally, 
pathological studies from autopsies report LBs in carriers of PINK1 mutation and one 
variant of LRRK2 mutation (G2019S) but not in carriers of PARK2 mutations or other 
LRRK2 mutations (Samaranch et al., 2010, Poulopoulos et al., 2012). PARK2 and 
PINK1 mutations lead to cell loss restricted to the VM. Heterozygous PARK2 carries 
have been associated with LB pathology (Pramstaller et al., 2005). Patients with 
mutations in the α-synuclein develop more severe autonomic dysfunction and cognitive 
decline than normal PD patients (Zarranz et al., 2004, Somme et al., 2011). Mutations in 
LRRK2, PARK2 and PINK1 genes have been associated with the impairment of 
autophagy-lysosomal pathways which, in turn, might result in the increased 
accumulation of α-synuclein protein and induce neurotoxicity in nigral DA neurons 
(Narendra et al., 2008, Narendra et al., 2010, Dehay et al., 2013). PINK1 and DJ-1 have 
been implicated in mitochondrial functions and mutations in the genes might disrupt the 
normal activity of the mitochondria leading to abnormal oxidative stress in cells and 
eventually cell death (Martinat et al., 2004, Narendra et al., 2010). However, the exact 
link between mutations in these genes and DA neuron loss in the SNpc and non-motor 
symptoms of PD remains unknown.  
1.2.4.2 Environmental risk factors 
The majority of sporadic PD cases occur without a known definite cause. Thus, 
it is more likely that a combination of genetic and environmental factors is implicated in 
the onset of idiopathic PD. Epidemiological studies revealed age (Bennett et al., 1996, 
Morens et al., 1996) and 1-methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine [MPTP, (Davis 
et al., 1979, Langston et al., 1983)] as two environmental risk factors for PD. The A9 
type DA neurons are more vulnerable to MPTP toxicity and repeated exposure to MPTP 
results in severe DA cell loss in the SNpc (Langston et al., 1984, Chung et al., 2005). 
Further studies failed to produce strong evidence for other environmental factors (Elbaz 
and Moisan, 2008). However, Paraquat, a widely used herbicide, has been shown to 
exert neurotoxic effects on DA neurons in the SNpc and therefore has been associated 
with an increased risk of PD incident; however, its penetration to the brain is highly 
limited by the blood-brain barrier (Naylor et al., 1995, McCormack et al., 2002). Also, 
insecticide rotenone (Betarbet et al., 2000) and fungicide Maneb (Hertzman et al., 1990, 
Thiruchelvam et al., 2000) have been proposed as potential risk factors of PD, however, 
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the evidence in literature is inconsistent and has been challenging to replicate in animal 
models of PD.   
Oxidative stress (Martinat et al., 2004), mitochondrial dysfunction (Narendra et 
al., 2008), environmental toxins (Elbaz and Moisan, 2008), cerebral ischemia, and 
excitotoxicity (Lotharius and Brundin, 2002) have all been proposed as possible 
mechanisms implicated in PD onset. Mitochondrial dysfunction caused by either 
environmental toxins or genetic mutations, or the interaction between the two, may 
induce excitotoxicity and oxidative stress in neurons leading to protein isoforms 
accumulating within cells and eventually the onset of neurodegeneration (Betarbet et al., 
2002). Even though three different populations of DA neurons form a continuous sheet 
throughout the midbrain, they exhibit different degrees of vulnerability to oxidative 
stress induced by the administration of neurotoxins, and results are consistent between 
animal models and patients with PD (Burns et al., 1983, Schneider et al., 1987, Gibb 
and Lees, 1991, German et al., 1996, Hung and Lee, 1998, Grant and Clarke, 2002, 
McCormack et al., 2006). The A9 type DA neurons in the ventral SNpc are the most 
vulnerable population, most likely due to the huge metabolic load they experience in 
order to sustain signalling with hundreds of thousands of target neurons (Lotharius and 
Brundin, 2002, Smits et al., 2006). The concept of free radical involvement in selective 
neurodegeneration is supported by increased basal lipid peroxidation in SNpc in PD 
patients (Dexter et al., 1989). Interestingly, the same cellular mechanisms have been 
proposed to cause neuronal loss in normal ageing and PD and a combination of genetic 
and environmental factors in PD might just accelerate an already ongoing process in the 
ageing brain (Collier et al., 2011). 
1.3 Animal models of Parkinson’s disease 
Animal models are research tools of paramount importance to study the 
pathogenesis and progression of human diseases as well as for the testing of novel 
therapeutics. Like many other human diseases, PD does not naturally occur in animals 
and, therefore, has to be artificially initiated. PD is a complicated multi-symptom 
disease with unclear molecular mechanisms for the observed pathology, which makes it 
hard to model. To date, no single animal model exists that would fully capture PD but 
there are a number of models available that incorporate particular aspects of the disease 
pathology and the choice of a suitable model always depends on the planned study, i.e. 
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the research question. Methods to induce DA neuron loss range from neurotoxins to 
overexpression and down-regulation of disease-related genes.  
1.3.1 6-hydroxydopamine model 
First demonstration of neurotoxic effects of 6-hydroxydopamine (6-OHDA) and 
the development of a 6-OHDA rat model of PD took place in the 1970s (Ungerstedt, 
1968, Ungerstedt and Arbuthnott, 1970). The neurotoxin 6-OHDA was demonstrated to 
be effective to the same extent in other species as well, e.g. mice, monkeys, cats, and 
dogs (Bezard et al., 1998). Only CA neurons are affected by the toxin while other cell 
types are spared because the neurotoxin 6-OHDA has a similar structure to DA and NA 
and is reuptaken by CA neurons through transporters in the membrane (Breese and 
Traylor, 1971). The toxin has an inhibitory effect on the mitochondrial compounds I and 
IV and two components that it produces inside the cells, hydrogen peroxide and 
paraquinone, are highly toxic (Glinka et al., 1997). Such high selectivity makes the 6-
OHDA toxin a perfect tool to target DA and/or NA pathways in the brain (Ungerstedt 
and Arbuthnott, 1970, Lotharius and Brundin, 2002, Blandini et al., 2008, Terzioglu and 
Galter, 2008). The neurotoxin cannot cross the blood-brain barrier and therefore is 
directly injected in to the brain regions of interest. Bilateral 6-OHDA lesions induce 
severe motor impairment, inability to swallow, absence of thirst, and may lead to death 
of animals (Ungerstedt, 1971a, Smith and Young, 1974). In contrast, unilateral lesions 
of SNpc, medial forebrain bundle (MFB) or the striatum are well tolerated by the 
animal, resulting in asymmetrical behavioural deficits with the benefit of the intact side 
of the brain providing an internal control (Ungerstedt et al., 1973). Administration of 
DA agonists, such as methamphetamine, is routinely used in the assessment of 6-OHDA 
lesions, by quantification of net circling behaviour towards the lesioned side. This 
occurs when the intact striatum is flooded with DA and drives ipsilateral rotations 
(Ungerstedt, 1971c). The magnitude of such behaviour depends on the degree of the 
lesion (Ungerstedt and Arbuthnott, 1970, Ungerstedt, 1971c, Torres et al., 2011). 
Similarly, other motor tests and sensory tests (e.g. stepping test, cylinder test, nose-
poking tests, etc.) assess the extent of DA depletion by comparing behavioural 
impairments on the two sides of the body (Dowd and Dunnett, 2005a, Dowd and 
Dunnett, 2005b).  This model has been widely used to assess the efficacy of new drugs, 
cell transplantation and gene therapies in reducing DA imbalance (Jiang et al., 1993, 
Collier and Sortwell, 1999, Bjorklund et al., 2002, Kirik et al., 2002, Dowd and 
Dunnett, 2004, Torres et al., 2007, Torres et al., 2008a, Grealish et al., 2010, Back et al., 
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2013). Apart from selective DA neuron loss in SNpc, 6-OHDA lesion model does not 
mimic any other features of PD pathogenesis. Nevertheless, it remains a relatively cheap 
and very useful model to understand DA function, assess replacement of lost DA 
neurons and restoration of DA supply to the striatum. Thus, this model was chosen for 
the research presented here. 
1.3.2 MPTP model 
The administration of another neurotoxin MPTP in mice, rats, monkeys, and 
guinea pigs, induces parkinsonian motor symptoms and mitochondrial dysfunction 
(Chiueh et al., 1984, Langston et al., 1984, Doudet et al., 1985, Gerlach et al., 1991, 
Heikkila and Sonsalla, 1992, Gerlach et al., 1996, Yazdani et al., 2006). MPTP can also 
induce such hallmarks of PD as motor impairments, oxidative stress,  energy failure and 
inflammation in humans (Langston et al., 1983). MPTP crosses the blood-brain barrier 
and is metabolized by astrocytes into the toxic MPP
+
, which then enters neurons via 
DAT where it inhibits complex 1 of the mitochondria causing oxidative stress and 
degeneration of the cell (Javitch et al., 1985). Both acute and chronic models of PD 
using different doses of MPTP have been developed over the years (Bezard et al., 1997, 
Iravani et al., 2005, Blesa et al., 2010). Susceptibility to MPTP, however, is highly 
variable between different mouse strains (Terzioglu and Galter, 2008) and was found to 
be lower in rats than in mice (Chiueh et al., 1984). Moreover, MPTP models lack 
inclusions and LB formation in the brain (Forno et al., 1993, Halliday et al., 2009). 
However, chronic administration of MPTP is probably the best model of PD in non-
human primates, as characterised by cardinal motor dysfunctions and responsiveness to 
levodopa therapy. Electrophysiological studies using this model identified the STN as a 
target for deep brain stimulation to alleviate motor symptoms and led to the emergence 
of this therapy in PD patients (Bergman et al., 1990, Limousin et al., 1995). The MPTP 
model has been used in genetically modified mice to study molecular mechanisms of 
PD (Vila et al., 2001, Dauer et al., 2002, Thomas et al., 2011) whereas MPTP models in 
monkeys are used to evaluate behavioural and non-motor symptoms of PD (Vezoli et 
al., 2011).   
1.3.3 Other neurotoxin models 
Striatal DA deficiency can be induced by pharmacological agents and 
environmental toxins to model symptoms of PD. Reserpine was the first such agent to 
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be used in rabbits. The mechanism behind reserpine induced akinesia is disruption of 
monoamine storage in synaptic vesicles (Carlsson et al., 1957). The same effect was 
later demonstrated in monkeys (Windle and Cammermeyer, 1958). Restoration of this 
deficit could be achieved by levodopa therapy (Carlsson et al., 1957, Gossel et al., 
1995). This provided evidence that DA depletion of the striatum causes motor 
symptoms of PD and eventually led to the development of the first neurotransmitter 
replacement therapy for the treatment of PD. However, reserpine provided only 
transient DA depletion of the striatum and did not cause any morphological changes in 
the DA neurons in SNpc. 
As mentioned earlier, evidence from PD patients and animal models suggests 
that oxidative stress and free radicals are involved in neurodegeneration (Dexter et al., 
1989, Yoritaka et al., 1996, Cassarino et al., 1997). Protein nitration is affected when 
neurons are subject to oxidative stress as seen from animal models and PD patients 
(Good et al., 1998, Giasson et al., 2000, Yu et al., 2010). Free 3-nitrotyrosine (3-NT) 
induced oxidative stress in the striatum of mice caused loss of DA neuronal terminals, 
degeneration of DA neurons in SNpc and the development of motor deficits (Mihm et 
al., 2001). However, this model fails to mimic the progressive nature of PD, no protein 
aggregations and cellular inclusions were found in DA neurons. Similarly to the 
reserpine model, the free 3-NT model is very limited but could be used for antioxidant 
therapy screening. 
Evidence from pesticide and herbicide models of PD is rather ambiguous with 
some studies showing a loss of DA neurons in SNpc after administration of paraquat 
(Brooks et al., 1999, McCormack et al., 2002) and other studies failing to replicate this 
(Thiffault et al., 2000, Thiruchelvam et al., 2000). Rotenone has also been used to 
model PD in mice (Inden et al., 2007, Inden et al., 2011) and rats (Betarbet et al., 2000, 
Alam et al., 2004). Although intravenous administration of rotenone has been shown to 
induce damage to DA neurons, α-synuclein aggregations and LB-like formation as well 
as oxidative stress and gastrointestinal problems in rats (Sherer et al., 2003, Cannon et 
al., 2009), again this has been difficult to reproduce in mice and monkeys (Ferrante et 
al., 1997, Thiffault et al., 2000, Kordower et al., 2006) and evidence of DA neuron loss 
in SNpc is slim (Wu and Johnson, 2011). It is not clear whether this model has any 
advantages over 6-OHDA or MPTP models. Furthermore, there is no strong evidence 
for rotenone-induced PD in humans (Blesa et al., 2012).  
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1.3.4 Genetic models 
Discovery of rare genetic mutations in familial cases of PD led to the 
development of transgenic animal models of PD (Dawson et al., 2010). Two mutations 
(A53T, A30P) in the α-synuclein gene have been linked to PD (Kruger et al., 1998). 
Mice expressing A53T human α-synuclein show severe motor phenotype and eventually 
paralysis as well as having LB-like inclusions but show no DA neuron loss in SNpc 
(Masliah et al., 2000, Giasson et al., 2002). This phenotype, however, is not found in 
A30P transgenic mice. Knockout models of α-synuclein showed that the loss of this 
protein has no effect on neurodegeneration (Blesa et al., 2012). A Drosophila knockin 
model of PD results in motor deficits, DA neuron loss, reduced TH expression in SNpc 
and intracellular inclusions (Feany and Bender, 2000). However, the exact function of 
α-synuclein is still elusive, let alone its involvement in PD. Similar to α-synuclein, 
knocking out LRRK2 has no effect on neuronal death and overexpression of LRRK2 in 
mice produces a only a minimal level of neurodegeneration (Li et al., 2009). Transgenic 
PARK1, DJ-1, and PINK1 animal models do not demonstrate any of the cardinal 
features of PD, only in PINK1 knockout mice is DA release in the striatum reduced 
(Moore and Dawson, 2008). Transgenic models are good tools for discovery of gene 
functions and modelling developmental diseases but generally fail to model disease of 
ageing. Recently, conditional transgenic models have become available, which allow 
genes to be switched on and off at adult age and it has been demonstrated that shutting 
down PARK1 expression in adult mice causes DA neuron loss in SNpc (Shin et al., 
2011). However, these types of models require high levels of mouse breeding expertise 
and are very laborious to generate and maintain. Another problem with transgenic 
mouse models of PD is that mouse life span might not be long enough to allow accurate 
modelling of PD. In other words, the role of age in aetiology of PD has to be borne in 
mind when working and translating any findings from rodent transgenic models. 
1.4 Conventional treatments for Parkinson’s disease 
There is no therapy available to cure PD, current treatments only alleviate the 
symptoms and substantially improve quality of life but do not stop the progression of 
the disease. Deep brain stimulation (DBS) is the major surgical approach, with levodopa 
therapy still remaining the most effective pharmacological treatment available but due 
to its long-term severe side effects every effort is made to postpone its usage. 
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1.4.1 Early pharmacological treatments 
Early medical interventions are aimed at stabilising levels of endogenous DA in 
the striatum by blocking its metabolisation. The selective type B monoamine oxidase 
(MAO-B) inhibitors, selegiline and rasagiline, when used as a mono-therapy, offer 
mildly effective symptomatic benefit as long as there is a sufficient number of DA 
terminals left in the putamen (Schapira, 2011, Pagonabarraga and Cruz Rodriguez-Oroz, 
2013). Rasagiline has been implicated in the delayed disease progression and might act 
as a disease modifying agent (Akao et al., 2002, Maruyama et al., 2002). MAO-B 
inhibitors are also used in later stages of PD in combination with levodopa therapy to 
prolong the effect of the latter (Minguez-Minguez et al., 2013, Pagonabarraga and Cruz 
Rodriguez-Oroz, 2013).  
Dopamine agonists are also used as a mono-therapy in the early stages of the 
disease to directly stimulate postsynaptic D1 and D2 receptors in the putamen (Perachon 
et al., 1999, Foley et al., 2004). They are slowly metabolised in the brain and provide a 
physiological and more continuous stimulation of the receptors than levodopa 
(Bonuccelli et al., 2009). They are a preferred first-line treatment in patients under the 
age of 55 but additional medical interventions are usually necessary within 3 years of 
diagnosis. DA agonists may also cause a wide range of side effects such as 
gastrointestinal problems, sleepiness and impulse control disorders but do not provoke 
dyskinesia (Lader, 2008, Lim et al., 2008, Micallef et al., 2009). The DA agonist 
Apomorphine is used as an adjunctive therapy to levodopa to help reduce motor 
fluctuations.  
1.4.2 L-DOPA therapy 
As the disease progresses and DA depletion of the putamen worsens, motor 
symptoms no longer respond to MAO-B and DA agonist mono-therapies. Therefore, all 
PD patients eventually require levodopa therapy. As mentioned in 1.3.3, administration 
of DA precursor L-3,4-dihydroxyphenylalanine (L-DOPA) to restore DA supply to the 
putamen was introduced nearly 60 years ago and has been the ‘gold-standard’ therapy in 
PD ever since (Carlsson et al., 1957, Birkmayer and Hornykiewicz, 1961, Worth, 2013). 
Peripherally administered L-DOPA is transferred across the blood-brain barrier through 
large amino acid transporters, and is converted into DA by remaining functional DA 
neurons and by 5-HT neurons and is stored in vesicles within neurons before being 
released in the synapse (Wade and Katzman, 1975, Carta et al., 2007). Uncontrolled 
18 
 
release of DA by 5-HT neurons, due to lack of feedback mechanisms, overstimulates 
DA receptors and the long-term effects of this can lead to severe and disabling motor 
complications (Cotzias et al., 1969, Rajput et al., 2002). Patients start to experience 
motor fluctuations between few hours of drug-induced “on” phase with therapeutic 
benefit and disease-induced “off” phase with behavioural decline and in severe cases 
immobility (Quinn, 1998, Obeso and Lang, 2006). The “off” phase is believed to occur 
due to impaired DA retention in the striatum caused by long-term administration of L-
DOPA (Murata and Kanazawa, 1993). The “on-off” phenomenon reflects fluctuations in 
absorption, transport and plasma concentrations of the drug and continuous 
administration of L-DOPA produces a stable clinical state (Nutt et al., 1984, Pincus and 
Barry, 1987, Eriksson et al., 1988).  
Hyperkinetic and dystonic involuntary movements, called L-DOPA-induced 
dyskinesias (LIDs), appear after long-term treatment and are the most disabling side 
effect of the levodopa therapy. LIDs are uncontrollable abnormal, sometimes painful, 
movements and postures affecting facial muscles, head, neck and in severe cases limbs 
(Thanvi et al., 2007, Goetz et al., 2008). Uncontrolled DA overstimulation of 
hypersensitive putamen by 5-HT neurons has been implicated in LIDs (Carlsson et al., 
2007, Carta et al., 2007, Munoz et al., 2008). Dyskinesias, in large, are a more severe 
manifestation of “on-off” motor fluctuations with “on-phase” LIDs, in response to high 
concentrations of L-DOPA in the brain and plasma, being the most common. However, 
manifestation of dyskinesias varies between patients and LIDs may also occur during 
“off” phases or in between “on” and “off” phases. As the disease progresses, higher 
doses of L-DOPA, required to alleviate motor symptoms, inevitably contribute to the 
increased risk of developing dyskinesias and their severity once they appear as 
demonstrated by a dose-dependent onset and worsening of LIDs in healthy and MPTP-
lesioned primates (Di Monte et al., 2000, Pearce et al., 2001) .  
Motor symptoms respond to L-DOPA treatment for 10-15 years but, as the 
disease progresses, symptomatic relief starts to wane after about 5-10 years and 40% of 
patients develop LIDs after 4-6 years of treatment (Marsden, 1994, Ahlskog and 
Muenter, 2001, Obeso and Lang, 2006). The risk of developing dynkinesias increases 
with every additional year on medication. Current anti-dyskinetic amantadine therapy, a 
weak glutamate N-Methyl-D-aspartic acid (NMDA) antagonist, is efficient only for a 
few years in a subset of patients (Elahi et al., 2012). Continuous infusion of L-DOPA 
results in a stable clinical state with markedly reduced “on-off” motor fluctuations and 
LIDs in mild and severe PD patients (Nutt et al., 1984, Antonini et al., 2007). However, 
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this novel therapy is very expensive and requires an invasive surgery to implant L-
DOPA intestinal-delivery system (Duodopa) and then subsequent constant maintenance 
of the portable Duodopa device. Also, cases of symptomatic peripheral neuropathy, 
sometimes severe, have been reported in patients receiving this treatment (Antonini et 
al., 2007, Manca et al., 2009, Muller et al., 2013).   
Due to heterogeneous manifestation of the PD in patients, effects of drug 
treatments considerably vary from patient to patient. Thus, clinicians are faced with a 
challenging task of developing pharmacological therapies, via different combinations of 
drugs and dosages, almost on a patient to patient basis. Moreover, none of the current 
pharmacological treatments stop progression of the disease, restore the functional 
circuitry in the brain or provide DA delivery to the putamen in the physiological 
fashion. All these factors together with inevitability of the severe side-effects such as 
LIDs require the development of alternative therapies.  
1.4.3 Surgical treatments 
In the 1940s and 50s before the introduction of L-DOPA as a treatment for PD, 
surgical lesions to the thalamus, globus pallidus, caudate nucleus and STN were used to 
alleviate motor symptoms such as tremor, muscle rigidity, bradykinesia and dyskinesia 
(Meyers, 1942, Meyers, 1951, Krayenbuhl and Yasargil, 1960, Svennilson et al., 1960, 
Krayenbuhl et al., 1961). However, the damage induced by bilateral electrolytic or 
thermolesions was severe and irreversible and the lesions were not well tolerated. DBS 
of the same structures replaced surgical lesions in the late 1980s. DBS involves the 
bilateral placement of several electrodes most commonly in the STN, GPi and thalamic 
ventralis intermedius nucleus (VIM) that stimulate the areas concerned and block the 
abnormal signalling in those nuclei. An external controller allows the patient to switch 
the device on and off (Benabid et al., 1987, Siegfried and Lippitz, 1994, Limousin et al., 
1995, Krack et al., 1998, Benabid et al., 1999, Caparros-Lefebvre et al., 1999). The 
optimal firing frequency, typically around 130 Hz, can be adjusted for each patient. All 
motor symptoms respond well to the stimulation of the STN, while stimulation of the 
VIM alleviates tremor and GPi stimulation most effectively treats LIDs and motor 
fluctuations (Benabid et al., 1999, Caparros-Lefebvre et al., 1999). In parallel to the 
DBS treatment, medication regimes are continued at lower doses which results in a 
further reduction in dyskinesias (Limousin et al., 1999, Mentzel et al., 2012). It is 
believed that DBS modifies irregular neuronal firing as demonstrated by animal studies 
(Lee et al., 2004, Chang et al., 2007), however, despite its widespread application, the 
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exact mechanisms underlying the effects of this therapy remain unclear. Similar to 
pharmacological treatments, DBS therapy only addresses the symptoms and does not 
have any effect on the progression of the disease. Neural transplantation is a more 
ambitious alternative approach to restore function, based on the idea that grafted foetal 
or stem cells can replace the lost DA neurons and their connections. 
1.5 Cell transplantation therapy for Parkinson’s disease 
In the early 20
th
 century, organ and tissue transplantation emerged as an exciting 
approach in medicine and research to replace and repair non-functional organs or parts 
of organs (Hamilton, 2012). Using cell transplantation to replace lost neurons, reverse 
the damage caused by neurodegeneration and restore normal function in the brain 
circuitry was an ambitious idea and attracted a lot of interest in the scientific 
community. One of the main early findings was that survival of the transplanted neural 
tissue in the host brain could be improved by using immature donor brain tissue from 
postnatal animals rather than adult brain tissue (Dunn, 1917). It was concluded that 
damage induced by severing axonal projections during tissue excision process was more 
detrimental in mature brains due to a highly complicated neuronal arborisation and the 
donor age was established as a very important factor influencing the efficacy of cell 
therapy. Precise targeting of specific brain regions for neural tissue transplantation in 
humans was not possible until the invention of the stereotaxic apparatus by two 
American neurosurgeons, Ernest A. Spiegel and Henry T. Wycis, in 1947 (reviewed in: 
Lasak and Gorecki, 2009). Also, the development of the strong immunosuppressive 
drug cyclosporine in the 1970s (Borel et al., 1976) allowed the progress of xenograft 
transplantation research and the start of clinical trials for transplantation in PD. Initally, 
patient’s own adrenal medullar cells, which produce CA, were successfully used for 
transplantation into the putamen in two studies (Backlund et al., 1985, Madrazo et al., 
1987) but the beneficial outcome of this approach was somewhat debatable because 
other studies found moderate improvement only in 19% of patients and associated this 
therapy with a high level of morbidity and mortality (Quinn, 1990, Goetz et al., 1991). 
Therefore, the focus of cell therapy research transferred to the use of foetal VM 
containing developing DA neurons obtained from surgical terminations of pregnancy.    
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1.5.1 Foetal cell transplantation in animal models 
Considering that there is a substantial DA neuron loss in the SNpc by the time 
PD patients present with diagnosable motor symptoms, cell replacement therapy has 
been widely investigated as an alternative to pharmacological and DBS treatments since 
the late 1970s (Bjorklund and Stenevi, 1979, Perlow et al., 1979, Bjorklund et al., 
1980a). During embryogenesis, DA neurons are born in the VM and extend axonal 
projections to the putamen guided by chemical signals forming the nigrostriatal pathway 
of the basal ganglia (Altman and Bayer, 1981, Specht et al., 1981, Bayer et al., 1995, 
Gates et al., 2004). Reconstruction of this pathway in the adult PD-affected brain 
presents a major challenge due to the large distance between the two cerebral targets 
that axons would have to cover and the absence of developmental chemoattractive and 
chemorepulsive cues. Adult myelinated pathways were shown to contain inhibitory 
factors that impede axonal growth and neural regeneration (Schnell and Schwab, 1990, 
Schwab, 1990). Indeed, animal studies confirmed that DA neurons transplanted into the 
SNpc alone did not achieve behavioural recovery in unilaterally 6-OHDA lesioned rats 
while single and multiple implants in the striatum reversed behavioural asymmetries 
(Dunnett et al., 1983). Similar studies in MPTP-lesioned monkeys showed no extensive 
axonal outgrowth rostrally along the MFB and modest but detectable behavioural 
improvement (Collier et al., 2002). Substantial restoration of efferent nigrostriatal 
connections and a lack of afferent striatonigral connections were demonstrated by 
ectopic transplantation of VM grafts into the rat striatum (Freund et al., 1985, Clarke et 
al., 1988, Doucet et al., 1989, Mendez et al., 1991). Transplantation of human foetal 
VM tissue into the cortex or ventricle adjacent to the DA-depleted striatum revealed 
target specific TH-ir fibre outgrowth in immunosuppressed rats (Stromberg et al., 
1992). Also, the degree of graft-derived DA innervation of the putamen in primates was 
found to influence behavioural recovery (Redmond et al., 2008). Grafted DA neurons 
synthesised and released DA at rates characteristic of the intact nigrostriatal system 
(Schmidt et al., 1982) and exhibited normal electrophysiological profile (Wuerthele et 
al., 1981). While these studies provided proof that nigral grafts in the putamen were 
able to supply DA continuously in a physiological manner, they also revealed a lack of 
graft regulation by the host. Simultaneous intrastriatal and itranigral DA neuron 
transplantation or multiple graft placements along the MFB restored the pathway in the 
adult 6-OHDA lesioned rat brain and achieved a greater behavioural recovery (Dunnett 
et al., 1989, Mendez et al., 1996). Also, foetal VM grafts transplanted into the SNpc and 
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the STN promoted the sensorimotor behavioural recovery obtained by intrastriatal grafts 
(Mukhida et al., 2001). Similarly, combined transplantation of multiple foetal VM grafts 
into the stratum and foetal striatal grafts, rich in GABA-ergic neurons, into the the SNpc 
induced additive effects of behavioural recovery observed in the forelimb akinesia test 
(Winkler et al., 1999). Later studies associated focal graft placement, not widespread 
multiple grafting, in the striatum with the development of hyperkinetic forelimb and 
facial movements (Maries et al., 2006). These findings suggest that transplantation into 
the putamen alone is not sufficient to restore the basal ganglia circuit and complete 
functional recovery of complex motor behaviours in 6-OHDA models with selective 
loss of DA neurons let alone PD. Therefore, the main strategy in clinical cell 
transplantation has been to place multiple foetal VM grafts ectopically primarily into 
the putamen and in some cases also into the caudate nucleus.  
Grafts transplanted as dissociated cell suspensions produced similar numbers of 
DA neurons as solid tissue grafts but induced a smaller host immune response 
(Bjorklund et al., 1980b, Bjorklund et al., 1983a, Bjorklund et al., 1983b, Freeman et 
al., 1995b, Redmond et al., 2008). Dissociation of the tissue into a cell suspension 
eliminates immunogenic vascular elements which might aid in the reduction of the 
immune response in the host brain. Animal studies in rodents and monkeys 
demonstrated that embryonic VM neurons must be collected for transplantation during 
the peak stage of DA neurogenesis when the neurons are already committed to the DA 
phenotype but before substantial outgrowth of axonal fibres occurs (Brundin et al., 
1985a, Simonds and Freed, 1990, Annett et al., 1997).  Transplantation of human foetal 
DA neurons into 6-OHDA lesioned immunosuppressed rats revealed that the best 
survival rates were achieved when the VM was derived from embryos aged 6 – 9 weeks 
after conception, Carnegie stage 15 – 23 (Freeman et al., 1995b). However, more recent 
studies in rodents, using rat embryonic VM, showed that transplantation of younger 
immature DA precursor cells improved the yield of TH-ir neurons in the graft and 
achieved a similar level of behavioural recovery (Torres et al., 2007, Torres et al., 
2008a, Bye et al., 2012). These results further highlighted the donor age as an important 
parameter and drew a lot of interest in the scientific community towards the use of 
younger donor age tissue for cell transplantation therapy.  
Detectable behavioural recovery was observed with only approximately 125 TH-
ir neurons in the nigral grafts derived from rat embryos and transplanted into the 
striatum of 6-OHDA lesioned rats (Brundin et al., 1985a). A number of animal studies 
in mice and rats demonstrated that grafts containing at least 200 – 1000 DA neurons 
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ameliorated a range of lesion-induced deficits in drug-induced rotational behaviour, 
spontaneous locomotor activity, lateralised choice reaction time task, rotarod test and 
corridor test (Bjorklund et al., 1980a, Dowd and Dunnett, 2004, Chaturvedi et al., 2006, 
Kuan et al., 2007, Heuer et al., 2013b, Heuer et al., 2013a). Similarly, embryonic DA 
neurons transplanted into the striatum of 6-OHDA lesioned marmosets significantly 
reduced amphetamine-induced rotations (Annett et al., 1997). Recent studies showed 
that mouse VM grafts contained both the A9 and the A10 type DA neurons and 
transplants derived from younger embryos were both enriched for Girk2-ir DA neurons 
and contained reduced numbers of 5-HT neurons (Thompson et al., 2005, Jonsson et al., 
2009, Grealish et al., 2010, Bye et al., 2012). The majority of DA neurons that co-
labelled with Girk2 were found in the periphery of the graft while DA neurons in the 
centre of the graft predominantly coexpressed calbindin (Thompson et al., 2005, Bye et 
al., 2012). Mouse grafts enriched for the A9 type DA neurons and transplanted into 6-
OHDA lesioned rats improved performance of animals on amphetamine-induced 
rotation test and cylinder test, while animals transplanted with the VM tissue selectively 
lacking in the A9 type DA neurons remained impaired  (Grealish et al., 2010). The 
number of the A9 type DA neurons in the grafts was found to be an important 
determinant of the degree of rotational recovery, the recovery of sensorimotor function 
in paw-reaching test, and the level of LID recovery (Kuan et al., 2007). Yields of the 
TH-ir cells and the A9 type DA neurons were lower, although the differences were 
statistically insignificant, in animals that were treated with L-DOPA prior to 
transplantation as compared to animals that received graft treatment only. Another study 
demonstrated that pre-exposure to chronic L-DOPA treatment significantly reduces 
behavioural and neurochemical efficacy of foetal DA neuron grafts (Steece-Collier et 
al., 2009)  These findings suggest that the A9 type DA neuron-enriched grafts can be 
derived from younger embryos and may be the key to an effective PD cell replacement 
therapy but that long-term L-DOPA treatment prior to transplantation might hamper the 
positive outcome.  
1.5.2 Foetal cell transplantation in patients 
Human foetal DA neurons used in transplantation research were derived from 
embryos collected from surgical terminations of pregnancies which raised important 
ethical questions that still remain subject to active debate (Boer, 1994). Nevertheless, 
based on the evidence obtained from animal studies the first open clinical trial of human 
foetal VM transplants started in 1989 in Sweden where 2 patients with MPTP-induced 
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parkinsonism received grafts into the putamen (Lindvall et al., 1989, Lindvall et al., 
1990). The patients showed significant clinical improvement and positron emission 
tomography (PET) detected increased 
18
fluorodopa (
18
F-dopa) binding in the putamen 6 
months after the surgery, marking the first milestone in the history of cell 
transplantation. A series of open labelled (Freed et al., 1992, Lindvall et al., 1992, 
Spencer et al., 1992, Molina et al., 1994, Peschanski et al., 1994, Freeman et al., 1995a, 
Levivier et al., 1997, Wenning et al., 1997, Kordower et al., 1998, Hagell et al., 1999, 
Brundin et al., 2000b, Mendez et al., 2002, Mendez et al., 2005) and two double-blind 
(Freed et al., 2001, Olanow et al., 2003) clinical studies have been conducted in several 
centres worldwide over the next 13 years, with more than 200 patients receiving foetal 
tissue transplants. These studies have provided proof of principle that (i) the grafted DA 
neurons can survive and reinnervate the surrounding tissue; (ii) the graft can integrate 
with the host brain and restore regulated DA release in a physiological manner; (iii) 
transplantation therapy can achieve measurable clinical improvement in a subset of 
patients. The next clinical trial has already been initiated with the transplantation 
surgeries scheduled to take place in 2014 (TransEUro). 
Behavioural improvements such as increased length of the “on” phase were 
detectable quite early, between 3 to 6 months after transplantation (Lindvall et al., 1989, 
Levivier et al., 1997). In most cases PET scans detected increased 
18
F-dopa uptake in 
the putamen and/or the caudate nucleus correlated with significant clinical 
improvements and in several cases patients were able to stop L-DOPA treatment 
(Lindvall et al., 1994). The preference for the postcomissural putamen and caudate 
nucleus as transplantation targets stems from the connectivity of these two brain regions 
with the motor and associative cortices, respectively. The putamen was the primary 
transplantation target both in open label and double-blind clinical trials and in some 
cases patients also received transplants into either the caudate nucleus or the SNpc in 
open label studies. American double-blind studies showed significant behavioural 
improvement among younger patients (60 years old or younger) but not in older patients 
and 15% of patients developed graft induced dyskinesias (GIDs) even after 
discontinuation of L-DOPA treatment (Freed et al., 2001). The second double-blind 
study, demonstrated clinical improvement in a subset of patients with milder PD and 
detected GIDs in 54% of grafted patients (Olanow et al., 2003). Exclusion of the 
caudate nucleus as the transplantation target might have contributed to the lower clinical 
improvement observed in these two studies because transplants in caudate nucleus alone 
were shown to be capable of inducing behavioural recovery in PD patients several 
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months after transplantation and maintaining it for 5 years (Lopez-Lozano et al., 1997). 
Some patients developed too severe dyskinesias and had to undergo DBS treatment of 
the GPi which resolved the side effects (Graff-Radford et al., 2006, Herzog et al., 2008). 
In both these studies, grafts were transplanted as solid tissue pieces, a transplantation 
method associated with significantly increased hyperkinetic movements in 6-OHDA 
lesioned rats (Steece-Collier et al., 2003). Mild GIDs were observed 3 years after 
transplantation in a subset of patients grafted in Swedish trials (Hagell et al., 2002). 
GIDs were an unexpected finding which halted clinical transplantation research for over 
10 years and forced scientists to go back to the bench and re-evaluate the methods.  
Post-mortem studies in two patients, grafted as part of double-blind trials, who 
continued to decline after transplantation surgery demonstrated reduced levels of TH 
and DAT immunoreactivity in the transplants and the presence of immune markers in 
the grafts despite good neuron viability (Kordower et al., 2008a, Kordower et al., 
2008b). Also, termination of immunosuppressive cyclosporine treatment reduced 
efficacy of some foetal transplants (Olanow et al., 2003). Solid tissue grafting approach 
used in these studies was implicated in the host immune response in animal studies 
(Redmond et al., 2008). This suggests that slow ongoing immune response is facilitated 
by solid tissue transplantation method and might detrimentally influence grafted foetal 
neuron function contributing to the disappointingly low clinical improvement in PD 
patients.  
Nevertheless, data from grafted patients continues to emerge. Despite an 
ongoing disease progression, [11C]-raclopride PET scans of the synaptic DA release by 
grafted neurons demonstrated maintenance of restored levels of D2 receptor binding in a 
patient 10 years after transplantation surgery (Piccini et al., 1999). Patients, who already 
showed modest clinical improvements within the first year after transplantation surgery, 
continued to improve further for the next 2 years and some showed an additional 
increase in the 
18
F-dopa uptake in the putamen since the first PET scan (Lindvall et al., 
1994, Piccini et al., 2000). These findings suggest that clinical recovery in PD patients 
depends on DA delivery to the putamen as well as the functional integration of the graft 
within the host brain. Robust, albeit quite low, survival of transplanted DA neurons, 
typically only 5 – 10%, was observed in post-mortem studies of grafted patients from 
different research centres (Kordower et al., 1996, Kordower et al., 1997b, Mendez et al., 
2005, Kordower et al., 2008a, Kordower et al., 2008b, Li et al., 2008, Mendez et al., 
2008).  
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Post-mortem analysis of the brain tissue from two patients demonstrated that, 
although numerous TH-ir cells were present in the implants, PD-induced LB pathology 
transferred from the host tissue into grafted nigral neurons in 14-year-old transplants 
from double-blind clinical trials (Kordower et al., 2008a, Kordower et al., 2008b). A 
Swedish study showed the presence of α-synuclein-ir LBs in some grafted neurons 
while the majority of DA neurons remained unimpaired in two patients 11 – 16 years 
after surgery (Li et al., 2008). These observations provided the first evidence that PD 
was an ongoing process, which could propagate from the host to graft tissue and affect 
both in a similar manner while leaving the grafts functional until death. In contrast, 
another post-mortem analysis of 5 PD patients 9 – 14 years after transplantation 
revealed no LB pathology in the implanted neurons and excellent survival of DA 
neurons with very little inflammation in the grafts (Mendez et al., 2008). These findings 
are important for the understanding of the aetiology of pathogenesis in VM DA neurons 
and future use of cell transplantation therapy. 
Both A9 and A10 type DA neurons were found in the grafts transplanted into the 
post-commissural putamen and the SNpc (Mendez et al., 2005). A higher proportion of 
TH-ir neurons coexpressed Girk2 (68 – 71%) than calbindin (26 – 48%) in grafts in the 
putamen and fewer TH-labelled neurons coexpressed Girk2 in grafts in the SNpc. 
Girk2-ir neurons were predominately found in the periphery of the graft while in the 
centre of the graft DA neurons were more often calbindin-ir or did not co-label with 
either Girk2 or calbindin. DA neuron survival was 15 – 30% in grafts in the putamen in 
contrast with 4 – 8% survival in transplants in the SNpc suggesting that differences may 
exist in survival depending on region specific factors and conditions. Another study 
from the same centre demonstrated similar Girk2 and calbindin expression patterns in 
VM DA neurons grafted into the putamen (Mendez et al., 2008). Although grafts also 
contained 5-HT neurons, no GIDs were observed in any subjects. Uncontrolled release 
of DA by 5-HT neurons in the grafts was shown to exacerbate LIDs in animals and to 
influence apomorphine-induced dyskinesias in animal models of GIDs (Carlsson et al., 
2007, Carta et al., 2007). Also, in PD patients, who showed functional improvements 
after receiving a cell transplant, post-mortem analysis revealed astrocytes around and 
inside the VM grafts, potentially graft-derived astrocytes (Mendez et al., 2005). 
Astrocytes play a crucial role in the development of DA VM neurons and animal studies 
demonstrated that immortalized human foetal VM astrocytes potentiated in vitro 
differentiation of human embryonic stem cells (hESCs) into engraftable A9 type DA 
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neurons (Roy et al., 2006). However, it is still unclear whether graft-derived astrocytes 
are crucial for the efficacy of cell transplantation therapy. 
 Foetal DA VM transplantation has achieved the most clinical improvement in 
younger patients as demonstrated by several studies discussed above and still presents a 
promising treatment for PD. However, a very limited supply of foetal tissue, a 
requirement for six to eight donors per unilateral transplantation, a lack of full quality 
control, logistic challenges, a high variability in functional outcomes, and significant 
ethical concerns, all have prevented the use of human embryonic tissues for 
transplantation from being developed into a therapy. Hence, we see a widespread search 
for alternative sources of effective transplantable tissues that circumvent or avoid these 
constraints. 
1.5.3 Alternative cell sources for transplantation therapy 
Human neural progenitor cells (HNPCs) represent an alternative source of 
transplantable neurons for cell therapy in PD. HNPCs derived from the embryonic 
forebrain can be easily expanded in large numbers and maintained long-term in vitro 
(Svendsen et al., 1998, Carpenter et al., 1999, Caldwell et al., 2001). When transplanted 
into the adult rat brain, they were shown to exhibit high survival rates (Fricker et al., 
1999, Englund et al., 2002). However, HNPCs survived poorly when transplanted into 
the DA-depleted striatum of 6-OHDA lesioned rats and did not achieve significant 
behavioural recovery (Svendsen et al., 1997). Also, transplants in the SNpc of 6-OHDA 
lesioned rats did not improve behavioural recovery in animals despite good cell survival 
rates and significant degree of cell migration towards the striatum along the nigrostriatal 
pathway (Burnstein et al., 2004). Survival rates of HNPCs were greatly improved when 
the tissue was grafted into the STN of 6-OHDA lesioned rats and correlated with a 
significant recovery of the amphetamine-induced rotational behaviour (Anderson and 
Caldwell, 2007). Once again, it has been demonstrated that the STN plays a key role in 
the recovery of the normal basal ganglia function. Grafted cells produced vascular 
endothelial growth factor (VEGF), showed extensive migration and were observed 
throughout the grafted hemisphere including the striatum. HNPCs are believed to 
support the host environment and promote neuroprotection by remaining in the 
immature state and releasing trophic factors (Ourednik and Ourednik, 2004, Pluchino et 
al., 2005). This therapy merely plays a supportive role in the recovery process and, on 
its own, is not sufficient to address PD-induced neurodegeneration and associated 
behavioural deficits. 
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Stem cell transplantation is a promising therapy for PD but research in this field 
is still in its infancy. hESCs can potentially provide an unlimited supply of DA neurons 
for transplantation generated in standardised and quality-controlled conditions, but they 
are not yet as efficient as human foetal VM tissue in yielding high DA neuron survival 
rates after transplantation. One reason for this might be that stem cell grafts do not 
contain the range of cell types found in the developing midbrain, many or all of which 
might be involved in the differentiation and survival of dopamine neurons.  
We already know that human pluripotent stem cells (hPSCs) can be 
differentiated into midbrain DA neurons (Perrier et al., 2004), but when transplanted 
into the striatum stem cell-derived DA neurons generally show poorer in vivo 
performance than foetal transplants (Roy et al., 2006, Cho et al., 2008). Recent studies 
demonstrated successful induction of DA neurons from VM floor plate (FP) precursor 
cells derived from either hESCs or induced pluripotent stem cells [iPSCs from a 
sporadic PD patient; (Kriks et al., 2011)]. In vivo survival and function of these FP-
derived human DA neurons was demonstrated in PD models using three host species 
and, while the yield of DA neurons in the grafts was improved and amphetamine-
induced rotational behaviour was fully restored, behavioural deficits in stepping and 
cylinder tests were only partially restored. Both A9 and A10 type DA neurons were 
present in the grafts. Another study demonstrated that co-grafts of rat foetal VM and 
pituitary homeobox 3 (Pitx3) overexpressing neural stem cells were enriched for the A9 
type DA neurons and achieved improved behavioural recovery in 6-OHDA lesioned rats  
(O'Keeffe et al., 2008). These results highlight the importance of the A9 type DA 
neurons in mediating the functional benefits of cell transplants in PD. The enhancement 
of the survival and function as well as safety of stem cell-derived DA grafts still 
remains a major challenge faced by the scientific community before this therapy can be 
brought into the clinic.  
1.6 Development of mesencephalic dopamine neurons 
An understanding of the normal development of DA neurons in the VM is 
thought to be the key to determining the cell population most suitable for DA neuron 
transplantation therapy in PD. Neurogenesis of VM DA neurons and the formation of 
the nigrostriatal pathway are directed by a combination of spatially and temporally 
restricted chemical cues. Hence, the optimal cell type for transplantation may be found 
in different VM regions at different developmental stages and therefore may express 
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distinct markers. Also, distinct factors may be required to correctly specify and 
differentiate DA neural progenitor cells, extracted at different time points during 
embryogenesis, into mature DA neurons to obtain appropriate innervation of the host 
brain region after transplantation. 
Neural tube pattering into four domains along the anterior-posterior and dorso-
ventral axes is the first necessary step in DA neuron development (Verney et al., 2001). 
One of these domains is the floor plate, a glia-rich structure, which in the VM gives rise 
to DA neurons (Bonilla et al., 2008). Early studies of the ontogeny of the rat VM 
demonstrated that developing DA neurons aligned along radial glial cells, which 
originated in the aqueduct region and extended to the pial surface (Shults et al., 1990). 
Recent studies in mice confirmed that floor plate cells that give rise to DA neurons 
express transcription factor Gli1 a day before they start to express glycoprotein sonic 
hedgehog (Shh) and the expression of Gli1, initially confined to the VM midline at 
embryonic day (E)7.5, expands laterally and then is downregulated in the VM midline 
(Blaess et al., 2011). Gli1, a zinc finger transcription factor in the Shh signalling 
pathway, is transcribed in cells that receive high levels of Shh signalling and are close 
to the Shh source (Bai et al., 2002). Thus, secretion of Shh directs expression of Gli1 in 
a medio-lateral direction and then expression of Shh expands in the same direction 
further directing floor plate cell specification. Being downstream of Shh signalling, Gli1 
signalling is of vital importance for normal DA neuron development (Cayuso et al., 
2006). Another similar study showed that Gli1 lineage, following lateral expansion, 
exclusively contributed to the lateral domain of the VM while Shh lineage expanded 
more broadly across the VM (Hayes et al., 2011). Also, early Gli1 and Shh lineages 
were demonstrated to specify DA neurons of the SNpc while late Gli1 and Shh lineages 
maintained their progenitor state for a longer period of time in the posterior VM to 
extend the production of DA neurons in the VTA. This step in the neurogenesis of DA 
neurons is often referred to as regionalisation.  
Further floor plate cell specification is directed by a complex combination of 
intrinsic and extracellular signals, including Wnt signalling and continued Shh 
signalling (Joksimovic et al., 2009, Hayes et al., 2011). Expression of LIM homeobox 
transcription factor 1 (Lmx1a) by floor plate cells and expression of proneural (basic 
helix-loop-helix) bLHL transcription factors Mash1 and Neurogenin-2 (Ngn2) in the 
ventricular zone within and lateral to the floor plate are essential for regulating 
neurogenesis in the developing VM (Thompson et al., 2006, Kim et al., 2007, Nelander 
et al., 2009). Loss-of-function studies demonstrated that Ngn2 is required for normal 
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VM DA neuron development and correct fate specification (Andersson et al., 2006, 
Kele et al., 2006). The forkhead/winged helix A2 (FoxA2) transcription factor is 
another key factor involved in VM DA neuron generation and its expression in the 
human floor plate extends laterally beyond the Lmx1a domain and Mash1/Ngn2 domain 
(Nelander et al., 2009). Finally, as DA neural precursor cells exit the mitotic progenitor 
stage they begin to express the orphan Nuclear receptor related-1 gene (Nurr1), Pitx3 
and TH, thereby finalising VM identity (Andersson et al., 2006, Smits et al., 2006, 
Nelander et al., 2009). Newly born VM DA neurons send axonal projections towards 
appropriate cerebral targets under the guidance of chemoattractive and chemorepulsive 
cues (Gates et al., 2004). Axonal outgrowth is initially attracted to the MFB and 
directed away from the midbrain followed by chemoattraction to the striatum. By E19, 
TH-ir fibres extend rostrally into the developing striatum in rats. In human embryos, 
first TH-ir cells in the VM are detectable 5 – 6 weeks post-conception and a large 
increase in DA neurons is observed between 6 – 8 weeks followed by a cessation of DA 
neurogenesis at 10 – 11 weeks (Freeman et al., 1991, Almqvist et al., 1996, Nelander et 
al., 2009).   
1.7 Aims of this thesis 
Although animal studies have provided a substantial amount of evidence that 
DA neuron transplantation is a promising treatment for PD, clinical trials have failed to 
report consistent clinical efficacy of this therapy in patients. Furthermore, pre-clinical 
studies showing improved yield of both global DA neurons and of functionally 
important A9 type DA neurons in grafts derived from immature VM tissue have raised 
questions about the currently accepted human embryonic donor age for this therapy.  
We are now able to distinguish A9 and A10 DA neuronal subtypes within the graft 
using co-labelling with Girk2 and calbindin, respectively. The main aim of the current 
thesis was to investigate the populations of A9 and A10 type DA neurons in the rat PD 
model, looking at how these cells are distributed within the grafts, how the DA neuron 
yields are affected by the donor age of the tissue implanted, and whether or not survival 
and differentiation of the implanted cells are influenced by the host environment.  
This thesis focuses on the rat foetal VM transplantation in the 6-OHDA,  
unilaterally lesioned rat model and characterises in depth the A9 and A10 type DA 
neuron subpopulations in the VM grafts. Since grafts derived from younger donor 
embryos significantly improve DA neuron yield, this work first measures the impact of 
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the donor age on the neuronal composition of intrastriatal rat VM grafts and the 
distribution of A9 type and A10 type DA neurons within the graft. Following on from 
this, commitment of DA neural precursor cells to the two DA neuron phenotypes, and 
how this is affected by the host environment was investigated, by grafting rat E12 and 
E14 VM tissue into different cerebral targets. Brain regions were chosen that receive 
either the A9 type DA, A10 type DA or NA innervation and the influence of these 
different transplantation sites on the neuronal composition of VM grafts was analysed. 
Finally, the ability of immature VM DA neuronal cell precursors to proliferate in the 
host and give rise to the two DA neuron subpopulations was determined by birth dating 
cells within intrastriatal rat E12 and E14 VM grafts after transplantation. 
The main aims of this PhD work were: 
1. To assess the impact of the donor age on the A9 type and A10 type DA neuron 
populations in intrastriatal VM grafts (Chapter 3) 
2. To investigate the influence of the transplantation site on the DA neuron 
phenotypes in the grafts (Chapter 4) 
3. To determine whether DA cell birth after transplantation gave rise to a specific 
DA neuron subpopulation in the grafts (Chapter 5) 
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2.1 Experimental animals 
All experiments were conducted under UK Home Office personal and project 
licences in accordance with the requirements of the UK Animal (Scientific Procedures) 
Act 1986. Every effort was made to minimise the number of animals used and their 
suffering. Sprague Dawley (SD) rats, weighing 200 – 250 g, were supplied by Charles 
River UK and housed under standard conditions with ad libitum access to food (14% 
protein, Harlan) and water under 14h:8h light-dark cycle. Female (4 per cage) and male 
(1 per cage) rats were housed in standard cages (length: 54 cm, width: 37 cm, depth: 21 
cm) lined with hygienic animal bedding (Lignocel). Animals were provided with a 
cardboard tube and wood stick for environmental enrichment. 
2.2 Procurement of donor embryos 
2.2.1 In-house breeding protocol 
Pregnant SD dams were bred in-house following a previously established 
protocol (Weyrauch et al., 2009). On the morning of breeding day, females in oestrus 
were established by the vaginal lavage method. The rat was slightly restrained in one 
hand, with her back to the palm, to obtain a vaginal smear. A fire-polished glass pipette 
with a rubber bulb was used to flush 200 µl of sterile saline (0.9% Sodium chloride, 
Baxter) into the vagina which was then sucked back in to the pipette. The collected 
sample was then smeared onto a glass slide and analysed under a Leica light microscope 
with the condenser diaphragm closed to provide differential contrast. The rat was 
designated as being oestrus cycle if the sample contained predominantly cornified 
epithelial cells with few uncornified epithelial cells and no inflammatory cells (Figure 
2.1). Eligible females were paired with a male at 1:1 ratio in the male’s home cage for a 
maximum of three hours, typically between 10:30 a.m. and 1:30 p.m. Females then 
returned to their home cages and the day of mating was recorded as E0 (Weyrauch, 
2009). 
Figure 2.1 Photomicrograph of the vaginal 
smear illustrating oestrus stage. Scale bar: 100 
µm [modified from Weyrauch et al (2009)]. 
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2.2.2 Confirmation of pregnancy 
At 10 a.m. on the morning of E12, rats were lightly anaesthetised in an induction 
chamber with 2-3% Isoflurane (AbbVie Ltd) in oxygen and the pregnancy was 
confirmed if palpation of the abdomen revealed several swellings in the uterine horns. 
Embryos were harvested straight away if the desired embryonic age was E12, 
alternatively pregnant dams returned to their home cages until E14.  
2.2.3 Procurement of embryos 
Pregnant dams were terminally anaesthetised with an intra-peritoneal (i.p.) 
injection of 400 mg/kg pentobarbital sodium (200 mg/ml Euthatal, Merial Animal 
Health Ltd) and subsequently killed by cervical dislocation. The embryos were excised 
from the uterine horns and transferred to the laboratory in Hanks’ balanced salt solution 
(HBSS, Gibco). The embryos were placed on their side in HBSS in a petri dish and their 
crown-rump length (CRL; Figure 2.2) was measured under a Leica binocular 
microscope using a ruler placed under the petri dish. The short mating-period protocol 
used here produced embryos with a mean CRL of 6.1 ± 0.36 mm at E12 and 11.21 ± 
0.44 mm at E14 (CRL reported as mean ± standard deviation), even though E14 
embryos were slightly bigger than expected, results were comparable to a recently 
updated staging scale  (Torres et al., 2008b).    
2.3 Surgery 
Animals were first anaesthetised in the induction chamber with 3-4% Isoflurane 
in oxygen prior to being transferred to a Kopf stereotaxic frame where anaesthesia was 
maintained at 2-3% Isoflurane in a 2:1 mixture of oxygen and nitrous oxide. Blunt ear 
bars were used to restrain the animal in the frame with the nose bar set at -4.5 mm 
below the intra-aural line. Animals received post-operative analgesia during each 
surgical session. Once in the frame rats were injected subcutaneously (s.c.) with 30 µl of 
Metacam (Boehringer Ingelheim) using an insulin syringe. Also, 5 ml of 0.18% sodium 
Figure 2.2 Schematic representation of the 
CRL measurement in an embryo (adapted 
from Dunnett and Bjorklund, 1992).  
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chloride, 4% glucose (Aquapharm) were injected s.c. for hydration. Upon completion of 
the surgery, the wound was cleaned and sutured with Vicryl 4-0 sutures [coated 
VICRYL® (polyglactin 910) Sutures, ETHICON, VWR] and the animal was placed in 
a recovery chamber at 30˚ C until fully awake and mobile. Health and weight of the 
animals were monitored daily for first 3 days following the surgery and then weekly.    
2.3.1 Medial forebrain bundle lesions 
For the unilateral nigro-striatal lesion, the animals received an intra-cerebral 
injection of 6-OHDA into the right MFB (Figure 2.3) following a recently refined 
protocol (Torres et al., 2011). The neurotoxin 6-OHDA was supplied as 5 mg of 
hydrobromide salt powder, of which 0.2 mg (4%) was ascorbic acid, added for 
stabilisation (Sigma-Aldrich). The toxin was dissolved in 0.8 ml of sterile saline, 
divided into 100 µl aliquots and frozen quickly for future use. The resulting solution 
contained 25 mM 6-OHDA (equivalent to 5.14 mg/ml free-base weight of 6-OHDA) 
and 0.025% ascorbic acid. Each animal received a single injection of 3 µl of the 6-
OHDA toxin at the following stereotaxic coordinates: -4.0 mm caudal from bregma 
(AP); -1.3 mm lateral from the midline (ML); -7.0 mm deep from dura (DV). The toxin 
was delivered at a rate of 1 µl/min using a 30 gauge stainless steel cannula connected by 
polyethylene tubing to a 10 µl Hamilton syringe mounted on a Harvard micro-drive 
infusion pump. The toxin was allowed to diffuse for 2 minutes after the injection before 
the cannula was carefully withdrawn.  
A B C 
Figure 2.3 Photomicrographs of TH-immunoreactivity in coronal sections through the adult rat 
brain. Administration of the 6-OHDA neurotoxin into ascending DA fibres in the right MFB 
resulted in ipsilateral (A) DA depletion in the striatum and (B) retrograde DA neuron death in 
the substantia nigra (C) Grafted embryonic VM tissue partially reinstated lost DA supply and 
innervation of the striatum (E12 VM graft is shown here). Scale bar: 1 mm. 
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Figure 2.4 Dissection of the VM tissue from an embryo (modified from Dunnett and Bjorklund 
1992). (A) Using scissors, the embryo was decapitated and a cut was made between the forebrain 
and the eye. (B) The skin and skull were pulled out with the forceps and (C) the brain was 
removed. (D-G) The VM was dissected from the mesencephalic flexure (m) using tectum (tc) and 
thalamus (th) as landmarks. (H) The ventral meningeal layer of tissue was carefully removed from 
the E14 VM pieces. 
2.3.2. Ventral mesencephalon transplantation 
The VM tissue was derived from either E12 or E14 rat embryos and DA cell-
rich grafts were prepared as a cell suspension according to a standard protocol (Dunnett 
and Bjorklund, 1992, 1997). After the CRL measurements had been obtained, embryos 
were decapitated and the brains were collected in HBSS. Using scissors and fine point 
forceps, each VM was dissected as shown in Figure 2.4. Note that the ventral meningeal 
layer of tissue was removed from the E14 VM pieces but was included in E12 VM 
dissections because it was too friable to be removed. 
Pooled VMs from all donors in each litter were washed in HBSS and then 
incubated in 500 µl of pre-heated (37˚ C) 0.1% trypsin (Trypsine EDTQ 0.05%, Gibco) 
with 0.05% DNAse (Deoxyribonuclease I from bovine pancreas, Sigma-Aldrich) in 
Dulbecco’s minimum Eagle Medium F-12 (DMEM, Gibco) for 20 minutes at 37˚ C. 
The trypsin was then removed and the tissue incubated in 500 µl of DNAse (0.05% in 
DMEM medium) for 5 minutes at 37˚ C. After removal of the supernatant, the tissue 
was suspended in 200 µl of DNAse and gently triturated with 1000 µl and 200 µl Gilson 
pipettes to create a homogenous single cell suspension. Cell viability was assessed from 
2 x 2 µl samples of the cell suspension each diluted with 8 µl of 0.4% Trypan blue 
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solution (Sigma) and counting cells using a haemocytometer slide. The cell suspension 
was then centrifuged at 2,000 rpm for 2 minutes, after which all the supernatant was 
removed, and the pellet of cells was re-suspended in a sufficient volume of 
DMEM/DNAse to obtain the required concentration of either one full VM (Chapters 3 
and 5) or one half of a VM (Chapter 4) per 2 μl. The final cell suspension was stored at 
room temperature during surgery. As expected, Figure 2.5 shows that E12 rat embryos 
contained fewer cells per VM than E14 rat embryos (Mann Whitney test, p<0.001). 
Note that the numbers of cells per VM in each experiment were consistently lower than 
those previously reported for SD rat embryos of the same age (Torres et al., 2007). This 
highlights the importance of user-to-user variability in embryonic dissections in cell 
transplantation therapy research. 
Each animal was transplanted with the number of cells equivalent to the same 
proportion of the VM in 2 µl of the cell suspension to allow a valid comparison to be 
made between grafts of different donor ages. Depending on the experiment, grafts were 
implanted into either the DA depleted striatum alone or, in combination with grafts into 
the nucleus accumbens (N.Acc.), PFC and hippocampus. Each chapter specifies the 
stereotaxic co-ordinates used, as determined from the stereotaxic rat brain atlas (Paxinos 
and Watson, 2003). Cells were transplanted as a single deposit at 2 depths 0.5 mm apart. 
The cell suspension was injected into the brain at a rate of 1 µl/min over 2 minutes 
using the same set up as for the 6-OHDA lesion surgery. After the first minute, the 
cannula was raised 0.5 mm and the second half of cells was injected at the new depth. 
The cannula was left in place for 3 minutes after the injection before being withdrawn to 
Figure 2.5 Average numbers of cells per VM dissected from E12 and E14 rat embryos. Data 
presented as group mean ± standard error of mean (SEM), significance level: *** p<0.001. 
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prevent drawback of the cells up the needle track. As shown in Figure 2.3C, this method 
achieved a good distribution of the cells within the host striatum.    
2.4 Amphetamine-induced rotations 
The extent of DA depletion in the striatum was evaluated 2 and 4 weeks post-
lesion based on the drug-induced rotational behaviour. Amphetamine 
(Methamphetamine hydrochloride, Sigma) was dissolved is sterile saline at 2.5mg/ml 
and administered via i.p. injection at a dose of 1ml/kg, immediately prior to testing. The 
animals were placed in 30 cm round bottomed bowls housed in 50 cm high perspex 
cylinders and harnessed to an automated rotometer system (Rotomax System, AccuScan 
Instruments Inc.) following a previously established protocol (Ungerstedt and 
Arbuthnott, 1970). The collected data is reported as the net number of rotations 
(ipsilateral minus contralateral) over the full 90 min session. Rats with net rotation 
scores of ≥ 540 turns in the second session were deemed sufficiently depleted of DA 
and were included in the experiments. This threshold has been reported as a reliable 
indicator of animals with stable lesions and more than 95% DA neuron loss in the 
ipsilateral SNpc (Dowd and Dunnett, 2005a, Torres et al., 2011). Grafted rats were 
tested 4 and 6 weeks post-implantation using the same method. Drug-induced rotation 
tests were performed blind to the treatment of the animals.   
2.5 Perfusion 
Upon completion of the experiment, the animals were terminally anaesthetised 
with the i.p. injection of 400 mg/kg Euthatal. When the rat no longer responded to both 
tail pinch and foot pinch the thorax of the animal was opened up to expose the heart. A 
small haemostat clamp was used to clamp the descending aorta and prevent flow of 
solutions to the lower body. The perfusion needle was then inserted in to the left 
ventricle via a small incision, and the right atrium was cut to allow egress of the 
perfusion solutions. Solutions were then delivered using a peristaltic pump at a flow rate 
of 50 ml/min. The upper body vasculature was first flushed with 100 ml of 0.1M 
phosphate buffered saline [PBS; 90 g of Di-Sodium hydrogen orthophosphate (VWR 
Chemicals) and 45 g of Sodium chloride (Fisher Scientific) in a final volume of 5 L of 
distilled water adjusted to pH 7.3 with orthophosphoric acid (Fisher Scientific)]. 
Flushing of the vasculature with PBS was followed by perfusion with 250 ml of 1.5% 
paraformaldehyde (PFA, Fisher Scientific) made in the same 0.1M PBS delivered over 
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a 5 min period. After perfusion the brains were removed from the skull and post-fixed 
in the same fixative solution overnight before being transferred into a solution of 25% 
sucrose in PBS. After equilibration in the sucrose solution, 40 µm thick coronal sections 
through the brain were cut on a Leica freezing stage sledge microtome, collected into 
0.05% sodium azide (Fisher) in 0.1M TRIS buffered saline [TBS; 48 g TRIS base 
(Sigma), 36 g Sodium chloride in a final volume of 4 L of distilled water adjusted to pH 
7.4 with concentrated hydrochloric acid (HCl; Fisher Scientific)], and stored at +4˚ C 
prior to staining (Chapters 2 and 3). In the experiment described in Chapter 5, brain 
sections were stored at -20˚ C in a cryoprotective solution [4.36 g Di-Sodium hydrogen 
orthophosphate and 1.256 g of Sodium dihydrogen phosphate (Fisher Scientific) in a 
final volume of 800 ml of 30% Glycol (Sigma-Aldrich), 30% Glycerol (Sigma-Aldrich) 
in distilled water]. 
2.6 Histological Methods 
2.6.1 Immunohistochemistry 
All IHC was performed on free floating sections on an automated shaker. Each 
chapter contains detailed information on the number of sections used (i.e. either a 1:6 or 
a 1:12 series of sections) and the antibodies used. In each experiment, free floating 
sections were collected in 15 ml Perspex containers (Greiner) capped using a fine nylon 
mesh that allowed the pots to be filled and emptied of solutions, whilst retaining the 
sections. Series of sections in the same experiment were batch processed simultaneously 
using the same solutions of antibodies to ensure that incubation times and washes were 
identical for all brains.  
Sections were first washed in TBS (3 x 10 min), then transferred into a solution 
of distilled water with 10% Methanol (Fisher) and 10% hydrogen peroxide (30% 
hydrogen peroxide solution, VWR) for 5 minutes to quench endogenous peroxidases 
that might interfere with the final horseradish peroxidase colour reaction. After another 
three washes the sections were incubated for 1 hour in a blocking solution of 3% normal 
horse serum (NHS, Gibco) in TXTBS [0.2% Triton X-100 (Sigma) in TBS, pH 7.4] to 
prevent non-specific binding of antibodies to the section. Subsequently, the sections 
were bathed in 1% NHS in TXTBS solution containing the primary antibody for 60 
hours at +4˚C with agitation. After thorough washing in TBS (3 x 10 min), tissue 
sections were immersed in the secondary biotinylated antibody solution containing 1% 
NHS in TBS overnight at room temperature. On the next morning, three washes of TBS 
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followed before the Vectastain Elite ABC solution (Vector) with 1% NHS in TBS was 
applied for 3 hours. Brain sections were rinsed in TBS (3 x 10 min) and then in 0.05M 
TRIS non-saline buffer [2 x 5 min; (TNS, pH 7.4)] prior to being incubated in a 0.8% 
solution of 3.3’ – Diaminobenzidine tetrahydrochloride hydrate (DAB, Sigma) in TNS 
with 0.03% hydrogen peroxide for 5 – 10 minutes until the strong brown specific 
staining was complete. The sections were given a final 3 x 10 min washes in TBS, 
before being mounted on gelatine coated microscope slides and allowed to dry 
overnight at room temperature. The next day, slides were dehydrated by immersion in 
an ascending series of alcohols [75%, 90%, and 100% ethanol (Sigma) in distilled 
water], for 10 minutes each, then immersed in xylene (Fisher Scientific) 10 minutes to 
clear the tissue and cover-slipped using di-styrene plasticizer and xylene mounting 
medium (DPX, VWR). 
Fluorescent IHC staining was performed as described above with the difference 
that there was no quenching step at the beginning of the staining process. Also, 
following the application of the tertiary antibody sections were washed in TBS (3 x 10 
min) and mounted on microscope slides in TNS to avoid formation of salt crystals 
within the tissue that would fluoresce under the microscope. In double and triple 
staining, primary antibodies where applied together, for all antibody concentrations and 
pairings see Table 2.1.  
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Primary Secondary Tertiary 
Name, 
Concentration 
Supplier 
Name, 1:200 
Concentration 
Supplier 
Name, 1:200 
Concentration 
Supplier 
Immunoperoxidase Staining (Chapters 3, 4 and 5) 
Rabbit anti-
TH, 1:2000 
Millipore 
Biotynilated 
anti-Rb 
Vector 
Streptavidin-
biotin-
horseradish 
peroxidase 
Vector 
Mouse anti-
NeuN, 1:1000 
Biotynilated 
anti-Ms 
Sheep anti-
BrdU, 1:1000 
Abcam 
Biotynilated 
anti-Sh 
Double TH / Girk2 fluorescence labelling (Chapters 3 and 4) 
Mouse anti-
TH, 1:1000 
Millipore 
Anti-Ms 
Alexa 594 or 
488 
Molecular 
Probes 
 
Rabbit anti-
Girk2, 1:250 
Alomone 
Biotynilated 
anti-Rb 
Vector 
Steptavidin 
Cy2 or Cy3 
Jackson 
Double TH / Calbindin fluorescence labelling (Chapters 3 and 4) 
Rabbit anti-
TH, 1:2000 
Millipore 
Anti-Rb 
Alexa 488 
Molecular 
Probes 
 
Mouse anti-
Calbindin, 
1:10 000 
Sigma 
Biotynilated 
anti-Ms 
Vector 
Steptavidin 
Cy3 
Jackson 
Double Girk2 / Calbindin fluorescence labelling (Chapter 3) 
Rabbit anti-
Girk2, 1:250 
Alomone 
Anti-Rb 
Alexa 488 
Molecular 
Probes 
 
Mouse anti-
Calbindin, 
1:10 000 
Sigma 
Biotynilated 
anti-Ms 
Vector 
Steptavidin 
Cy3 
Jackson 
Triple BrdU / Girk2 / TH (Chapter 5) 
Sheep anti-
BrdU, 1:1000 
Abcam 
Anti-Gt  
Alexa 488 Molecular 
Probes 
 
Rabbit anti-
Girk2, 1:250 
Alomone 
Anti-Rb 
Alexa 594 
Mouse anti-
TH, 1:1000 
Millipore 
Biotynilated 
anti-Ms 
Vector 
Streptavidin 
Alexa 350 
Molecular 
Probes 
Triple BrdU / calbindin / TH (Chapter 5) 
Sheep anti-
BrdU, 1:1000 
Abcam 
Anti-Gt  
Alexa 488 
Molecular 
Probes 
 Mouse anti-
Calbindin, 
1:10 000 
Sigma 
Anti-Ms 
Alexa 594 
Rabbit anti-
TH, 1:2000 
Millipore 
Biotynilated 
anti-Rb 
Vector 
Streptavidin 
Alexa 350 
Molecular 
Probes 
Table 2.1 A summary of antibodies used for immunohistochemistry 
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2.6.2 Cresyl Violet Staining 
Cresyl Violet (Nissl) stain was used for anatomical analysis of sections and 
labelling of all grafted neurons where Neuronal Nuclei (NeuN) staining could not be 
performed. The brain sections were mounted on gelatine coated microscope slides, dried 
overnight, dehydrated in an ascending series of alcohols (75%, 95% and 100% ethanol; 
10 minutes each) before delipidisation in 50% chloroform (Sigma) solution in ethanol 
for 20 minutes. The tissue was then re-hydrated in a descending series of 95% ethanol, 
75% ethanol and distilled water (10 minutes each) prior to being stained in 0.7% cresyl 
fast violet (CV, Sigma) solution in distilled water with 0.5% sodium acetate (Sigma) at 
3.5 pH. The sections were saturated with the dye, then washed in distilled water and the 
excess dye was differentially removed during dehydration in the ascending series of 
alcohols, for a minimum of five minutes in each alcohol solution, adjusted to obtain the 
optimal degree of staining. Slides were then cleared in xylene before cover-slipping in 
DPX. 
2.6.3 Haemotoxylin Stain 
Following 5-Bromodeoxyuridine (BrdU, Sigma-Aldrich) DAB IHC, the brain 
sections were mounted onto gelatine coated glass slides and allowed to dry overnight 
before exposure to a solution of Mayers Haemalum (Raymond A Lamb Ltd) for 1 
minute. The slides were then washed in distilled water for 5 minutes and the stain fixed 
by placing the slides in a container with running tap water for 20 minutes. The sections 
were then dehydrated in the ascending concentrations of alcohols, and slides cover-
slipped as described above. 
2.7 BrdU Methods 
2.7.1 BrdU incorporation 
BrdU was added to sterile saline with 10% ethanol at a concentration of 60 
mg/ml, sonicated for 15 minutes and then heated in a water bath at 55º C for 1.5-2 hours 
until fully dissolved. Immediately after that, BrdU was administered via i.p. injection 
(120 mg/kg) into grafted animals. 
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2.7.2 BrdU immunohistochemistry 
To detect BrdU post-mortem, free-floating sections were washed in TBS and 
incubated in 1M HCl for 1 hour in a 37ºC water bath. This unfolds double stranded 
deoxyribonucleic acid (DNA) and allows the primary antibody to attach to the BrdU. 
The brain sections were then washed in TBS to remove residual HCl before proceeding 
with the standard IHC protocol. 
2.8 Quantification and microscopy 
All quantifications of cell populations in the grafts were performed blind to the 
experimental condition.  
2.8.1 Light microscopy 
TH-ir neurons were counted from all sections containing the graft on a Leica 
DMRB light microscope at x10 magnification and BrdU-ir nuclei in grafted cells were 
quantified at x20 magnification using a 10x10 eyepiece graticule. Total numbers of DA 
neurons and BrdU-ir cells in the grafts were estimated using the Abercrombie correction 
formula (Abercrombie, 1946):  
where n = number of counted cells, F = 1/frequency of sections (1/6 or 1/12), T 
= thickness of the section (40 µm), d = mean diameter of cells.  
Volumes of grafts were calculated from cross-sectional areas of grafts measured 
on a 1:6 or 1:12 series of TH-stained sections through the entire graft as follows: 
where A = area of the graft, T = thickness of the section (40 µm), F = 1/section 
frequency.    
Neuron quantification in the grafts from CV and NeuN stained sections was 
carried out on an automated stereology microscope (Olympus BX50) at x100 
magnification using image analysis C.A.S.T. – grid software version 1.6 (Olympus). 
The area of the graft was outlined by the user and the software set up randomised 
statistical sampling within the defined area so that at least 150-200 cells per animal were 
counted from at least 200 sampling fields. Sampling parameters, i.e. area of the 
sampling frame (285 µm
2
) and step size between the samples, were held constant for all 
𝑁 = 𝑛 × 𝐹 ×
𝑇
𝑇 + 𝑑
  (1) 
𝑉 = 𝐴 × 𝑇 × 𝐹 
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animals in each experiment. In the case of very small grafts, the step size was 
proportionally reduced, e.g. by 25%. The total number of neurons in the grafts was 
estimated using the following formula: 
where n = number of counted cells, A = area of the graft, a = total sampling area, 
F = 1/section frequency (12), T = thickness of the section (40 µm), d = mean diameter 
of cells. 
2.8.2 Fluorescent microscopy 
To quantify cells labelled with fluorochromes, pictures of all sections containing 
the graft were taken on a Zeiss Image Z2 microscope at x10 magnification (Figure 
2.6A) and single-, double- and triple-labelled cells were counted in Adobe Photoshop 
CS5 software (Adobe Systems, Inc). The total number of cells was estimated using the 
Abercrombie method as described in 2.8.1. Using a grid generated in Photoshop as a 
reference, a 230 µm high strip (2.5 grid divisions) was selected from the widest area of 
the graft (Figure 2.6B) and the distribution of Girk2-ir/TH-ir and Calbindin-ir/TH-ir 
neurons within the graft was analysed by counting cells in the fields sampled from 
either the periphery (25% of width of the graft from each side) or the centre (50%) of 
the graft and grouping them accordingly for statistical analysis.   
2.9 Statistical Analysis 
Statistical analyses were performed in SPSS Statistics 20 (IBM Corporation). 
Details of statistical methods used to analyse data are specified in each chapter. In short, 
general linear model (GLM) Univariate function was used to perform two-factor and 
higher analyses of variance (two-way and higher ANOVAs) to analyse data from IHC 
staining. GLM with repeated measures was used to analyse DA neuron subpopulations 
and their distribution in the grafts as well as drug-induced rotational behaviour. 
Bonferroni correction for multiple comparisons was used to reveal significant 
differences between individual groups. One-way ANOVAs were performed where 
appropriate. Results were considered to be significant if p<0.05 (*), however higher 
significance levels (** p<0.01, *** p<0.001) are also reported in the text. 
    
𝑁 =   
𝑛 × 𝐴
𝑎
 × 𝐹 ×
𝑇
𝑇 + 𝑑
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Figure 2.6 (A) Photomicrographs of all coronal sections through the striatum that contain the graft 
illustrating Girk2 (red) and TH (green) staining in the graft derived from E12 VM. TH-ir and 
Girk2-ir/TH-ir neurons were counted in Photoshop software. (B) Representation of sampled fields 
in the periphery (blue rectangles) and the centre of the graft. Scale bar: 100 µm. 
A 
B 
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Chapter 3. Analysis of Dopamine Neuron Subtypes in 
Ventral Mesencephalic Grafts 
 
Summary 
The aims of this chapter were to determine the survival and distribution of the 
A9 type and A10 type DA neurons within the implants derived from rat E12 and E14 
VM tissue. To that end, 6-OHDA unilaterally lesioned rats received grafts into the 
striatum. Younger donor grafts produced significantly more DA neurons, and more 
importantly, significantly more A9 type DA neurons, which induce functional recovery 
in lesioned animals. E14 grafts displayed a typical morphology with the majority of the 
DA neurons located in the periphery of the graft rather than in the centre while a more 
homogeneous distribution of TH-ir neurons was observed in grafts in the E12 group. 
The majority of DA neurons in the periphery of all grafts were of A9 type while in the 
centre of the graft similar proportions of DA neurons were of either subtype. This 
suggests that the striatal environment may influence differentiation of DA neural 
precursor cells and may attract A9 type DA neuron migration towards the periphery of 
the graft. 
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3.1 Introduction 
The longstanding problem of relatively poor survival of transplanted DA 
neurons has greatly hampered the use foetal VM tissue for the treatment of PD. In the 
last 30 years, researchers have refined the methods for the dissection of the VM, 
preparation of the cell suspensions, and the implantation of DA neurons leading to 
improved reproducibility of the results and increased graft survival. However, typically 
only 5 – 10% of untreated transplanted DA neurons survive in grafts both in animal 
models (Brundin et al., 2000a) and human patients (Kordower et al., 1996, Kordower et 
al., 1997a, Kordower et al., 2008a, Kordower et al., 2008b). The low DA neuron yield 
in transplants is considered to be a major reason for the poor clinical outcome of the 
transplantation therapy seen in many trials. 
In an attempt to improve the survival of transplanted DA neurons, the optimal 
embryonic donor age for DA grafts was recently readdressed. The yield of TH-ir 
neurons was greatly improved in grafts derived from the rat E12 VM tissue, which  is 2 
days younger than E14-derived grafts that have been broadly used for transplantation 
studies in animal models over the years  (Torres et al., 2007). The same study also 
reported that the similar extent of striatal reinnervation was achieved by single 
placement  grafts derived from E12 and E14 VM tissue, and the survival of DA neurons 
was boosted up to a survival rate of 35% of the expected complement of TH-ir neurons 
in the adult VM by using grafts derived from younger embryos. A similar impact of the 
donor age was observed in mouse VM grafts where DA neuron yield was 2.6-fold 
higher in grafts derived from the E10 VM tissue as compared to the E12 VM tissue 
(Bye et al., 2012). In another study, multiple rat E12 VM-derived intrastriatal grafts 
produced even higher yields of DA neurons (75% survival rate) and reinnervated a 
greater volume of the striatum but did not offer behavioural recovery beyond levels that 
were achieved by E14 VM-derived transplants (Torres et al., 2008a). This suggests that 
either a more extensive reinnervation of the stratum is required to further improve the 
behavioural recovery or that there is a limit to the behavioural recovery that can be 
achieved by DA supply to the striatum. Nevertheless, the VM tissue derived from 
younger embryos is believed to be a better source of transplantable DA neurons due to 
higher graft survival rates it is able of achieving.  
DA neural precursor cells contained in the developing VM comprise two major 
populations: A9 type DA neurons of the SNpc that give rise to the nigrostriatal pathway 
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and A10 type DA neurons of the VTA that give rise to the mesolimbic and mesocortical 
pathways (Dahlstrom and Fuxe, 1964). In the adult human and mouse VM, TH-ir 
neurons located in the SNpc are large and angular in shape and coexpress Girk2, whilst 
TH-ir neurons located in the VTA and dorsal tier of the SNpc are smaller and round in 
shape and coexpress calbindin (Thompson et al., 2005, Reyes et al., 2012). Several 
studies have demonstrated that these distinctive features of the two DA neuron 
populations seem to be retained after transplantation of embryonic VM and can be used 
to distinguish DA neurons of the SNpc- and VTA-phenotypes in the graft (Mendez et 
al., 2005, Thompson et al., 2005, Grealish et al., 2010, Bye et al., 2012). By retrograde 
axonal tracing, Thompson and colleagues showed that innervation of the DA-depleted 
striatum was derived almost exclusively from the A9 type DA neurons located in the 
periphery of the graft while the A10 type DA neurons, densely distributed within the 
centre and scattered throughout the periphery of the graft, innervated the PFC and 
probably other targets in the forebrain. Grealish and colleagues demonstrated the 
importance of the A9 type DA neurons in mediating functional recovery by showing 
that mouse grafts with a typical A9/A10 composition restored 6-OHDA lesion-induced 
deficits in rats while animals transplanted with the VM tissue which was selectively 
lacking A9 type DA neurons remained impaired. This raises the possibility that 
improved graft survival without enhanced behaviour achieved by rat E12 VM 
transplants as compared to E14 VM transplants (Torres et al., 2008a) might be linked to 
distinct patterns of preferential differentiation and/or survival of one population of DA 
neurons over another in grafts derived from different donor age embryos, an issue which 
has not yet been addressed experimentally. 
3.1.1 Aims of the chapter 
The present experiment was undertaken to determine whether donor age had an 
impact on the two DA neuron populations in transplants derived from rat E12 and E14 
VM tissue. The aims of this experiment were: 
1. To determine the A9 type and A10 type DA neuron yields in E12 and E14 VM 
grafts 
2. To investigate the distribution of the two DA neuron phenotypes within the 
grafts  
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3.2 Experimental Procedure 
All of the methods used in this study are described in Chapter 2. In this 
experiment, female SD rats (n = 18) received a unilateral lesion to the right MFB via the 
injection of 6-OHDA (Chapter 2.3.1) and the lesions were confirmed with drug-induced 
rotation tests (Chapter 2.4). The animals were allocated into 2 homogeneous groups 
based on the number of amphetamine-induced ipsilateral rotations (mean ± SEM; E12: 
1154.1 ± 119.5; E14: 1152.1 ± 116) and no statistical differences between the groups 
were confirmed with a one-way ANOVA (Group, F(1,16) = 0.00; n.s.). 
Six weeks post-lesion, two VM cell suspensions from one E12 and one E14 
litters were prepared for grafting as described in Chapter 2.3.2 (E12: 128,500 cells/VM, 
viability – 94.27%; E14: 294,600 cells/VM, viability – 92.61%). Every animal received 
a graft containing cell numbers equivalent to 1 VM in 2 µl of the cell suspension via the 
injection into the striatum at stereotaxic co-ordinates AP: +0.6 mm, ML: -3.0 mm, DV: 
-5.0 mm (Paxinos and Watson, 2003). Efficacy of grafts was assessed with drug-
induced rotation tests 4 and 6 weeks post-graft. All animals were transcardially perfused 
7 weeks after transplantation and coronal brain sections were collected for IHC 
processing (Chapter 2.5).  
A one-in-twelve series of sections was stained for CV (Chapter 2.6.2). A second 
series was stained for DAB TH; three series were processed for TH and Girk2, TH and 
calbindin, and Girk2 and calbindin, respectively, using fluorescent double labelling IHC 
(Chapter 2.6.1). Stained cells were counted blind to the experimental condition abiding 
by the stereological principles (Chapter 2.8). Double labelled cells in the centre and the 
periphery of the graft were counted as described in Chapter 2.8.2. 
Statistical analyses were performed in SPSS as described in Chapter 2.9. 
Behavioural data from drug-induced rotation tests was analysed using a two-way 
ANOVA with repeated measures. One-way ANOVAs were performed to analyse cell 
counts obtained from CV staining, DAB TH staining, graft volumes, DA neuron density 
in the grafts, as well as to compare percentages of double labelled cells from 
Girk2/calbindin staining. DA neuron subpopulations and their distribution within the 
graft were analysed using two- and three-way ANOVAs with repeated measures, 
respectively.  A two-way ANOVA with repeated measures was used to analyse the A9 
type and the A10 type DA cell diameters. Bonferroni correction for multiple 
comparisons was used to reveal significant differences between individual groups and 
results were considered to be significant if p<0.05 (*). 
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3.3 Results 
3.3.1 Functionality of the grafts 
The ability of the graft to release DA and ameliorate lesion-induced rotational 
asymmetry in response to amphetamine was assessed by recording the net number of 
drug-induced rotations (ipsilateral minus contralateral) towards the lesioned side, 
performed over 90 minutes at 4 weeks and 6 weeks post-transplantation (Figure 3.1). 
Post-lesion, all animals rotated ispilaterally in response to the dopaminergic drug, the 
classic motor deficit induced by the unilateral 6-OHDA lesion to the MFB. Six weeks 
after transplantation two animals in the E14 group did not show any improvement and 
were excluded from subsequent analysis. Later, TH IHC confirmed virtually no 
surviving DA neurons in the striatum of these rats. In other animals, graft-derived DA 
release in the striatum significantly ameliorated the lesion-induced rotational behaviour 
4 weeks and 6 weeks after transplantation (within subject factor – Transplantation, F(2, 
28) = 43.18, p<0.001). There were no significant differences in the net number of 
rotations between the two donor age groups (Donor Age, F(1,14) = 0.51, n.s.; Donor Age 
x Transplantation, F(2, 28) = 2.19, n.s.). Animals in the E12 group already showed a 
significant behavioural recovery in the first 4 weeks after transplantation (p<0.01) while 
animals in the E14 group remained partially impaired 4 weeks post-grafting but 
significantly improved during the following 2 weeks (p<0.01). 
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Figure 3.1 Amphetamine-induced rotational behaviour in lesioned and grafted rats in the E12 (red) 
and the E14 (blue) groups. Both donor age graft groups produced a significant recovery of the lesion-
induced behavioural deficit. There was a (***) change from ipsilateral rotation observed post-lesion to 
a net contralateral rotation post-grafting, the classic over-compensatory response (F(2,28) = 43.18, 
p<0.001). Data are presented as a mean number of net rotations (ipsilateral minus contralateral) over 
90 minutes; error bars indicate SEM; significance levels: ** p<0.01, *** p<0.001. 
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3.3.2 Total cell yield in the grafts 
Examination of CV stained sections revealed well positioned grafts in the 
striatum of all 9 animals in the E12 group and 7 animals in the E14 group. Grafts 
contained homogeneously distributed mixed populations of neuronal and non-neuronal 
cells without any evidence of inflammatory reaction within the graft or in the 
surrounding striatum (Figure 3.2). To estimate the total number of neurons in the grafts 
CV stained cells were counted using the Nissl body distribution within the cell body as 
Figure 3.2 Photomicrographs of CV staining in the intrastriatal grafts in the E12 (A) and the E14 
(B) groups 7 weeks post-transplantation. Mixed populations of neuronal and non-neuronal cells 
were homogeneously distributed within the grafts. Higher magnification of grafts showing cell 
morphology and distribution in grafts in the E12 (C) and in the E14 groups (D). Scale bars: 500 µm 
(A, B); 25 µm (C, D). (E) Total number of CV-stained neurons in grafts in each donor age group. 
Transplants derived from the E12 VM tissue yielded 3-fold more neurons than E14 VM-derived 
grafts (F(1,14) = 56.38, p<0.001). Columns depict group means; error bars illustrate SEM; 
significance level: *** p<0.001.   
A B C 
D 
E 
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criterion to identify neurons. Cells were considered neuronal if Nissl bodies stained by 
CV clearly demonstrated the soma. We recognise that CV staining methos is an 
imperfect way to estimate neuronal number but for technical reasons it was unavoidable 
in this experiment. Despite the fact that implanted E14 VM tissue contained twice as 
many cells as E12 VM tissue, grafts in the E12 group yielded 3-fold more neurons than 
grafts in the E14 group at 7 weeks after transplantation. This suggests that cells derived 
from younger embryonic tissue might survive transplantation, differentiate and mature 
in the host significantly better than cells derived from more mature tissue. Also, there 
might be greater numbers of neural precursors in the E12 VM tissue than in the E14 
VM tissue that continue to proliferate after transplantation, thus contributing to higher 
yields of cells. As shown in Figure 3.2E, stereological analysis of CV stained sections 
revealed that E12 grafts contained significantly more neurons than E14 grafts (F(1,14) = 
56.38, p<0.001). 
3.3.3 DA neuron yield in the grafts 
Examination of TH-stained sections showed large numbers of TH-ir cells in the 
grafts with extensive transplant-derived reinnervation of the surrounding striatum 
(Figure 3.3). In the E12 group, grafts displayed a homogeneous distribution of TH-ir 
neurons throughout the graft together with areas of dense DA innervation within the 
graft. The majority of TH-ir neurons in the periphery of the graft had an angular and 
elongated shape while the cells within the centre of the graft typically had a round, 
symmetrical morphology. Fewer DA neurons were observed in transplants in the E14 
group with most TH-ir neurons located in the periphery of the graft and only a few seen 
in the centre of the graft. As shown in Figure 3.3E, 5.23-fold more DA neurons were 
found in transplants in the E12 group than E14 group indicating that younger E12 DA 
neural precursor cells survived the transplantation, differentiated into mature DA 
neurons and integrated in the host striatum better than more mature DA neurons in the 
E14 VM tissue (F(1,14) = 30.66, p<0.001). When compared with 40,000 DA neurons in a 
healthy adult rat VM (German and Manaye, 1993), TH-ir cell yield in grafts in the E14 
group represents 4% of the expected complement of DA neuron population in the adult 
VM. A significantly higher DA neuron yield was seen in grafts in the E12 group and 
corresponded to 19% of the expected adult complement. Based on an adjacent series of 
sections that was stained for CV, the percentage of TH-ir neurons was calculated and 
shown to differ significantly between the two donor age groups (F(1,14) = 12.18, p<0.01; 
Figure 3.3F). Thus, although significantly more neurons were found in grafts derived 
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from the E12 VM tissue as compared to the E14 VM tissue, the increase in DA neuron 
population outweighed the general gain in neuron yield. 
 
 
A B 
C D 
E 
F 
Figure 3.3 Photomicrographs of DA grafts derived from E12 and E14 donor embryos (TH stained 
sections). (A) A low power image of the representative graft in the E12 group containing many TH-
ir cells in the periphery of the graft and clusters of DA cells in the centre of the graft, and dense 
innervation of the striatum. (B) A low power image of the graft in the E14 group containing less TH-
ir neurons, which are mostly located in the periphery of the graft, and innervating a smaller volume 
of the striatum. Higher magnification of implanted TH-ir neurons showing cell morphology in grafts 
in the E12 (C) and in the E14 groups (D). Scale bars: 500 µm (A, B); 25 µm (C, D). (E) Total 
numbers of DA neurons in the grafts. Grafts in the E12 group contained significantly more TH-ir 
neurons than grafts in the E14 group (F(1,14) = 30.66, p<0.001). (F) Effect of the donor age on the 
percentage of TH-ir/CV-stained neurons in the grafts. A significantly higher percentage of neurons 
were of DA phenotype in grafts in the E12 group than E14 group (F(1,14) = 12.18, p<0.01). Data are 
presented as group means; error bars illustrate SEM; significance levels: ** p<0.01, *** p<0.001.  
 
*** 
** 
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As seen in Figure 3.3, grafts derived from the E12 VM tissue were notably 
larger than grafts in the E14 group and occupied a large part of the striatal volume. In 
addition, transplants in the E12 group were unusually large in a rostro-caudal direction, 
in some cases extending more than 2 mm. Not only did the DA grafts derived from 
younger embryos occupy a 3.76-fold larger volume of the striatum (Figure 3.4A; F(1,14) 
= 40.09, p < 0.001), they were also more densely populated with TH-ir neurons (Figure 
3.4B; F(1,14) = 8.52, p < 0.05). 
 
  
 
 
  
Figure 3.4 (A) A summary of graft volumes in each donor age group. Grafts derived from the E12 
VM tissue were significantly bigger than grafts obtained from the 14 VM tissue (F(1,14) = 40.09, 
p<0.001). (B) DA neuron density in grafts in each donor age group. TH-ir cells displayed a 
homogeneous and more denser distribution in grafts in the E12 group as compared to E14 group 
(F(1,14) = 8.52, p<0.05). Columns depict group means; error bars illustrate SEM; significance levels: * 
p<0.05; *** p<0.001. 
A B 
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3.3.4 The A9 and A10 type DA neurons in the grafts 
Two subpopulations of TH-ir neurons were identified in the grafts based on the 
coexpression of Girk2 and calbindin proteins, respectively. The majority of TH-ir cells 
co-labelled with Girk2 in all grafts and a smaller subpopulation of TH-ir neurons 
coexpressed calbindin. A few Girk2-ir and calbindin-ir neurons that were negative for 
TH were observed in the grafts in the two series double labelled for Girk2/TH and 
calbindin/TH, respectively. In the sections stained for Girk2/calbindin, a small number 
of calbindin-ir neurons in the grafts also coexpressed Girk2; however, it was not clear 
whether they were TH-ir because triple labelling was not performed in the current 
A B 
C D 
E F 
Figure 3.5 Coronal sections through the grafts in the E12 group illustrating double fluorescent 
labelling for (A, B) Girk2(green)/TH(red), (C, D) calbindin(red)/TH(green), and (E, F) 
Girk2(green)/calbindin(red). Scale bars: 200 µm (A, C, E); 20 µm (B, D, F). 
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experiment. Previous studies have suggested that 5 – 25% of calbindin-ir/TH-ir cells co-
label with Girk2 in the adult mouse and human VM (Thompson et al., 2005, Reyes et 
al., 2012). In the present experiment, 17.49 ± 1.93% and 11.62 ± 2.23% of calbindin-ir 
cells co-labelled with Girk2 in the E12 and E14 groups, respectively, but the difference 
between the two donor age groups was not significant (F(1,14) = 3.97, n.s.). 
Cell counts revealed that grafts derived from E12 VM tissue yielded 
significantly higher numbers of both the A9 type and A10 type DA neurons than 
transplants in the E14 group (Figure 3.6; Donor Age, F(1,14) = 38.86, p<0.001). A highly 
significant difference between the two subpopulations of DA neurons in the grafts was 
found (within-subject factor – Staining, F(1,14) = 66.77, p<0.001; Staining x Donor Age, 
F(1,14) = 32.31, p<0.001). Implants in the E12 group contained significantly more A9 
type than A10 type DA neurons (p<0.001) and, although grafts in the E14 group also 
yielded higher numbers of Girk2-ir/TH-ir cells than calbindin-ir/TH-ir cells, the 
difference was not significant. Grafts in the E12 group were significantly more enriched 
for the A9 type DA neurons than transplants in the E14 group (within subject factor – 
Cell count %, F(1,14) = 2021.19, p<0.001; Donor Age, F(1,14) = 77.12, p<0.001) as 
indicated by a higher percentage of TH-ir neurons double labelled with Girk2 (80% and 
68%, respectively; p<0.001). Also, a higher percentage of DA neurons were of the A10 
phenotype in implants derived from the E12 VM tissue than E14 VM tissue (27% and 
24%, repsectively; p<0.05). Note that the percentages of TH-ir neurons double labelled 
with Girk2 and calbindin added up to more than 100% in grafts in the E12 group, at 
least 8% of DA neurons did not coexpress either the Girk2 or calbindin comarkers in 
transplants in the E14 group. A higher proportion of TH-ir neurons that do not belong to 
either DA phenotype observed in grafts in the E14 group might be a result of inability 
of implanted post-mitotic DA neurons committed to the A10 phenotype to assume the 
A9 phenotype under the influence of the striatal environment. There is a possibility that 
without access to A10 functional targets in the striatum these neurons silence their A10 
phenotype.    
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Graft morphology was looked at to determine the distribution of DA neurons in 
the graft, with particular reference to their position either in the periphery or in the 
central core of the graft. Analysis showed that the majority of TH-ir neurons in the 
periphery were of the A9 phenotype in all grafts while, similar proportions of the TH-ir 
neurons coexpressed either Girk2 or calbindin in the centre of the grafts (Figure 3.7). 
The composition of the periphery of the graft was confirmed to be significantly different 
than the composition of the centre of the graft (within-subject factor – Location, F(1,14) = 
6.63, p<0.05). In the periphery of the transplant, significantly more TH-ir neurons 
coexpressed Girk2 than calbindin both in the E12 group (p<0.001) and E14 group 
(p<0.01). In the centre of the graft, no significant differences were found between the 
percentages of DA neurons that co-labelled with either Girk2 or calbindin. Also, the 
distribution of A9 type DA neurons within the graft was significantly different from the 
distribution of the A10 type DA neurons (within-subject factor – Staining, F(1,14) = 
12.56, p<0.01). In the E12 group, a higher percentage of TH-ir neurons coexpressed 
Girk2 in the periphery than in the centre of the graft (p<0.01). Conversely, a higher 
percentage of TH-ir neurons co-labelled with caldindin in the centre of the graft than in 
the periphery of the graft (p<0.05). This suggests that younger DA neural precursor 
cells in the periphery of the graft might be directed towards the nigral phenotype by the 
environmental cues present in the surrounding striatum while, in the centre of the graft, 
Figure 3.6 Total numbers of Girk2-ir/TH-ir (green) and calbindin-ir/TH-ir (orange) neurons in the 
grafts. Grafts in the E12 group produced higher numbers of both DA neuron subtypes than in the 
E14 group. Also, Girk2-ir/TH-ir neurons were more abundant than calbindin-ir/TH-ir neurons in 
grafts in the E12 group. Significant differences between individual groups are depicted on the 
graph. Columns depict group means; error bars illustrate SEM; significance level: *** p<0.001. 
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similar proportions of DA neural precursor cells survive and/or differentiate into either 
DA neuron phenotype. Although, the majority of A9 type DA neurons were also found 
in the periphery of transplants in the E14 group, no significant differences in the 
proportion of A9 and A10 phenotypes between the periphery and the centre were 
detected. The donor age influenced only the percentage of TH-ir neurons that 
coexpressed calbindin in the periphery of grafts with a higher proportion of DA neurons 
in the periphery of grafts being of the A10 phenotype in transplants derived from older 
VM tissue (p<0.01). This suggests that post-mitotic DA neurons contained in the E14 
VM tissue might be more committed to the VTA-phenotype and are less likely to 
assume SNpc identity under the influence of the striatal environment. Interestingly, 
proportions of TH-ir cells that co-labelled with either Girk2 or calbindin in the 
periphery of the graft added up to almost 100% in both donor age groups. Whereas 
there were 30% of TH-ir neurons in the centre of the grafts in both groups that did not 
co-express neither Girk2 nor calbindin. This suggests that differentiation of DA neural 
precursor cells might be influenced by the environment in the centre of the graft. Also, 
the total yield of TH-ir neurons in the periphery of the graft was higher than in the 
centre of the graft, 3-fold in the E12 group (p<0.001) and 5-fold in the E14 group 
(p<0.01). This indicates that either the survival of DA neurons might be significantly 
influenced by the local environment within the graft or that transplanted DA neurons 
migrate towards the periphery of the graft towards their functional targets. 
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Girk2-ir/TH-ir cells displayed predominantly angular and elongated morphology 
while calbindin-ir/TH-ir were smaller and round in shape, and as demonstrated in 
Figure 3.8, a significant difference in cell diameters was found in both donor age groups 
(F(1,14) = 14.93, p<0.01). 
Figure 3.7 A summary of the distribution of the A9 type and A10 type DA neurons within the grafts. 
The majority of DA neurons coexpressed Girk2 in the periphery of the grafts while similar proportions 
of TH-ir neurons co-labelled with either Girk2 or calbindin in the centre of the grafts in both donor age 
groups. The A9 type DA neurons were predominantly found in the periphery of grafts; however this 
was significant only in the E12 group. The A10 type DA neurons were predominantly found in the 
centre of grafts in the E12 group while they displayed a more homogeneous distribution in grafts in the 
E14 group. Significant differences between individual groups are depicted on the graph. Columns 
depict group means; error bars illustrate SEM; significance levels: * p<0.05, ** p<0.01, *** p<0.001. 
Figure 3.8 A summary of cell diameters in 
grafts in the E12 and E14 groups. The A9 
type DA neurons were significantly bigger 
than the A10 type DA neurons in both 
donor age groups. Individual differences 
between the groups are depicted on the 
graph. Data are presented as group means 
± SEM, significance level: * p<0.05. 
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3.4 Discussion 
This study has confirmed previously published results demonstrating that grafts 
derived from the rat E12 VM tissue yield significantly higher DA neuron numbers than 
E14 VM-derived grafts (Torres et al., 2007, Torres et al., 2008a). When compared with 
40,000 DA neurons in the healthy adult rat VM (German and Manaye, 1993), the 
present DA neuron yield in grafts in the E12 group represents 19% of the expected adult 
complement, a much better result than conventional E14 grafts, which were able to 
achieve only 4%. The two principal TH-ir cell types in adult VM are: (1) large, angular 
Girk2-ir cells predominantly found in the SNpc and (2) smaller, round calbindin-ir cells 
mainly restricted to VTA regions (Thompson et al., 2005, Reyes et al., 2012). It has 
been hypothesised that E12 and E14 grafts might be different in terms of the A9 and 
A10 DA neuron subtypes they contain.   
In PD, neurodegeneration in the SNpc occurs in a distinct pattern with A9 type 
DA neurons in the ventral tier of the SNpc rapidly disappearing and A10 DA neurons in 
the dorsal tier of the SNpc remaining intact until late stages of the disease (Braak et al., 
2003). The differential distribution of Girk2 channels, ion channels modulating 
neuronal excitability (Lacey et al., 1987), in DA neurons has been suggested to 
contribute to this early selective cell loss of the ventral tier. This has prompted the use 
of Girk2 as a marker of A9 type DA neurons. Previous studies in rodents have 
demonstrated widespread Girk2 messenger ribonucleic acid (mRNA) expression in both 
the SNpc and the lateral VTA DA neurons with higher levels of mRNA expression 
found in the SNpc than the VTA (Schein et al., 1998, Chung et al., 2005, Eulitz et al., 
2007). Localisation of the Girk2 protein initially was reported to be restricted to neurons 
in the ventral tier of the SNpc in mice, rats and humans (Mendez et al., 2005, Thompson 
et al., 2005) but later studies have demonstrated that the entire SNpc and lateral but not 
midline regions of the VTA contain Girk2-ir DA neurons in mice and humans (Lammel 
et al., 2008, Reyes et al., 2012). Also, a highly variable overlap between Girk2 and 
calbindin coexpression in TH-ir neurons was observed in the aforementioned studies, 
with 5 – 25% of calbindin-ir/TH-ir also being positive for Girk2. Differences in the 
reported results on Girk2 protein localisation may have been influenced by a number of 
factors, which include species differences, changes with age and post-mortem delay, 
different fixation procedures, the use of different antibodies.  
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Thompson and colleagues (2005) have shown that cell morphology and 
Girk2/calbindin expression in DA neurons were retained after transplantation and could 
be used to distinguish between the A9 type and A10 type DA cells in the grafts. The 
present results suggest that TH-ir cells in embryonic rat grafts can be distinguished as 
two major subtypes of DA neurons based on their cell morphology and coexpression of 
either Girk2 or calbindin. In both donor age groups, grafts contained large populations 
of Girk2-ir/TH-ir and calbindin-ir/TH-ir cells. However, there was an overlap between 
the two cell populations as indicated by the sum of proportions of TH-ir neurons that 
coexpressed either Girk2 or calbindin in grafts in the E12 group being higher than 
100%. At least a 7% overlap existed in grafts derived from younger embryos, a figure 
that is within a previously reported range of 5 – 25% overlap in Girk2 and calbindin 
expression in DA neurons (Thompson et al., 2005, Reyes et al., 2012). TH-ir neurons 
that co-labelled with Girk2 were larger in size and displayed an angular cell 
morphology as compared to smaller and round in shape calbindin-ir/TH-ir cells in both 
donor age groups. 
Grafts derived from younger VM tissue produced neuron yields of 126229 ± 
10023, which were almost equal to the number of cells transplanted (128,500 
cells/graft). As the implanted cell suspensions contained a mixture of neuronal and non-
neuronal cells, the high yield of CV-stained neurons in the grafts suggests that neural 
precursor cells in the E12 VM tissue continued to proliferate after transplantation 
significantly contributing to neuron-rich grafts. Indeed, previous research in our lab has 
demonstrated that cells grafted at E12 continued to proliferate in the host for at least 2 
days post-transplantation significantly contributing to high DA neuron yields 
(Weyrauch, 2009). Transplants in the E12 group yielded higher numbers of both the A9 
type and A10 type DA neurons and were more enriched for the functionally important 
DA neurons of the nigral phenotype than grafts derived from E14 VM tissue. Previous 
studies have demonstrated that the A9 type DA neurons are an important determinant 
for behavioural recovery. Reinnervation of the DA-depleted striatum has been shown to 
be derived predominantly from the A9 type DA neurons in the grafts (Thompson et al., 
2005). Another study has shown that transplants selectively lacking in the A9 type DA 
neurons produced only a partial recovery of drug-induced rotational behaviour in 6-
OHDA lesioned rats (Grealish et al., 2010). Previous studies using grafts derived from 
E12 rat embryos have demonstrated a 5-fold increase in DA neuron yield but that 
behavioural recovery of lesion-induced deficits was no better than that observed with 
E14 VM-derived grafts (Torres et al., 2008a). The present results show that transplants 
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derived from younger embryos produce 5-fold more A9 type DA neurons than grafts 
obtained from E14 VM tissue which suggests that similar behavioural recovery in 
animals in the E12 and E14 groups cannot be associated with different preferential 
yields of one DA phenotype over another in grafts derived from different donor age 
embryos.  
Results from this study allow to make a direct comparison of the distribution of 
the A9 type and A10 type DA neurons within rat E14 VM-derived grafts and mouse 
E12.5 VM-derived grafts, as these two ages are considered to correspond to similar 
developmental stages of the embryogenesis in the two rodent species (Thompson et al., 
2005). In the E12.5 mouse grafts, large A9 type DA neurons, which expressed Girk2, 
were mostly found at the periphery of the graft whilst smaller A10 type DA neurons, 
which expressed calbindin, were abundant in the centre of the graft. Similarly, in the 
present study, the periphery of the rat E14 VM-derived grafts was predominantly 
composed of the A9 type DA neurons. However, the proportions of the two populations 
of DA neurons in the centre of grafts were highly variable between the subjects, with 
most DA neurons being of the A9 phenotype, but this difference was not significant. 
Such great variance of the present results may be due to a significantly lower yield of 
TH-ir neurons in the centre than in the periphery of the grafts. Using an unbiased 
method of visual field sampling in the centre and in the periphery of the graft (Chapter 
2.8.2), on average 3 TH-ir neurons were captured in the centre of E14 VM-derived 
grafts. Nevertheless, a 4-fold higher proportion of TH-ir neurons coexpressed Grik2 in 
the centre of rat E14 VM-derived grafts as compared to mouse E12.5 VM-derived grafts 
suggesting that, in rats, DA neurons may not need to be located at the periphery of the 
graft to survive and project to the surrounding striatum to differentiate into the A9 type 
DA neurons (though, the majority are).   
The distribution of the A9 type and A10 type DA neurons in grafts derived from 
the E12 VM tissue was similar to the E14 VM-derived grafts. However, the A10 type 
DA neurons were more represented in the centre rather than in the periphery of the graft 
in the E12 group. Also, the proportion of the A10 type DA neurons in the periphery of 
the graft was two-fold smaller in the E12 group than E14 group but the associated 
increase in the proportion of the A9 type DA neurons in the periphery of the graft in the 
E12 group was not significant. Moreover, while there was a 7% overlap in the 
percentages of TH-ir neurons that coexpressed either Girk2 (71%) or calbindin (36%) in 
the periphery of the graft in the E14 group, at least 5% of TH-ir neurons in the periphery 
of the graft in the E12 group failed to co-label with either Girk2 or calbindin. This 
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might indicate that DA neural precursor cells derived from younger donor tissue are 
able to use environmental cues in the striatum to direct their differentiation away from 
the A10 phenotype and towards the A9 phenotype with some of the DA neuron 
progenitor cells succeeding in that endeavour and some failing to become either type of 
DA neurons. Also, the yield of TH-ir neurons was higher in the periphery of the graft 
than in the centre in both donor age groups. It is unlikely that the survival of DA 
neurons is affected by the environment within the graft as CV-stained grafts display a 
homogeneous neuron distribution within the graft; however this was not quantified in 
the present study. Implanted cells have been shown to be able to migrate up to several 
hundred microns away from the needle tract further into the target area (Schmidt et al., 
1981, Sotelo and Alvaradomallart, 1987). Thus, another possibility is that DA neurons, 
attracted by the environmental cues in the striatum, might be migrating towards the 
periphery of the graft post-transplantation. 
A significant 5-fold increase in the number of A9 type DA neurons in the grafts 
derived from younger embryos reported here has important implications for cell 
transplantation therapy for PD. At present, post-mitotic DA neurons are derived from 
human embryos aged 6 – 9 weeks post-conception, and due to major cell loss post-
transplantation (90-95% of grafted DA cells die in the host), 6 – 8 human donor 
embryos are required per unilateral transplant in PD patients. The difficulty of sourcing 
this number of embryos of the correct age within a time window of 3 – 4 days has been 
one of the major limitations of translation of this therapy into widespread use. An 
improved yield of DA neurons provided by both rat and mouse grafts derived from 
younger VM tissue suggests that it ought to be possible to achieve a similar 
improvement of human foetal transplantation therapy by using younger DA neural 
precursor cells (Torres et al., 2007, Torres et al., 2008a, Bye et al., 2012). Post-mortem 
studies of PD patients that received DA transplants have demonstrated that 68 – 71% of 
TH-ir neurons in the graft coexpressed Girk2 and 26 – 48% co-labelled with calbindin 
indicating that human foetal DA neurons retain Girk2/calbindin expression after 
transplantation (Mendez et al., 2005). Moreover, grafts derived from younger rat 
embryos here and younger mouse embryos in the previous study reported in the 
literature (Bye et al., 2012) contained a higher proportion of TH-ir neurons that 
coexpressed Girk2 suggesting that, in addition to the improved yield of the A9 type DA 
neurons, an improved enriched composition of the grafts can be achieved by using 
younger embryonic VM tissue. The goal is to use one human embryo per patient for PD 
transplantation, and the results from grafts derived from younger donors in animal 
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models indicate that the required number of surviving DA neurons and the proportion of 
the nigral type DA neurons could be achieved by using younger human donors. 
3.5 Conclusion 
The present experiment has further underlined the significant impact of the 
donor age on grafted DA neuron yield. Harvesting rat foetal VM tissue before the peak 
of DA neurogenesis has significantly improved yields of DA neurons and, more 
importantly, also yields of A9 type DA neurons, which are an important determinant for 
functional recovery. The A9 type DA neurons were found to be influenced by the 
environment within the graft with the majority of DA neurons of nigral phenotype 
located in the periphery of the graft while the distribution of the A10 type DA neurons 
was more homogeneous. Also, the current data suggest that DA neural precursor cells 
derived from younger donor tissue might be able to use environmental cues in the 
striatum to direct their differentiation away from the A10 phenotype and towards the A9 
phenotype. A future experiment will investigate the influence of the environment in the 
transplantation site on the two DA neuron subpopulations in grafts derived from the E12 
VM and E14 VM tissue. 
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Chapter 4 The Influence of Environment on the 
Dopaminergic Grafts 
 
Summary 
The aims of this chapter were to investigate the influence of the transplantation 
site on (i) the A9 type and A10 type DA neuron yield in the graft and (ii) distribution of 
the two DA cell subpopulations within the graft. To that end, 6-OHDA unilaterally 
lesioned rats received E12 VM- and E14 VM-derived implants into either the striatum, 
N.Acc, PFC or the hippocampus. The transplantation site was shown to have little 
impact on both the total number of neurons and the DA neuron yield in the grafts. A 
higher yield of TH-ir cells was observed in the E12 grafts than equivalent E14 grafts in 
all four transplantation sites. This is comparable to previously observed properties of the 
rat E12 VM tissue to yield a several-fold greater number of DA neurons than equivalent 
E14-derived grafts (Chapter 3 and Torres et al., 2007). A9 type DA neurons were found 
to be influenced both by the environment within the graft and by the host environment 
in the transplantation site to a higher extent than the A10 type DA neurons. The highest 
yield of A9 type DA neurons was found in grafts implanted into the striatum, which 
receives the A9 type DA innervation from the midbrain, followed by a progressive 
decrease in the number of A9 type DA neurons in grafts in the N.Acc, PFC and the 
hippocampus in the absence of the A9 type DA innervation. Also, A9 phenotype was 
more influenced by the transplantation site in younger DA precursor cells in E12 grafts 
than in post-mitotic DA neurons in the E14 grafts. The evidence suggests that 
differentiation of DA neural precursor cells rather than their survival might be affected 
by the afferent DA innervation of the transplantation site. Also, the A9 type DA neurons 
failed to reach the normal cell body size in E12 grafts in the PFC and hippocampus, 
most likely due to being less metabolically active in the absence of target innervation. 
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4.1 Introduction 
Donor age effect in DA neuron grafts has been the subject of interest for some 
time now (Torres et al., 2007, Torres et al., 2008a, Jonsson et al., 2009). VM tissue 
derived from E12 rat embryos provided a 5-fold greater yield of DA neurons than E14 
VM-derived grafts but achieved similar levels of recovery in lesioned rats (Torres et al., 
2008a). This suggests that a threshold number of DA neurons in the graft are required to 
provide sufficient DA supply and reinnervation of the lesioned striatum to restore 
behavioural deficits but a further increase in DA neuron yield does not improve the 
recovery. Previous studies have demonstrated that further recovery of finer motor skills 
requires a more global restoration of the basal ganglia circuitry which can be achieved 
by simultaneous grafts in the striatum, the SNpc and the STN (Mukhida et al., 2001, 
Mukhida et al., 2008). The subtypes of dopamine neurons within embryonic VM grafts 
have been the focus of many studies (Mendez et al., 2005, Thompson et al., 2005, 
Grealish et al., 2010). It has been proposed that the restoration of function by DA grafts 
is mainly due to the presence of the A9 type DA neurons of SNpc within the graft which 
re-innervate the surrounding striatum (Kuan et al., 2007, Grealish et al., 2010). Whereas 
the A10 type DA neurons of the VTA appear to innervate extra-striatal targets and are 
considered less important in restoring behavioural deficits (Thompson et al., 2005, 
Kuan et al., 2007, Grealish et al., 2010). 
The A9 and A10 DA neuron subtypes were identified in mice VM grafts based 
on the coexpression of Girk2 and calbindin in DA neurons, respectively, and cell 
morphology (Thompson et al., 2005). DA neuron subtypes in grafts derived from rat 
E12 and E14 VM tissue have been characterised in the previous experiment (Chapter 3). 
Implants in the E12 group were significantly more enriched for the A9 type DA neurons 
than transplants in the E14 group as indicated by a higher percentage of TH-ir cells 
double labelled with Girk2 (80% and 68%, respectively). The periphery of the grafts 
contained predominantly A9 type DA neurons in both donor age groups with a two-fold 
reduction in the A10 type DA neurons in the periphery of grafts in the E12 group as 
compared to the E14 group. The centre of grafts in the E12 group contained the same 
levels of two different DA neuron subtypes. More A9 type than A10 type DA neurons 
were observed in the centre of grafts in the E14 group but the difference was not 
significant. A third of neurons positive for TH in the centre of grafts in both donor age 
groups failed to co-label with either Girk2 or calbindin. However, there was a 15% 
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overlap between Girk2 and calbindin staining. Nevertheless, the fact that the two DA 
neurons subtypes were not homogeneously distributed within the graft might indicate 
that there is an environmental effect of the periphery and the centre of the graft on either 
survival or differentiation of DA neuron subtypes.  
Both DA neuron subtypes survive in VM grafts in the striatum and TH-ir 
neurons extend axonal projections to their normal targets depending on the phenotype, 
e.g. the A9 type DA neurons innervate the surrounding striatum, whereas the A10 type 
DA neurons project to the PFC (Thompson et al., 2005). This indicates that, depending 
on the afferent DA innervation, the host environment might favour the development and 
survival of either one or the other DA neuron subtype in the graft, an issue which has 
not yet been looked at experimentally. 
4.1.1 Aims of the chapter 
The current experiment investigated grafts derived from E12 and E14 rat VM 
tissue and implanted into different cerebral targets to determine if the site of 
transplantation affected the populations of DA cell phenotypes seen in the graft. The 
striatum receives the A9 type DA innervation from the SNpc and, as seen from previous 
studies, there are generally higher numbers of A9 type DA neurons than A10 type DA 
neurons in the graft (Chapter 2 and Bye et al., 2012). The N.Acc and the PFC, both 
receive the A10 type innervation from the VTA, which might influence the 
differentiation and survival of A10 type DA neurons in grafts transplanted into these 
regions. The hippocampus receives very sparse (<5%) DA innervation from the VTA 
and rich NA innervation from the LC and might serve as a control site (Lindvall and 
Bjorklund, 1974). In the present experiment, the striatum, N.Acc, PFC and the 
hippocampus were chosen as 4 implantation sites to determine if different cell 
populations and DA innervation targets in the host environment might affect the success 
of allogeneic DA neuron transplantation in terms of: 
1. Motor function recovery 
2. Neuron survival 
3. DA cell survival 
4. A9 and A10 DA neuron phenotype yield and distribution in grafts 
5. A9 type and A10 type DA cell size 
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4.2 Experimental Procedure 
To reduce the number of animals used in the experiment each animal received 2 
grafts into 2 different transplantation sites on the same side of the brain. Striatum and 
N.Acc can be considered independent from the PFC and hippocampus because they are 
not adjacent cerebral regions. Therefore, each animal received the first transplant into 
either the striatum or N.Acc and the second transplant into either the PFC or 
hippocampus.  
All of the methods used in this experiment are described in Chapter 2. Female 
SD rats (n = 36) were unilaterally lesioned with 6-OHDA (Chapter 2.3.1) and the 
lesions confirmed with drug-induced rotation tests (Chapter 2.4). Animals were 
balanced based on the number of amphetamine-induced net ipsilateral rotations and 
allocated into 8 groups so that the variance between the groups was minimal (Table 4.1; 
Group, F(7,28) = 0.01, n.s.; one-way ANOVA).  
Transplantation 
site 
Donor age 
Striatum  
PFC 
N.Acc  
PFC 
Striatum  
Hippocampus 
N.Acc  
Hippocampus 
E12 1242 ± 273 
(n = 5) 
1268 ± 260 
(n = 4) 
1307 ± 500 
(n = 4) 
1245 ± 264 
(n = 5) 
E14 1246 ± 195 
(n = 5) 
1270 ± 294 
(n = 4) 
1298 ± 428 
(n = 4) 
1245 ± 227 
(n = 5) 
Table 4.1 Group allocation for transplantation. Animals were distributed in 8 groups based on the number 
of amphetamine-induced net ipsilateral rotations following 6-OHDA lesion. One-way ANOVA, n.s. Data 
are presented as group means ± SEM. 
Six weeks post-lesion, three E12 and two E14 litters were harvested and VM 
cell suspensions were prepared for grafting as described in Chapter 2.3.2 (E12 1: 
63,500 cells/VM, viability data n/a; E12 2: 117,000 cells/VM, viability – 99.19%; E12 
3: 134,000 cells/VM, viability 98.27%; E14 1: 500,000 cells/VM, viability – 95.24%; 
E14 2: 535,000 cells/VM, viability – 95.22%). The PFC is a much smaller cerebral 
target than the striatum, N.Acc or the hippocampus and, for safety reasons, cell numbers 
equivalent to ½ VM per graft were used in the current experiment. Every animal 
received 2 grafts into the designated sites, each graft containing cell numbers equivalent 
to ½ VM in 2 µl of the cell suspension. Overall, a total of 9 animals received grafts of 
each donor age transplanted into each cerebral target. Stereotaxic co-ordinates were as 
follows: Striatum AP: +0.6 mm, ML: -3.0 mm, DV: -5.0 mm; N.Acc AP: +1.6 mm, 
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ML: -1.5 mm, DV: -7.5 mm; PFC AP: +4.7 mm, ML: -2.0 mm, DV: -1.9 mm; 
Hippocampus AP: -5.2 mm, ML: -5.2 mm, DV: -5.4 mm (Paxinos and Watson, 2003). 
Efficacy of the grafts was confirmed with amphetamine-induced rotation tests at 4 and 6 
weeks post-grafting. Following the final rotation test animals were sacrificed, 
transcardially perfused, the brains fixed, and coronal sections of brains collected for 
IHC (Chapter 2.5).  
A one-in-twelve series of sections was stained using IHC for DAB NeuN. A 
second one-in-six series was stained for DAB TH; two series were double labelled for 
TH and Girk2, and TH and calbindin, respectively (Chapter 2.6.1). Fluorescent and 
DAB cell counts were obtained blind to the experimental condition abiding by the 
stereological principles (Chapter 2.8). Counts of double labelled cells in the centre and 
the periphery of the graft were obtained as described in Chapter 2.8.2.  
Three measures of the number of TH-ir neurons in the grafts were obtained from 
three different stainings. The counts obtained from fluorescent Girk2/TH and 
calbindin/TH stainings were consistently higher than DAB TH-ir cell counts (Table 4.2; 
within-subject factor – Staining, F(2,132) = 181.99, p<0.001; two-way ANOVA with 
repeated measures; TH < Girk2/TH = calbindin/TH, p<0.001; Bonferroni correction). 
Given that the actual number of TH-ir cells is the same across three series of sections, 
the threshold for counting a cell as immunoreactive is lower in fluorescent staining than 
DAB staining. Additionally, sections containing the graft in the PFC were missing from 
the DAB TH staining. Therefore, the total number of TH-ir neurons per graft was 
calculated as an average TH-ir cell count from Girk2/TH and calbindin/TH staining for 
statistical analysis.  
 TH Girk2/TH calbindin/TH 
E12 2349 ± 153 3849 ± 204 3791 ± 211 
E14 1208 ± 158 2109 ± 211 2185 ± 217 
Table 4.2 A summary of TH-ir cell numbers/graft across all sites in the E12 and E14 groups obtained 
from three different stainings. In both donor age groups: TH < Girk2/TH = calbindin/TH (p<0.001). Data 
are presented as group means ± SEM. 
Statistical analyses were performed in SPSS as described in Chapter 2.9. A 
four–way ANOVA with repeated measures was used to analyse behavioural data from 
drug-induced rotation tests. This analysis was performed orthogonally, treating grafts in 
the striatum or N.Acc as the primary graft and grafts in the PFC or hippocampus as the 
secondary graft, to investigate whether PFC or Hippocampus subgroups differed in 
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either Striatum or N.Acc groups. Two-way ANOVAs were used to analyse NeuN-ir cell 
yield, TH-ir cell yield, graft volumes, and DA neuron density in the grafts. Three- and 
four-way ANOVAs with repeated measures were performed to analyse DA neuron 
subpopulations and their distribution within the graft, respectively. The A9 type and the 
A10 type DA cell diameters were analysed using a three-way ANOVA with repeated 
measures. Bonferroni correction for multiple comparisons was used to reveal significant 
differences between individual groups and results were considered to be significant if 
p<0.05 (*).   
4.3 Results 
4.3.1 Functionality of the grafts 
Rotational asymmetry in response to the indirect dopamine agonist, 
amphetamine, was assessed at 6 weeks post-lesion and at 4 and 6 weeks post-grafting. 
Post-lesion, net rotation in both groups of animals was ipsilateral toward the lesioned 
side in response to the amphetamine. Pre- and post-grafting rotational behaviour was 
significantly different in most animals (within-subject factor – Transplantation, F(2,56) = 
13.93, p<0.001). Grafts in the striatum and N.Acc produced significantly different drug-
induced rotational responses in animals (Primary graft, F(1,28) = 55.57, p<0.001). Six 
weeks after grafting all animals which had received grafts into the striatum now rotated 
contralaterally to the lesioned side (Figure 4.1A; p<0.001). Animals which had received 
grafts into the N.Acc continued to rotate ipsilaterally to the lesioned side, most probably 
due to DA release in the N.Acc having an excitatory effect and increasing the phenotype 
of drug-induced ipsilateral rotational behaviour (Figure 4.1B; p<0.05). Grafts in either 
the PFC or hippocampus did not influence drug-induced rotational response in animals 
(Secondary graft, F(1,28) = 1.31, n.s.; no associated significant interactions). Rotational 
behaviour in the E12 and E14 groups was generally very similar (Donor Age, F(1,28) = 
1.38, n.s.). Only post-grafting rotational behaviour induced by the grafts in the N.Acc 
was significantly different between the two donor age groups at both 4 and 6 week time 
points (p<0.05). In the E14 donor age group in the N.Acc, the asymmetry in post-lesion 
rotational behaviour was significantly lower than the asymmetry in rotational behaviour 
at both 4 and 6 weeks post-grafting (p<0.05). Grafts in the striatum induced a highly 
significant behavioural recovery in drug-induced rotations at 4 and 6 weeks post-
grafting in both donor age groups (p<0.001).  
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Three animals that received transplants into the N.Acc (one from the E14 and 
two from the E12 donor age group) rotated contralaterally to the lesioned side. 
Examination of TH-stained brain sections revealed that the animal from the E14 group 
had a graft in the dorsomedial striatum instead of N.Acc and therefore was transferred 
to the Striatum group for further analysis. The two animals from the E12 group had 
grafts that were equally positioned in the striatum and N.Acc which suggests that DA 
activity in the striatum over-compensated the DA activity in the N.Acc in response to 
the drug leading to the restoration of lesion-induced rotational asymmetry during the 
test. Because the grafts were nevertheless positioned in the N.Acc these animals were 
not excluded from the analysis of the environmental effects of the N.Acc on DA neuron 
phenotypes within the grafts.  
4.3.2 Surviving grafts in each transplantation site group 
TH and NeuN stained sections revealed well positioned grafts in most animals. 
In the E14 donor age group, two animals were missing grafts in the PFC and one in the 
hippocampus because the transplantation site was missed during the surgery, and as a 
result cells were most likely injected into the subdural space or a sub-ventricular space 
Figure 4.1 Drug-induced rotational response following an i.p. injection of 2.5mg/kg metamphetamine 
in lesioned and grafted rats in the E12 (red) and the E14 (blue) groups. Data are collapsed across the 
secondary graft factor. (A) Both donor age graft groups produced a recovery of the lesion-induced 
behavioural deficit in the striatal graft group. There was a change (***) from ipsilateral rotation 
observed post-lesion to a net contralateral rotation post-grafting, the classic over-compensatory 
response (p<0.001). (B) Animals in the N.Acc graft group exhibited enhanced (*) ipsilateral 
rotational behaviour post-grafting (p<0.05). Data are presented as a mean (ipsilateral minus 
contralateral) rotation score for each group over 90 minutes, error bars indicate ± SEM, significance 
levels: * p<0.05, *** p<0.001. 
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because no trace of cells was found. In the E12 donor age group, one graft was injected 
too anteriorly in the PFC and brain sections were too damaged to collect comparable 
cell counts for analysis (no sections containing this graft were present in the Girk2/TH 
and calbindin/TH stained sections) so the animal was excluded from the analysis. 
Additionally, NeuN staining of one brain in the E12 PFC group was too patchy to 
obtain a reliable NeuN-ir cell count. Two E12 and three E14 grafts in the PFC group 
penetrated into the subdural space but they, nevertheless, extended TH-ir fibres into the 
PFC so the animals were included in the analysis. Also, in some animals, the first 
collected PFC section contained a big portion of the graft in 4 E12 grafts and 4 E14 
grafts suggesting that there was a portion of the graft anterior to the first collected PFC 
section and it was lost. The resulting numbers of grafts in each group used in further 
analysis were as follows: Striatum – 9 E12 and 10 E14 grafts, N.Acc – 9 E12 and 8 E14 
grafts, PFC – 8 E12 (7 E12 grafts in the NeuN staining analysis) and 7 E14 grafts, 
Hippocampus – 9 E12 and 8 E14 grafts.  
4.3.3 Neuron yield in the grafts
Examination of NeuN-stained sections revealed surviving grafts in most animals 
with large numbers of NeuN-ir cells homogeneously distributed within the grafts as 
depicted in Figure 4.2A. Given that E14 VMs contained almost 5 times more cells than 
B A 
Figure 4.2 (A) A photomicrograph of the E12 
graft in the striatum stained for NeuN. There is 
a clear boundary between the graft and the 
surrounding striatum. NeuN-ir cells are 
homogeneously distributed within the graft. The 
density of NeuN-ir reactive cells appears to be 
higher in the graft than in the surrounding 
striatum. Magnification x10, scale bar: 200 µm. 
(B) NeuN-ir cells within the graft at a higher 
magnification, x40. Scale bar: 20 µm. 
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E12 VMs at the time of transplantation, the yield of NeuN-ir neurons might have been 
expected to be different between the two donor age groups. However, as shown in 
Figure 4.3, the yield of grafted neurons was not affected by the donor age group (F(1,59) 
= 0.51, n.s.) or the transplantation site group (F(3,59) = 0.45, n.s.) and neither by an 
interaction between the two factors (F(3,59) = 0.13, n.s.). This might be due to either 
poorer survival of differentiated cells in the E14 VM tissue or proliferation of neural 
cell precursors in the E12 VM tissue, or both.  
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4.3 Total NeuN-ir cell numbers in E12 and E14 grafts at all transplantation sites at 6 weeks post 
grafting. No significant differences were found between the donor age groups and transplantation site 
groups (n.s.). Columns depict group means; error bars illustrate SEM. 
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4.3.4 DA neuron yield in the grafts 
 
A B C D 
E F G H 
I Figure 4.4 Photomicrographs (x10) of E12 grafts 
in the striatum (A), N.Acc (B), PFC (C), and 
hippocampus (D), and E14 grafts in the same 
cerebral targets (E, F, G, and H, respectively) at 6 
weeks post transplantation. In most grafts, most 
DA cells were located at the periphery of the graft 
and extended axons to re-innervate the 
surrounding environment. However, E12 grafts in 
the hippocampus contained a significant 
population of TH-ir cells in the core. (I) A higher 
magnification photomicrograph (x40) of TH-ir 
neurons in the striatal graft clearly shows DA cells 
extending axons into the surrounding tissue. Scale 
bars: 200 m (A – H) and 20 m (I).  
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Examination of TH-stained sections showed large numbers of TH-ir cells in all 
surviving grafts with extensive innervation by the grafts of the surrounding striatum, 
N.Acc and to some extent PFC as expected (Figure 4.4). Surprisingly, extensive TH-ir 
fibre outgrowth was also observed in the grafts in hippocampus (Figure 4.4D, H). E14 
grafts contained most TH-ir neurons in the periphery of the graft and only a few in the 
centre of the graft. E12 grafts displayed a more homogeneous distribution of cells and a 
high density of TH processes within the graft. The group means of TH-ir cell numbers 
(derived from implantation of ½ VM) are shown in the table below the graph in Figure 
4.5A. A two-way ANOVA analysis confirmed a main effect of the donor age group 
(F(1,60) = 36.18, p<0.001), a main effect of the transplantation site group (F(3,60) = 2.98, 
p<0.05) and no interaction (F(3,60) = 2.12, n.s.) on the total TH-ir cell numbers in the 
grafts. E12 grafts produced a significantly higher yield of TH-ir cells than E14 
transplants in the striatum (p<0.001), N.Acc (p<0.05) and hippocampus (p<0.01). 
Interestingly, in the E12 donor age group grafts in the striatum were the most populous 
in TH-ir cells numbers than grafts in any other location whereas for the E14 donor age 
group the largest grafts were in the N.Acc. Also, grafts in the hippocampus contained 
unexpectedly high numbers of TH-ir cells, especially in the E12 donor age group. 
Analysis of simple effects confirmed a significant effect of transplantation site in the 
E12 donor age group (F(3,60) = 4.65, p<0.01) but not the E14 donor age group (F(3,60) = 
0.41, n.s.). However, only grafts in the striatum yielded a significantly higher number of 
TH-ir neurons than grafts in the PFC in the E12 donor age group (p<0.01).  
Given that the total number of surviving neurons was not significantly different 
between the groups, there should be a higher percentage of TH-ir/NeuN-ir cells in the 
E12 donor age group than E14 group to account for a significantly higher dopamine 
neuron yield in E12 grafts. As expected, a two-way ANOVA confirmed a main effect of 
the donor age group (F(1,59) = 24.02, p<0.001; Figure 4.5B) but no effect of the 
transplantation site group (F(3,59) = 0.44, n.s.) or an interaction between the two factors 
(F(3,59) = 0.67, n.s.). Grafts derived from E12 rat embryos yielded a higher percentage of 
TH-ir/NeuN-ir neurons than E14 grafts in the striatum (p<0.01), N.Acc (p<0.01) and the 
hippocampus (p<0.05) but not the PFC.  
77 
 
E12 grafts were slightly bigger in volume than E14 grafts in all transplantation 
sites (F(1,60) = 4.12, p<0.05; Figure 4.6A), despite the smaller numbers of cells 
implanted. Despite the fact that brain tissue in each transplantation site is different in 
cell composition and density it did not affect the growth of grafts (Transplantation Site, 
F(3,60) = 0.06, n.s.; Donor Age x Transplantation site, F(3,60) = 0.22, n.s.). No significant 
differences in graft volume between individual groups were found. Analysis of DA cell 
densities in the grafts (Figure 4.6B) showed a main effect of the donor age group (F(1,60) 
= 14.30, p<0.001) but again no main effect of the transplantation site group (F(3,60) = 
0.76, n.s.) and no interaction between the two (F(3,60)  = 0.96, n.s.). TH-ir cell density 
was significantly higher in E12 grafts than E14 grafts in the striatum (p<0.01) and 
N.Acc (p<0.05). Thus, the increase in the total number of TH-ir cells in grafts derived 
from younger donor tissues can be attributed to a denser distribution of DA neurons 
within the graft which is accompanied by a slight increase in the graft volume. 
  
Figure 4.5 (A) Total TH-ir cell numbers in E12 and E14 grafts in all implantation sites at 6 weeks 
post grafting. There was a significant difference in total TH-ir neuron numbers between the two 
donor age groups (F(1,60) = 36.18, p<0.001). Significant differences in DA neuron yield between E12 
and E14 grafts at different transplantation sites are depicted on the graph. The transplantation site had 
a significant main effect on the DA neuron yield (F(3,60) = 2.98, p<0.05). E12 grafts in the Striatum 
group produced significantly higher TH-ir cell numbers than E12 grafts in the PFC (p<0.01). (B) 
Effect of the donor age group and the transplantation site group on the percentage of TH-ir/NeuN-ir 
neurons. There was no significant effect of the transplantation site and no interaction, but there was a 
significant effect of the donor age group (F(1,59) = 24.02, p<0.001). Significant differences between the 
two donor age groups at different levels of the transplantation site group are depicted on the graph. 
Columns depict group means; error bars illustrate SEM; significance levels: * p<0.05, ** p<0.01, 
*** p<0.001. 
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Figure 4.6 (A) A summary of graft volumes in each donor age and transplantation site group. E12 
grafts were significantly bigger (F(1,60) = 4.12, p<0.05). There was no effect of the transplantation site 
group or an interaction between the two factors. (B) TH-ir cell density in the grafts in each group. 
There was a main effect of the donor age group (F(1,60) = 14.30, p<0.001), DA neuron density was 
significantly higher in E12 grafts than E14 grafts in the Striatum and N.Acc. Again there was no main 
effect of the transplantation site group and no interaction between the two factors. Columns depict 
group means; error bars illustrate SEM; significance levels: * p<0.05, ** p<0.01. 
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4.3.5 DA neuron subtypes in E12 and E14 grafts
 
Girk2 / TH calbindin / TH 
Figure 4.7 Coronal 
sections through the grafts 
in the striatum and N.Acc 
illustrating Girk2 (red) and 
TH (green) expression in A, 
C, E, G and calbindin (red) 
and TH (green) expression 
in B, D, F, H in E12 and 
E14 VM grafts. Lower 
power images represent the 
E12 (A, B) and E14 (C, D) 
grafts in the striatum. 
Girk2-ir/TH-ir double 
labelled cells were 
predominantly found in the 
periphery of grafts in both 
donor age groups (A, C) 
whereas calbindin-ir/TH-ir 
cells were clustered within 
the core of grafts (B, D). 
E12 (E, F) and E14 (G, H) 
grafts in the N.Acc double 
labelled for Girk2/TH (E, 
G) and calbindin/TH (F, 
H). Similarly to the striatal 
grafts DA neurons in the 
periphery predominantly 
coexpressed Girk2. Higher 
power images of the E14 
graft in the N.Acc double 
stained for Girk2/TH (I) 
and the E12 graft in the 
N.Acc labelled for 
calbindin/TH (J). Scale bar: 
200 m (A - H) and 100 
m (I, J). 
A B 
C D 
E F 
G H 
I 
J 
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Fluorescent double IHC for Girk2/TH and calbindin/TH revealed surviving A9 
and A10 type DA neurons in all grafts (Figure 4.7). Girk2 and caldindin co-localised 
with TH in the cytoplasm of grafted neurons as demonstrated in Figure 4.7I and J, 
respectively. The yield of A9 type DA neurons was predicted to be higher in the 
striatum and A10 type DA neuron yield was expected to be higher in the N.Acc and 
PFC due to differential A9 and A10 type innervation of these brain regions. Indeed, 
there was a highly significant difference between A9 and A10 type DA neuron yields 
(within-subject factor – Staining, F(1,60) = 111.48, p<0.001). There was a main effect of 
the donor age group (F(1,60) = 31.59, p<0.001) and the transplantation site group (F(3,60) = 
14.19, p<0.001) as well as an interaction between the two factors (F(3,60) = 4.48, p<0.01). 
The number of Girk2-ir/TH-ir cells was significantly higher than calbindin-ir/TH-ir cell 
counts in the striatum and surprisingly in the N.Acc in both donor age groups (p<0.001) 
and lower in the hippocampus in E12 grafts (p<0.05; Figure 4.8A). In comparison to 
E14 grafts, E12 grafts produced a higher yield of both Girk2-ir/TH-ir cells and 
calbdindin-ir/TH-ir cells in the striatum (p<0.001) and N.Acc (p<0.05) and a higher 
yield of calbindin-ir/TH-ir cells in the hippocampus (p<0.05). This effect of the donor 
age group was not unexpected since E12 grafts yielded a significantly higher number of 
TH-ir cells than E14 grafts in all transplantation sites apart from the PFC. Girk2-ir/TH-
ir cells were abundant in grafts in the striatum and N.Acc in both donor age groups. 
There were noticeably fewer Girk2/TH double labelled cells in grafts in the PFC and 
hippocampus as depicted in Figure 4.8B. Differences in the number of calbindin-ir/TH-
ir cells in grafts in different transplantation sites were less prominent (Figure 4.8C). 
There was no effect of the transplantation site on the number of calbindin-ir/TH-ir cells 
in E14 grafts (F(3,60) = 0.85, n.s.) but there was an effect of the transplantation site in the 
E12 group (F(3,60) = 3.5, p<0.05), grafts in the striatum yielded a significantly higher 
number of A10 type DA neurons than grafts in the PFC (p<0.05). 
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Figure 4.8 (A) A summary of Girk2-ir/TH-ir and calbindin-ir/TH-ir cell yields in grafts. Significant 
differences between the two populations of DA neurons were observed in E12 and E14 grafts in the 
striatum and N.Acc, and E12 grafts in the Hipp. (B) Survival of Girk2-ir/TH-ir neurons (data is 
extracted from Figure 4.8A for presentation clarity). Effect of the transplantation site on the number 
of A9 type DA neurons was more prominent in the E12 donor age group. Individual differences 
between the groups are depicted on the graph. (C) Survival of the A10 type DA neurons was less 
affected by the transplantation site (data is extracted from Figure 4.8A for presentation clarity). Only 
E12 grafts in the striatum differed significantly from E12 grafts in the PFC (p<0.05). Columns 
depict group means; error bars illustrate SEM; significance levels: * p<0.05, ** p<0.01, *** 
p<0.001. 
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In order to account for the difference in TH-ir cell numbers, the survival of TH-
ir neurons that double-labelled with Girk2 and calbindin was calculated as a percentage 
of overall number of TH-ir neurons. The percentages of Girk2-ir/TH-ir and calbindin-
ir/TH-ir cells in the striatum and N.Acc added up to 105%, suggesting at least a 5% 
overlap in Girk2 and calbindin stainings (Figure 4.9A). Interestingly, the sum of 
percentages of A9 and A10 type DA neurons was 78% and 69% in grafts in the PFC 
and hippocampus, respectively, indicating that almost a third of TH-ir neurons were 
neither of A9 nor A10 type. There was a highly significant difference between the 
percentages of A9 and A10 type DA neurons in the grafts (within-subject factor – 
Staining, F(1,60) = 268.87, p<0.001). As expected, significant differences between the 
percentages of Girk2-ir/TH-ir and calbindin-ir/TH-ir neurons (Figure 4.9A) 
corresponded to significant differences between the A9 and A10 type DA neurons in 
different graft groups (Figure 4.8A). There was a main effect of the transplantation site 
group (F(3,60) = 91.81, p<0.001) but no main effect of the donor age group (F(1,60) = 1.14, 
n.s.) and no significant interaction (F(3,60) = 1.82, n.s.). The gain in the Girk2-ir/TH-ir 
and calbindin-ir/TH-ir cell yields in the E12 donor age group did not outweigh the 
general increase in the number of TH-ir neurons between the two donor age groups. A 
significantly higher percentage of Girk2-ir/TH-ir cells was observed in grafts in the 
striatum than N.Acc and it continued to decrease in grafts in the PFC and hippocampus 
(Figure 4.9B). Thus, although the total number of TH-ir neurons was affected by the 
environment, the decrease in Girk2-ir/TH-ir cell numbers outweighed the general 
decrease. There was a small increase in the percentage of calbindin-ir/TH-ir cells in 
grafts in the N.Acc as compared to grafts in other transplantation sites in both donor age 
groups (Figure 4.9C). However, even though there was a main effect of the 
transplantation site on the percentage of calbindin-ir/TH-ir cells (F(3,60) = 4.68, p<0.01) 
no significant differences between the groups were found.     
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Figure 4.9 (A) A summary of the percentage of Girk2-ir/TH-ir and calbindin-ir/TH-ir cell yields in 
grafts. Significant differences between the proportions of the A9 and A10 type DA neurons were 
observed in all graft groups apart from the E14 PFC; E12 grafts were not significantly different from 
E14 grafts. (B) Percentage of Girk2-ir/TH-ir neurons (data is extracted from Figure 4.9A for 
presentation clarity). Effect of the transplantation site on the number of A9 type DA neurons was 
more prominent in the E12 donor age group. Individual differences between the groups are depicted 
on the graph. (C) Percentage of calbindin-ir/TH-ir neurons (data is extracted from Figure 4.9A for 
presentation clarity). No significant differences in the gain or loss of the A10 type DA neurons 
between the transplantation sites were found (n.s.). Columns depict group means; error bars illustrate 
SEM; significance levels: * p<0.05, ** p<0.01, *** p<0.001. 
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The composition of the periphery was generally very different from the 
composition of the core within the graft (within-subject factor – Location, F(1,60) = 
47.29, p<0.001). The A9 type DA cells were affected more than the A10 type DA 
neurons by the environment within the graft (Location x Staining, F(1,60) = 55.04, 
p<0.001; A9 – p<0.001; A10 – n.s.). Girk2-ir/TH-ir neurons were found predominantly 
in the periphery of grafts rather than in the core while calbindin-ir/TH-ir neurons were 
distributed more homogeneously within the graft (Figure 4.10A, B). In N.Acc grafts, 
both A9 and A10 type DA neurons were found mostly in the periphery of grafts but in 
grafts in the Striatum group this was true for Girk2-ir/TH-ir
 
and not calbindin-ir/TH-ir 
neurons. There was a significantly higher percentage of A10 type DA neurons in the 
periphery of grafts than in the centre in N.Acc grafts in both donor age groups (p<0.05). 
This suggests that environmental cues in the N.Acc might have influenced either the 
differentiation or survival, or both, of A10 type DA neural precursor cells. Interestingly, 
percentages of Girk2-ir/TH-ir and calbindin-ir/TH-ir cells in the periphery of grafts 
added up to 90-100% in all groups apart from the Hippocampus group. There were 
≈50% of TH-ir cells in the centre of the graft in all groups that did not coexpress neither 
Girk2 nor calbindin suggesting that they most likely silenced their A9 and A10 
phenotypes. 
There was no main effect of the donor age group (F(1,60)
 
= 2.67, n.s.) but there 
was a strong main effect of the transplantation site group (F(3,60)
 
= 3.44, p<0.05) and a 
strong interaction between the donor age and transplantation site groups (F(3,60)
 
= 2.96, 
p<0.05). Only the percentage of Girk2-ir/TH-ir cells in the periphery of grafts was 
affected by the transplantation site in both donor age groups (F(3,60)
 
= 10.50, p<0.001). 
The percentage of A9 type DA neurons in the periphery of grafts was significantly less 
in grafts in the hippocampus than in the striatum and N.Acc (p<0.01) in the E12 donor 
age group. In E14 grafts, the percentage of Girk2-ir/TH-ir cells was significantly less in 
the periphery of grafts in the PFC (p<0.05) and hippocampus (p<0.01) than in the 
striatum. Without the necessary environmental cues DA precursors might have failed to 
survive or mature into functional A9 type DA neurons in the periphery of grafts in the 
PFC and hippocampus. There was a higher percentage of calbindin-ir/TH-ir neurons in 
the periphery of E12 grafts in the N.Acc than in other transplantation sites but the 
difference was not significant. Transplantation site did not affect the percentage of A10 
type DA neurons neither in the periphery nor in the centre of grafts.  
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The yields of DA neurons in the periphery and the centre of grafts were assessed 
from two TH-ir cell counts from Girk2/TH and calbindin/TH stainings (Figure 4.11). 
There were significantly more DA neurons in the periphery than in the centre of grafts 
(within-subject factor – Location, F(1,60) = 16.30, p<0.001). However, this difference 
was significant only in grafts in the striatum and N.Acc in the E14 donor age group 
Figure 4.10 Percentages of Girk2-ir/TH-ir and calbindin-ir/TH-ir neurons in the periphery and in the 
centre of E12 (A) and E14 grafts (B) at 6 weeks post-transplantation. (A) Compared to the 
hippocampus, grafts in the striatum and N.Acc had a significantly higher percentage of Gitk-2-ir/TH-
ir cells in the periphery of grafts. (B) E14 grafts in the striatum had a significantly higher percentage 
of Gitk-2-ir/TH-ir cells in the periphery of grafts than grafts in the PFC and hippocampus. (A, B) 
The A9 type DA neurons were residing predominantly in the periphery rather than the core of grafts 
while A10 type DA neurons were more homogeneously distributed within the graft. Significant 
differences between individual groups are depicted on the graph. Columns depict group means; error 
bars illustrate SEM; significance levels: * p<0.05, ** p<0.01, *** p<0.001. 
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(Figure 4.11B). As expected, TH-ir cell yields were higher in grafts in the E12 donor 
age group than E14 group (Donor Age, F(1,60) = 4.26, p<0.05). The transplantation site 
had an effect on the yield of DA neurons in the periphery but not the centre of grafts 
(Location x Environment, F(3,60) = 4.56, p<0.01), significant differences are summarised 
in Figure 4.11A, B.   
 
 
 
 
 
Figure 4.11 Total numbers of TH-ir cells from Girk2/TH and calbindin/TH stainings in the periphery 
and in the centre of E12 (A) and E14 grafts (B). (A) In the E12 donor age group, grafts in the striatum 
had significantly more surviving DA neurons in the periphery of grafts than grafts in the hippocampus 
and N.Acc. (B) In the E14 donor age group, there were significantly more surviving TH-ir cells in the 
periphery than the centre of grafts in the striatum and N.Acc. The yield of DA neurons was 
significantly lower in the periphery of grafts in the hippocampus than in the periphery of grafts in the 
N.Acc. The graph depicts significant differences between individual groups for pooled TH-ir cell 
yield data from two stainings to increase the power of the analysis. Columns depict group means; 
error bars illustrate SEM; significance levels: * p<0.05, ** p<0.01, *** p<0.001. 
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4.3.6 A9 and A10 type DA cell sizes 
A9 and A10 type DA neuron diameters are shown in Figure 4.12. Girk2-ir/TH-ir 
cells were significantly bigger than calbindin-ir/TH-ir cells in all transplantation sites in 
both donor age groups (F(1,32)
 
= 267.85, p<0.001). A9 type DA neurons in E14 grafts 
were bigger than in the E12 grafts (F(1,32)
 
= 41.78, p<0.001). The transplantation site had 
a significant effect on the size of A9 type DA neurons (F(3,32)
 
= 10.56, p<0.001). Girk2-
ir/TH-ir cells in E14 grafts were significantly bigger than in E12 grafts in all 
transplantation sites. Also, Girk2-ir/TH-ir cells were significantly bigger in E12 grafts 
in the striatum than in the PFC and hippocampus. There were no significant differences 
in the A10 type DA cell diameters in the grafts between donor age groups and 
transplantation sites.  
Figure 4.12 (A) Girk2-ir/TH-ir cell diameters. A9 type DA neurons were bigger in E14 grafts than 
E12 grafts. Also, Girk2-ir/TH-ir cells were bigger in the striatum than the PFC and hippocampus in 
the E12 donor age group. (B) Calbindin-ir/TH-ir cell diameters. The A9 type DA neurons were 
significantly bigger than the A10 type DA neurons in all groups. A10 type DA neurons were of 
similar size in all groups. Significant differences between individual groups are depicted on the 
graph. Columns depict group means; error bars illustrate SEM; significance levels: * p<0.05, ** 
p<0.01, *** p<0.001. 
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4.4 Discussion 
In the developing peripheral and central nervous systems, neuronal innervation 
is guided by environmental cues such as trophic factors exerted by the target tissues 
during critical stages of development (Hendry, 1975, Landmesser, 1978). Removal of 
target organs prevents the survival of neurons innervating the target, and, conversely, 
experimentally induced increase in targets produces an increased survival of the 
innervating neurons. The degree of innervation, the patterning of the regenerating axons 
and the sprouting of appropriate transplanted neurons into the target have all been 
shown to be influenced by the environment in sympathetic ganglia (Olson and 
Malmfors, 1970), hippocampus (Bjorklund and Stenevi, 1981), and the striatum 
(Thompson et al., 2005). This neuron-target interaction has been studied by 
transplanting different types of neurons into the same target and tracking their afferent 
projections, which can form distinctly different patterns depending on the type of 
neurons grafted (Nilsson et al., 1988, Bjorklund et al., 1990, Clarke et al., 1990). For 
instance, DA neurons from the VM after transplantation to the hippocampus ramified 
extensively in the denervated perforant path zone but showed no tendency to grow into 
the normal terminal zones of the noradrenergic afferents (Bjorklund et al., 1976). 
Significant differences in the A9 and A10 type DA neuron populations within striatal 
grafts observed in our previous experiments as well as independent studies (Mendez et 
al., 2005, Thompson et al., 2005) suggest that the host striatum may influence the 
development and/or survival of DA neuron subtypes in the grafts. 
In this experiment the environment was shown to have little influence on the 
total number of neurons in the grafts derived from E12 and E14 rat embryos and 
transplanted into the striatum, N.Acc, PFC and hippocampus. All grafts contained 
differentiated TH-ir neurons, with the TH-ir neuronal component representing 12.48% 
and 5.15% of the transplanted neurons in E12 and E14 grafts, respectively. A higher 
yield of TH-ir cell numbers in E12 grafts than equivalent E14 grafts in all four 
transplantation sites is comparable to previously observed properties of the rat E12 VM 
which yields a several-fold greater number of TH-ir neurons than equivalent E14-
derived grafts (Chapter 3 and Torres et al., 2007). The transplantation site affected the 
TH-ir neuron yield only in E12 grafts, with the grafts in the PFC producing a lower 
number of TH-ir neurons than grafts in the striatum. As mentioned in Chapter 4.3.2, not 
all sections of the PFC containing the graft were collected for immunohistochemistry. 
Thus, this drop in the TH-ir cell yield in E12 grafts in the PFC could be an artefact of 
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missing anterior sections of the PFC that contained the graft. Moreover, functionality of 
the VM graft cannot be assessed based solely on the number of TH-ir cells because TH 
is not selective in labelling the two DA neuron subtypes. Therefore, when assessing the 
effect of the transplantation site on the development and survival of DA neurons, it is 
more important to look at the DA neuron subtypes. 
All grafts contained both the A9 type and A10 type DA neurons. The yield of 
A9 type DA neurons followed an expected pattern with the highest number of Girk2-
ir/TH-ir cells found in grafts in the striatum, which receives the A9 type DA innervation 
from the midbrain, followed by a progressive decrease in the number of A9 type DA 
neurons in E12 grafts in the N.Acc, PFC and hippocampus in the absence of the A9 type 
DA innervation. E14 grafts in the striatum and N.Acc yielded similar numbers of the A9 
type DA neurons indicating that the survival of developmentally older DA cells was less 
affected by the presence of environmental cues. Nevertheless, in the absence of the A9 
type targets for innervation, E14 grafts in the PFC and hippocampus produced lower 
numbers of the A9 type DA neurons than grafts in the striatum and N.Acc. The A10 
type DA innervation of the N.Acc and PFC did not result in a significant increase in the 
number of A10 type DA neurons as compared to grafts in the striatum and 
hippocampus. There was a slight increase in the number of A10 type DA neurons in 
E14 grafts in the N.Acc but it did not reach statistical significance. Despite different 
types of DA innervation of the striatum, N.Acc and PFC, all grafts in these 
transplantation sites contained more A9 type than A10 type DA neurons, an effect 
which was seen in both donor age groups. Only in the grafts in the hippocampus, was 
there a big enough decrease in the number of A9 type DA neurons to bring their yield 
below the yield of the A10 type DA neurons in both donor age groups. Despite a 
significantly higher yield of TH-ir cells in the E12 grafts, the percentages of A9 type 
and A10 type DA neurons in grafts in each transplantation site were similar between the 
two donor age groups. Interestingly, the effect of the transplantation site on the 
percentages of Girk2-ir/TH-ir and caldindin-ir/TH-ir cells was identical to significant 
differences in the total number of A9 type and A10 type DA neurons in grafts in 
different transplantation sites. Thus, although the total number of TH-ir cells was 
affected by the environment, the differences in the number of A9 type DA neurons in 
grafts between different transplantation sites were not due to DA neuron death but 
rather due to silencing of the A9 phenotype of DA neurons in the absence of the A9 
type target innervation in the host brain. Indeed, the sum of percentages of A9 and A10 
type DA neurons in the striatum and N.Acc was ≈105% whereas in the PFC and 
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hippocampus it was 78% and 69%, respectively, indicating that almost a third of TH-ir 
neurons were neither of A9 nor of A10 type in grafts in the PFC and hippocampus. The 
absence of an effect of the transplantation site on the total number of A10 type DA 
neurons could be due to the fact that a unilateral 6-OHDA lesion of the median 
forebrain bundle causes only a partial loss of DA neurons in the VTA and subsequently 
achieves only a partial denervation of the N.Acc and PFC. Previous studies indicated 
that post lesion amphetamine-induced rotation rates comparable with those observed in 
the present experiment are associated with DA depletions of more than 99% in the 
striatum and 25% in the N.Acc caused by DA neuron losses of more than 99% in the 
SNpc and 50% in the VTA (Olds et al., 2006).  
It is important to consider the number of a therapeutic cell type as a function of 
graft volume in transplantation-based therapies for brain repair. Grafts should produce a 
sufficient cell yield to achieve the desired functional effect, while the graft size should 
be small enough as not to cause any damage to the host brain at the site of 
transplantation. Based on the average cell densities and graft volumes, the density of the 
A9 type DA neurons at each graft site was in the order of 1.3 – 5.8 × 103 Girk2-ir/TH-ir 
neurons/mm
3
 and the density of the A10 type DA neurons was 1.6 – 2.8 × 103 
calbindin-ir/TH-ir neurons/mm
3
. In this context, the present results, even for grafts in 
the hippocampus, compare favourably to findings from human VM transplantation into 
the putamen of patients with PD. Recent post-mortem studies in two patients showed 
that a therapeutic benefit up to 3 years after transplantation was achieved by grafts with 
the DA neuron density in the order of 0.2 to 2.4 × 10
3
 DA cells/mm
3
  (Mendez et al., 
2005). Thus, despite a significant loss of the A9 phenotype of DA neurons in grafts in 
the N.Acc, PFC and hippocampus, the cell densities observed in all grafts remained 
within the known functional range.       
The present findings revealed that the A9 type DA neurons clustered at the 
periphery of grafts in the striatum, N.Acc and PFC, but not in the hippocampus, 
whereas the distribution of the A10 type DA neurons was more homogeneous within the 
graft. The striatum was found to positively influence the yield of the A9 type DA 
neurons in the periphery of grafts as compared to transplants in PFC and hippocampus 
in both donor age groups, and additionally in E14 grafts in the N.Acc. Furthermore, E12 
grafts in the N.Acc contained slightly more A10 type DA neurons in the periphery of 
grafts than grafts in the striatum but the difference was not significant. Not surprisingly, 
the effect of the environment on two DA neuron subtypes was more detectable in the 
periphery of grafts rather than in the centre because neurons in the periphery of grafts 
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are more exposed to the environmental cues and are more likely to be affected by them. 
However, it is important to note that the measured effect represents a combination of the 
effect of the transplantation site on the graft and the effect of the environment within the 
graft on two DA neuron populations. TH-ir neurons in the core of grafts are less likely 
to be affected by the host environment cues because they are not directly exposed to 
them but they will be affected by the local microenvironment within the graft. Indeed, 
the TH-ir cell yield was affected by the transplantation site in the periphery but not in 
the core of grafts, whereas local environment within the graft caused a decrease in the 
total number of TH-ir neurons within the core as compared to the periphery in E14 
grafts in the striatum and N.Acc. Location within the graft might have a greater 
influence on the differentiation, survival and migration of the A9 type DA neurons than 
the A10 type DA neurons. The A9 type DA neurons are known to be more susceptible 
to oxidative stress (Lotharius and Brundin, 2002, Smits et al., 2006) and therefore their 
survival might be affected more within the core of the graft than in the periphery with a 
less well established blood and nutrient supply. This was reflected, at least in part, in the 
fact that the A9 type DA neurons were predominantly found in the periphery of grafts 
than in the centre in all transplantation sites. Even when there were no environmental 
cues in the cerebral environment to attract their migration to and/or survival in the 
periphery of grafts, the A9 type DA neurons still survived better in the periphery than in 
the core of grafts.  The distribution of the A10 type DA neurons was more 
homogeneous within the graft regardless of the transplantation site indicating that these 
neurons were less dependent on cues or resources from the host environment for their 
survival. 
The TH-ir reactive fibres extending from the developing VM do not reach the 
ganglionic eminence until day 19 of embryonic development in the rat (Gates et al., 
2004). Thus, there is also a possibility that DA neuron precursors in the core of grafts 
do not die, but instead fail to differentiate into a certain DA neuron subtype in the 
absence of functional connections and as a result silence their Girk2/calbindin 
expression altogether and differentiate into a different type of CA neuron. Indeed, ≈50% 
of TH-ir neurons in the core of the grafts did not coexpress neither Girk2 nor calbindin.  
Also, a great portion of TH-ir cells in grafts in the hippocampus (41% in the E12 group, 
33% in the E14 group) failed to co-express either Girk2 or calbindin. Developmental 
signals available within the graft might not have sufficed to drive DA precursors 
towards the correct developmental pathway. Both E12 and E14 rat VM, especially in 
E12 grafts, contain a mix of differentiated and undifferentiated DA precursors, and 
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current evidence suggests that not only their survival but also to a great extent their 
differentiation into either type of DA neurons are affected by both the location within 
the graft and the host environment of the transplantation target. Grafts derived from E10 
mice donor tissue (equivalent to E11.5 in rats) are enriched with mitotic DA neuroblasts 
which contribute to a higher yield of the A9 type DA neurons within the grafts in the 
mouse striatum (Bye et al., 2012). This suggests that younger DA neurons have better 
responsiveness to guidance cues present within the grafts and the surrounding striatum. 
Studies have demonstrated that such responsiveness is downregulated in older neurons 
(Van den Heuvel and Pasterkamp, 2008).  Indeed, in this experiment we observed that 
the transplantation site affected E12 grafts to a greater extent than E14 grafts. 
The transplantation site also affected the DA neuron cell sizes. The A9 type DA 
neurons were once again generally bigger than the A10 type DA neurons as already 
seen in previous studies (Chapter 3 and Thompson et al., 2005). Interestingly, E14-
derived A9 type DA neurons were bigger than E12-derived A9 type DA neurons in all 
transplantation sites. Most importantly, the A9 type DA neurons were smaller in E12 
grafts in the PFC and hippocampus than in the striatum. Cell body size is dependent on 
the metabolic activity of the cell, and clearly in E12 grafts in the PFC and hippocampus, 
in the absence of target innervation, the A9 type DA neurons were less active and failed 
to reach the normal cell body size. In vitro studies have demonstrated that the presence 
of normal target tissues results in the increase in fibre elongation, cell body and nuclear 
size, and catecholamine and TH content in cultured sympathetic neurons (Chamley and 
Dowel, 1975, Coughlin et al., 1978).  
4.5 Conclusion 
This experiment has demonstrated a significant effect of the transplantation site 
on both DA neuron phenotypes in the grafts and the distribution of A9 and A10 type 
DA neurons across the periphery and the centre of the graft. Also, there was a 
significant effect of the environment on the percentage of A9 type but not A10 type DA 
neurons in the grafts. The evidence suggests that the environment affects differentiation 
of DA neurons more than their survival. It is unclear however, as to what extent post-
graft proliferation and differentiation of DA precursor cells contribute to different A9 
and A10 type DA neuron populations and their distribution within the graft. A future 
experiment will investigate proliferation of DA neural precursor cells post-grafting and 
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the contribution of cell birth in the host to the yield of A9 type and A10 type DA 
neurons in intrastriatal grafts. 
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Chapter 5. The A9 and A10 Type Dopamine Neuron 
Proliferation Post-grafting in Ventral Mesencephalon 
Transplants 
 
Summary 
The aims of this chapter were (i) to quantify the populations of the A9 type and 
A10 type DA neurons in grafts derived from E12 and E14 VM rat tissue, and (ii) to 
determine whether proliferation of A9 type DA precursor cells contributes to the 
enriched composition of younger donor tissue grafts. To that end, 6-OHDA unilaterally 
lesioned rats received E12 and E14 VM transplants and a sub-cohort of grafted animals 
in each group were injected i.p. 4 hours post-transplantation with 120mk/kg BrdU to 
label mitotic cells. The results revealed no toxic effect of the BrdU dose on the DA 
neuron yield in the grafts. Grafts derived from younger donor tissue contained bigger 
subpopulations of DA progenitors that continued dividing in the host striatum and 
subsequently matured into A9 type and A10 type DA neurons. The A9 type DA neuron 
birth post-grafting significantly enriched E12 grafts with the SNpc DA neurons with 
little effect on the VTA DA neurons as compared to grafts in the E14 group. Also, the 
majority of DA neurons born post-grafting were found at the periphery of the graft 
rather than in the centre of grafts suggesting that direct access to the functional targets 
in the striatum may be necessary for mitotic DA precursor cells to survive and 
differentiate into mature neurons.  
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5.1 Introduction 
Clinical trials of cell transplantation therapy in PD have so far been based on the 
use of postmitotic DA neurons obtained from the developing human embryonic VM, 
aged 6-9 weeks post-conception (Freeman et al., 1995a, Hagell et al., 1999, Brundin et 
al., 2000b, Baker et al., 2000, Freed et al., 2001, Olanow et al., 2003). This critical time 
window corresponds to the peak ontogeny of DA neurons when their fate is already 
determined but the cells have no extensive outgrowth of neuritic processes yet, which 
may compromise DA neuron survival during graft tissue dissection and preparation for 
implantation (Freeman et al., 1995b). Historically, the time of maximal neurogenesis for 
midbrain DA neurons in the rat has been considered to occur at E14, at a CRL of 10.5-
11.5mm (Bjorklund et al., 1980b, Altman and Bayer, 1981, Brundin et al., 1985b, 
Brundin et al., 1988, Dunnett and Bjorklund, 1992). At this stage, a high proportion of 
DA neurons are about to complete differentiation or already express TH but still have 
small, or no, axonal arbours. Other studies have suggested that only DA neurons that 
underwent their final division in utero before removal from the donor embryo were able 
to survive transplantation, develop into mature DA neurons and make functional 
connections with the host striatum (Sinclair et al., 1999). Thus, E14 rat embryos have 
been the predominant source of midbrain DA neurons in cell transplantation research in 
animal models of PD over the years (Barker et al., 1995, Barker et al., 1996, Agrawal et 
al., 2004, Dowd and Dunnett, 2004, Breysse et al., 2007, Kuan et al., 2007, Terpstra et 
al., 2007). Grafts derived from the rat E14 VM and the equivalent gestation human VM 
yielded DA neuron survival rates of 5 – 10% of the expected adult DA complement and 
restored behavioural deficits (Fawcett et al., 1995, Barker et al., 1996, Dowd and 
Dunnett, 2004, Sortwell et al., 2004). Embryonic VMs both younger and older than E14 
produced even smaller yields of DA neurons and were dismissed as the donor tissue for 
transplantation until 7 years ago. 
Most recent studies suggest that TH-ir neurons can be identified in the 
developing rat VM as early as E12 and that by E14 large numbers of DA neurons 
extend axonal projections (>1 mm) to the ventral forebrain (Gates et al., 2004). Re-
examination of the ontogeny of SNpc DA neurons reveals that up to 80% of DA 
neurons in the SNpc might be born over a 24-hour period on E12 in SD rats (Gates et 
al., 2006). These younger DA precursor cells have been shown to provide an enhanced 
DA neuron yield in grafts and restore behavioural deficits in 6-OHDA lesioned rats 
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(Torres et al., 2007, Torres et al., 2008a). Transplanted E12 VM tissue contains a 
mixture of differentiated DA neurons that have already undergone final mitosis and 
developing DA neural progenitor cells that continue to proliferate in the host and mature 
into functional DA neurons after transplantation (Weyrauch, 2009). Levels of continued 
cell division in the A9 and A10 subpopulations of DA neurons in the graft remain 
unknown. In Chapter 4, we have already demonstrated that both E12 and E14 A9 type 
DA precursor cells might be less committed to their neuronal fate than the A10 type DA 
precursor cells at the time of transplantation and that, in the absence of correct 
functional targets, a substantial number of A9 type DA precursor cells either fail to 
follow the correct developmental pathway or silence their A9 phenotype. This suggests 
that it is predominantly the A9 type and not the A10 type DA precursor cells that 
contribute to DA neuron birth post-transplantation.  
Dividing cells and their lineages can be traced using the thymidine analogue 5-
bromo-2-deoxyuridine (BrdU), which is incorporated into the newly synthesized DNA 
instead of thymidine during the S-phase of the cell cycle and therefore is used to 
specifically label dividing cells (Kriss and Revesz, 1962, Yamada et al., 2005). The cell 
cycle of embryonic neural progenitor cells is 12-14 hours and the S-phase equates to 
one third or half of this period (Hayes and Nowakowski, 2000, Hayes and Nowakowski, 
2002). Reliable long-term labelling of mitotic grafted cells in adult rodents with no 
BrdU-associated toxic effects has been demonstrated with BrdU doses of >100mg/kg 
(Weyrauch, 2009, Bye et al., 2012). 
5.1.1. Aims of this chapter 
The present study was undertaken to determine the origin of ongoing DA 
precursor cell division within grafts derived from rat E12 and E14 VM tissue. BrdU was 
used to label mitotic DA precursor cells that continued to proliferate after 
transplantation. The aims of this experiment were: 
1. To quantify levels of continued cell birth in the A9 and A10 subpopulations of 
DA neurons in both E12 and E14 grafts 
2. To determine whether the enrichment for A9 type DA neurons seen in VM grafts 
originates from increased cell birth of the A9 type DA neural progenitors post-
transplantation 
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5.2 Experimental Procedure 
This study initially was planned as a pilot experiment aimed to test BrdU 
labelling of dividing DA neurons in grafts after transplantation in a small cohort of 
animals (n = 6). However, based on the previous work done in our lab demonstrating 
successful labelling of dividing grafted neurons using the same dose of BrdU the 
decision was made to transplant a second cohort of animals to complete the data for 
a full experiment (n = 16). Thus, the grafts in each group were derived from multiple 
cell suspensions in each donor age group, which is essential for studies of this kind.  
 All of the methods used in this experiment are described in Chapter 2. In this 
study, 22 female SD rats received a unilateral lesion to the right MFB via the 
injection of 6-OHDA (Chapter 2.3.1) and were assessed for motor deficits using 
drug-induced rotation tests (Chapter 2.4). Due to the temporary unavailability of 
methamphetamine at the time, D-Amphetamine (Sigma-Aldrich) was used to assess 
rotational behaviour after lesion and after grafting in the first cohort of animals. 
Methamphetamine was used for the drug-induced rotation test in the second cohort 
of animals. In agreement with previous studies (Romero et al., 2006), both drugs 
elicited a similar rotational behaviour in the two cohorts of animals (one-way 
ANOVA with repeated measures; Drug, F(1,20) = 1.89, n.s.). The rats were allocated 
into 2 homogeneous groups based on their performances on the drug-induced 
rotation test post-lesion (E12: 1391.1 ± 84.3; E14: 1407 ± 155; mean ± SEM) and no 
statistical differences between the groups were confirmed with a one-way ANOVA 
(Group, F(1,20) = 0.01, n.s.).   
Six weeks post-lesion, the animals received an intrastriatal transplant 
containing cell numbers equivalent to 1 VM in 2 µl of the cell suspension as 
described in Chapter 2.3.2. Stereotaxic co-ordinates for the placement of grafts into 
the striatum were as follows: AP: +0.6 mm, ML: -3.0 mm, DV: -5.0 mm (Paxinos 
and Watson, 2003). In the E12 group, one animal in the first cohort did not recover 
after the transplantation surgery. An additional lesioned animal received an E12 
transplant during a different surgery session to replace the lost animal and complete 
the group numbers. The second cohort of animals (n = 8) was grafted from a single 
E12 cell suspension. There were no significant differences between the three E12 
cell suspensions used to graft 11 animals (E12 1: 101,000 cells/VM, viability – 
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94.33%; E12 2: 100,000 cells/VM, viability – 94.9%; E12 3: 109,000 cells/VM, 
viability – 91.93%). In the E14 group, one suspension per cohort was used to graft 3 
animals in the first cohort and 8 animals in the second cohort (E14 1: 497,500 
cells/VM, viability – 95.3%; E14 2: 503,000 cells/VM, viability – 92.31%). Again, 
no significant differences between the two E14 cell suspensions were identified. In 
both donor age groups, 3 grafted animals in the first cohort and 5 out of 8 grafted 
animals in the second cohort received i.p. injections of BrdU (120mg/kg) within 4 
hours after transplantation (see Chapter 2.7.1 for details on BrdU preparation). Drug-
induced rotation tests were performed 4 and 6 weeks post-transplantation to assess 
graft functionality. All animals were transcardially perfused 7 weeks after 
transplantation and coronal brain sections were collected for IHC processing 
(Chapter 2.5).  
Brain tissue from both cohorts of animals was processed together for IHC 
analysis. A one-in-twelve series of sections was processed for BrdU-
immunoreactivity using DAB and subsequently for nuclei staining using Mayer’s 
haematoxylin. Two one-in-twelve series of sections were processed for BrdU, Girk2, 
TH and BrdU, calbindin, TH, respectively, using fluorescent triple labelling IHC 
(refer to Chapter 2.6 for more details and antibody concentrations). Cells were 
counted blind to the experimental condition abiding by the stereological principles 
(Chapter 2.8). The total number of TH-ir neurons per graft was calculated as an 
average TH-ir cell count obtained from BrdU/Girk2/TH and BrdU/calbindin/TH 
stainings. Due to very low numbers of triple labelled cells per graft, especially in the 
centre of the graft (in most cases only 1 triple labelled cell in the centre of the graft 
was found), a standard method of unbiased sampling of the periphery and the centre 
of the graft (see Chapter 2.8.2) was not applicable. Instead, analysis of the total 
number of counted triple labelled cells either in the periphery or the centre of the 
graft is presented here. 
Statistical analyses were performed in SPSS as described in Chapter 2.9. 
Behavioural data was analysed using a three-way ANOVA with repeated measures. 
One- and two-way ANOVAs were used to analyse TH-ir cell yield and BrdU-ir cell 
yield. DA neuron subpopulations, their proliferation post-grafting and distribution 
within the graft were analysed using two- or three-way ANOVAs with repeated 
measures. Where applicable a Bonferroni correction for multiple comparisons was 
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used to reveal significant differences between individual groups and results were 
considered to be significant if p<0.05 (*). 
5.3 Results 
5.3.1 Functionality of the grafts 
The functional ability of the graft to release dopamine and restore lesion-
induced motor deficits was assessed by the drug-induced rotation test at 4 and 6 
weeks after transplantation. There were no differences in amphetamine-induced 
rotational behaviour at either time point between BrdU-treated animals and controls 
in both donor age groups (BrdU, F(1,18) = 2.06, n.s.; no significant interactions 
associated with BrdU). Therefore, subsequent analysis was performed on the 
combined data within each donor age group. Figure 5.1 shows the total number of 
net rotations performed over 90 minutes, ipsilateral minus contralateral to the 
lesioned side. Post-lesion, the animals rotated ipsilaterally to the lesioned side, a 
classic rotational behaviour induced by the 6-OHDA lesion to the nigrostriatal 
pathway in response to amphetamine. Fluorescent TH IHC revealed virtually no 
surviving TH-ir neurons in the lesioned SNpc but the extent of lesions was not 
quantified. In both donor age groups, grafts in the striatum significantly reduced the 
net number of rotations and ameliorated the lesion-induced rotational behaviour 4 
and 6 weeks post-transplantation (within-subject factor – Transplantation, F(2,40) = 
205.18, p<0.001). There were no differences in rotational behaviour between the E12 
and E14 groups (Donor Age, F(1, 20) = 0.16, n.s; Donor Age x Transplantation, F(2,40) 
= 0.09, n.s.). In both donor age groups, there was a significant decrease in the net 
number of ipsilateral rotations at 4 and 6 weeks post-grafting compared to post-
lesion (p<0.001). At 6 weeks post-grafting, most animals rotated contralaterally to 
the lesioned side, a classic over compensatory response. However, this further 
reduction in the net number of rotations at 6 weeks as compared to 4 weeks post-
transplantation was significant only in the E12 group (p<0.05). 
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5.3.2 Dopamine neuron yield in the grafts 
Examination of TH staining confirmed the presence of well positioned grafts 
in the dorsal striatum of most animals in both donor age groups. Grafts contained 
large numbers of surviving TH-ir neurons and extensively innervated the 
surrounding striatum. Larger TH-ir neurons with angular cell bodies resided in the 
periphery of the graft and smaller rounder TH-ir cells clustered in the centre of the 
graft. No surviving TH-ir neurons were found in the striatum of one animal in the 
E14 BrdU group. The staining was repeated on a one-in-six series in an attempt to 
detect surviving DA neurons in case the graft was very small. However, no sections 
containing the graft were present. Nevertheless, no toxic effect of the BrdU dose on 
the survival of TH-ir neurons was detected in either donor age group as depicted in 
Figure 5.2A (BrdU, F(1,18) = 0.01, n.s.; BrdU x Donor Age, F(1,18) = 0.35, n.s.). The 
animal that did not contain the graft was excluded from further analysis of DA 
neuron proliferation and maturation post-grafting. Grafts in the E12 group produced 
Figure 5.1 Amphetamine-induced net rotational behaviour post-lesion and post-grafting in the 
E12 (red) and E14 (blue) groups (data from BrdU-treated animals and controls is pooled 
together). Both E12 and E14 intrastriatal grafts produced a significant recovery of the lesion-
induced behavioural deficits. There was a highly significant change (***) from ipsilateral 
rotation observed post-lesion to a net contralateral rotation post-grafting, the classic over-
compensatory response (F(1,20) = 205.18,  p<0.001). Data are presented as a mean number of net 
rotations (ipsilateral minus contralateral) over 90 minutes, error bars indicate SEM, significance 
levels: * p<0.05, *** p<0.001. 
Amphetamine-induced rotations 
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a 2.28-fold higher yield of TH-ir neurons than grafts in the E14 group (Figure 5.2B). 
As previously, younger DA precursor cells yielded significantly higher numbers of 
DA neurons in the grafts (Donor Age, F(1,19) = 7.54, p<0.05).  
 
Figure 5.2 (A) TH-ir neuron yields in grafts in the E12 and E14 groups in animals that received 
a BrdU injection after transplantation and in control animals. No significant effect of the BrdU 
dose on the number of TH-ir neurons in the grafts was found. (B) Total TH-ir neuron numbers in 
the two groups 7 weeks post-transplantation. Grafts in the E12 group contained significantly 
more DA neurons than in the E14 group (data from BrdU-treated animals and controls is pooled 
together). Data are presented as group means, error bars correspond to SEM, significance level: 
* p<0.05. 
A. Survival of TH-ir neurons in BrdU 
injected and control animals 
B. Survival of TH-ir neurons in 
E12 and E14 grafts 
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5.3.3 Continued cell and DA neuron division in the grafts after transplantation 
All surviving grafts in both donor age groups exhibited similarly strong nuclear 
BrdU staining. Large populations of homogeneously distributed BrdU-ir cells were 
observed in grafts in the E12 group (Figure 5.3A, C). Grafts in the E14 group contained 
fewer BrdU-ir cells that were sparsely distributed within the graft (Figure 5.3B, D). 
When comparing the number of BrdU-ir cells per transplant, a significant difference 
between the two donor age groups was detected. As shown in Figure 5.4A, 11.74-fold 
more surviving cells incorporated BrdU shortly after transplantation in the E12 group 
than E14 group indicating that E12 VM contains a larger population of young precursor 
cells that continue to proliferate after transplantation and are able to survive and 
differentiate into mature functional cells (Donor Age, F(1,13) = 13.76, p<0.01). However, 
A B 
C D 
Figure 5.3 Photomicrographs of representative grafts derived from rat E12 (A, C) and E14 (B, 
D) VM showing surviving cells that continued to divide after transplantation (brown) 
counterstained with haematoxylin (blue) both at x10 (A, B) and x40 (C, D) magnification. There 
were very clearly discernible BrdU-ir cells in grafts in both donor age groups. Grafts in the E12 
group contained a dense population of BrdU-ir cells that were homogeneously distributed within 
the graft. Fewer BrdU-ir cells could be identified in grafts in the E14 group. Scale bars: 200 µm 
(A, B); 20 µm (C, D). 
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only a small number of BrdU-ir cells belonged to the DA neuron population in the 
grafts. In the E12 group, out of almost 6000 BrdU-ir cells in the grafts (5938.4 ± 
1357.8; mean ± SEM) only 158 ± 37.26 cells co-labelled with TH. In the E14 group, the 
mean number of DA neurons that incorporated BrdU was 32.71 ± 6.77 while the total 
yield of BrdU-ir cells was 506.04 ± 145.46.  There were significantly higher numbers of 
BrdU-ir/TH-ir neurons in the E12 group than E14 group (Figure 5.4B; Donor Age, 
F(1,13) = 9.64, p<0.01). The increase in the number of BrdU-ir/TH-ir neurons in grafts in 
the E12 group outweighed the general increase in the number of TH-ir neurons between 
grafts in the two donor age groups. Post-grafting proliferation of DA precursor cells 
contributed to a higher yield of DA neurons in the E12 group as indicated by a 
significant difference in the percentage of BrdU-ir/TH-ir neurons (Figure 5.4C; Donor 
Age, F(1,13) = 5.6, p<0.05).  
 
5.3.4 The A9 and A10 type DA precursors in the grafts 
Fluorescent triple BrdU/Girk2/TH and BrdU/calbindin/TH labelling successfully 
identified subpopulations of the A9 and A10 type DA neurons, respectively, that 
continued to divide in the host striatum after transplantation in grafts in both donor age 
Figure 5.4 (A) Total numbers of BrdU-ir cells in the grafts. Grafts in the E12 group contained 
significantly more BrdU-ir cells than E14 group. (B) Comparison of the numbers of surviving 
DA neurons that were mitotic at the time of transplantation. There was a significantly higher 
level of DA precursor cell proliferation post-grafting in grafts in the E12 group than E14 group 
as indicated by the difference in the number of BrdU-ir/TH-ir neurons in the grafts. (C) Effect of 
the donor age on the percentage of BrdU-ir/TH-ir neurons in the grafts. Grafts in the E12 group 
contained a significantly higher percentage of TH-ir neurons that co-labelled with BrdU. Data are 
presented as group means ± SEM, significance levels: * p<0.05, ** p<0.01. 
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groups. As depicted in Figure 5.5, strong nuclear BrdU staining co-localised with 
cytoplasmic Girk2/TH and calbindin/TH stainings of DA neurons. Fluorescent BrdU 
staining exhibited the same trend as DAB BrdU, grafts derived from E12 VM displayed 
abundant BrdU-ir cells and grafts in the E14 group contained fewer BrdU-ir cells. 
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BrdU / Girk2 / TH 
BrdU / Girk2 / TH 
BrdU / Girk2 / TH 
BrdU / Girk2 / TH 
BrdU / calbindin / TH 
BrdU / calbindin / TH 
BrdU / calbindin / TH 
BrdU / calbindin / TH 
Figure 5.5 Coronal sections through the striatum showing positive staining for BrdU, Grik2, TH (A) and BrdU, 
calbindin, TH (B) within E12 VM donor grafts at 6 weeks post-transplantation. A small population of both A9 
type and A10 type DA precursor cells were dividing and incorporated BrdU at 4 hours post-grafting and 
subsequently matured into functional DA neurons. A series of higher power panels illustrates the A9 type DA 
neurons (C-E) and the A10 type DA neurons (F-H) born in the graft. Scale bars: 100 µm (A, B); 20 µm (C-H).  
C 
A B 
F 
D 
E 
G 
H 
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As seen in previous experiments (Chapter 3, 4), grafts in the E12 group yielded 
higher numbers of both Girk2-ir/TH-ir and calbindin-ir/TH-ir neurons than grafts in the 
E14 group (Figure 5.6). A two-way ANOVA with repeated measures confirmed a highly 
significant difference between the numbers of A9 and A10 type DA neurons in the grafts 
(within-subject factor - Staining, F(1,19) = 41.05, p<0.001), a main effect of the donor age 
group (F(1,19) = 8.23, p<0.05) and a significant interaction (F(1,19) = 9.57, p<0.01). There 
were significantly more Girk2-ir/TH-ir neurons than calbindin-ir/TH-ir neurons in grafts 
both in the E12 (p<0.001) and E14 donor age groups (p<0.05). Grafts in the E12 group, 
contained significantly more A9 type and A10 type DA neurons than grafts in the E14 
group (p<0.01 and p<0.05, respectively). Grafts in the E12 group, contained not only an 
increased number of Girk2-ir/TH-ir neurons than grafts in the E14 group but also a higher 
proportion of TH-ir neurons that co-expressed Girk2 (80% and 73%, respectively) 
indicating an enriched composition (p<0.001). A similar proportion of TH-ir neurons co-
labelled with calbindin (22-23%) in grafts in both donor age groups. These results are 
comparable to previous findings described in Chapter 3. 
  
Cell counts of BrdU-ir/Girk2-ir/TH-ir and BrdU-ir/calbindin-ir/TH-ir cells were 
quite low in all grafts regardless of the donor age group (Figure 5.7). Nevertheless, 
grafts in the E12 and E14 groups showed distinctive differences between the two 
populations of DA neuron precursor cells that were still at the mitotic developmental 
Figure 5.6 Total numbers of Girk2-ir/TH-ir (green) and calbindin-ir/TH-ir (orange) neurons in the 
grafts (data from BrdU-treated animals and controls is pooled together). Grafts in the E12 group 
produced higher numbers of both DA neuron subtypes than in the E14 group. Also, Girk2-ir/TH-ir 
neurons were more abundant than calbindin-ir/TH-ir neurons in grafts in both donor age groups. 
Data presented as group means ± SEM, significance levels: * p<0.05, ** p<0.01, *** p<0.001. 
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stage at the time of transplantation and subsequently were capable of surviving and 
maturing into functional DA neurons in the host (within-subject factor – Staining, F(1,13) 
= 8.9, p<0.05). The numbers of both the A9 and A10 type DA neurons that co-labelled 
with BrdU were higher in grafts in the E12 group than E14 group (Donor Age, F(1,13) = 
9.68, p<0.01). More A9 type than A10 type DA neuron precursor cells continued to 
proliferate in the host after transplantation in grafts in the E12 group (p<0.01) while a 
similar number of BrdU-ir/TH-ir neurons coexpressed either Girk2 or calbindin in grafts 
in the E14 group (Staining x Donor Age, F(1,13) = 9.64, p<0.01). Grafts in the E12 group 
contained significantly bigger populations of both BrdU-ir/Girk2-ir/TH-ir and BrdU-
ir/calbindin-ir/TH-ir neurons than in the E14 group (p<0.01 and p<0.05). 
 
Grafts in the E12 group yielded significantly higher numbers of DA neurons 
than grafts in the E14 group and the number of triple labelled cells was calculated as a 
percentage of TH-ir neurons to account for the difference in overall TH-ir cell numbers. 
Post-grafting proliferation of either subtype of DA precursor cells contributed little to 
the total DA neuron yield in grafts in both donor age groups (Figure 5.8A). The 
percentage of TH-ir cells that co-labelled with BrdU/Girk2 in the E12 group was 
2.23±0.42% (mean ± SEM) while less than 1% of TH-ir neurons co-expressed 
Figure 5.7 A summary of BrdU-ir/Girk2-ir/TH-ir and BrdU-ir/calbindin-ir/TH-ir cell yields in 
grafts in the E12 and E14 groups. Grafts in the E12 group contained significantly bigger A9 type 
and A10 type DA neuron populations than the E14 group that had incorporated BrdU 4 hours 
after transplantation. Also, significantly more Girk2-ir/TH-ir neurons than calbindin-ir/TH-ir 
neurons co-labelled with BrdU in grafts in the E12 group. Data are presented as group means; 
error bars indicate SEM; significance levels: * p<0.05, ** p<0.01. 
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BrdU/Girk2 in the E14 group. In both donor age groups, less than 1% of DA neurons in 
the grafts were BrdU-ir/calbindin-ir. Nevertheless, there were significant differences 
between the percentages of triple labelled neurons in grafts in the E12 and E14 groups 
(within subject-factor – Staining, F(1,13) = 7.29, p<0.05; Donor Age, F(1,13) = 5.62, 
p<0.05; Staining x Donor Age, F(1,13) = 10.23, p<0.01). In the E12 group, a significantly 
higher percentage of DA neurons co-labelled with BrdU/Girk2 than BrdU/calbindin 
(p<0.01). Also, the percentage of BrdU-ir/Girk2-ir/TH-ir neurons was greater in grafts 
in the E12 group than E14 group (p<0.01). Furthermore, two thirds of BrdU-ir/TH-ir 
neurons co-labelled with Girk2 and one third co-expressed calbindin in grafts in the E12 
group (p<0.01). In the E14 group, the ratio of mitotic A9 type and A10 type DA 
neurons was 50/50 (Figure 5.7B). 
 
In order to account for differences between the A9 and A10 type DA neuron 
yields in grafts in the two donor age groups, the number of triple labelled cells was 
calculated as a percentage of corresponding DA neuron subtype population. As shown 
in Figure 5.9A, there was a significantly higher percentage of Girk2-ir/TH-ir neurons 
that co-labelled with BrdU in grafts in the E12 group than E14 group (F(1,13) = 8.66, 
Figure 5.8 (A) Percentages of TH-ir cells that co-labelled with BrdU/Girk2 and BrdU/calbindin in 
both groups. Post-grafting proliferation of the A9 type DA precursor cells in grafts in the E12 
group contributed the most to the total TH-ir cell yield as compared to all other groups. (B) 
Percentage of BrdU-ir/TH-ir that co-expressed either Girk2 or calbindin in both groups. In the E12 
group, two thirds of mitotic DA precursor cells that matured into functional neurons became the 
A9 type DA neurons and one third became the A10 type DA neurons. In the E14 group, equal 
numbers of BrdU-ir/TH-ir cells differentiated into A9 and A10 DA neurons. Columns depict group 
means; error bars illustrate SEM; significance level: ** p<0.01. 
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p<0.05). There was no difference between the percentages of calbindin-ir/TH-ir neurons 
in grafts in the E12 group and E14 group that incorporated BrdU after transplantation 
(Figure 5.9B; F(1,13) = 0.19, n.s). 
 
The majority of both types of triple labelled cells were found in the periphery of 
grafts in both donor age groups. Only a few BrdU-ir/Girk2-ir/TH-ir and BrdU-
ir/calbindin-ir/TH-ir cells resided in the centre of the graft. In both donor age groups, 
9% of counted BrdU-ir A9 type DA neurons resided in the centre of grafts while 91% of 
triple labelled cells were found in the periphery of grafts. Similarly, 9% of BrdU-ir A10 
type DA neurons resided in the centre of grafts and 91% in the periphery of grafts in the 
E12 group. In the E14 group, all BrdU-ir A10 type DA neurons were located in the 
periphery of grafts. However, in the E12 group, 50% of the grafts contained no BrdU-ir 
DA neurons of either phenotype in the core of the grafts. In the E14 group, only 1 
BrdU-ir/Girk2-ir/TH-ir cell was found in the centre of a single graft and no BrdU-
ir/calbindin-ir/TH-ir neurons resided in the centre of grafts. Figure 5.10 shows the 
numbers of triple labelled cells found either in the periphery or centre of the graft in 
both donor age groups. As expected more triple labelled cells of both types were found 
Figure 5.9 (A) Percentage of surviving A9 type DA neurons that continued to divide after 
transplantation. Grafts in the E12 group contained a significantly higher percentage of Girk2-
ir/TH-ir neurons that co-labelled with BrdU than grafts in the E14 group. (B) Percentage of 
surviving A10 type DA neurons that continued to proliferate post-grafting. No significant 
difference was found between grafts in the E12 and E14 groups. Columns depict group means; 
error bars illustrate SEM; significance levels: * p<0.05. 
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in the periphery than centre of the graft (within-subject factor – Location, F(1,13) = 17.52, 
p<0.01). Overall, significantly more A9 type than A10 type DA neurons co-labelled 
with BrdU (within-subject factor – Staining, F(1,13) = 8.94, p<0.05). Also, grafts in the 
E12 group contained more BrdU-ir DA neurons of both subtypes than grafts in the E14 
group both in the centre and periphery of the graft (Donor Age, F(1,13) = 9.67, p<0.01). 
Both BrdU-ir/Girk2-ir/TH-ir and BrdU-ir/calbindin-ir/TH-ir neuron yields in the 
periphery of the graft were significantly higher in grafts in the E12 group than E14 
group (p<0.05). The numbers of both A9 and A10 type DA neurons that were born in 
the host were higher in the periphery than centre of grafts in the E12 group (p<0.01 and 
p<0.001, respectively). In the E14 group, only the yield of BrdU-ir A10 type DA 
neurons in the periphery of the graft was significantly higher than in the centre of the 
graft (p<0.05). As shown before, there was a higher yield of BrdU-ir A9 type than A10 
type DA neurons in grafts in the E12 group so, not surprisingly, the number of counted 
BrdU-ir/Girk2-ir/TH-ir neurons in the periphery of grafts was significantly higher than 
BrdU-ir/calbindin-ir/TH-ir neurons (p<0.01). 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10 A summary of the numbers of BrdU-ir/Girk2-ir/TH-ir and BrdU-ir/calbindin-ir/TH-ir 
neurons and their location within the graft in both donor age groups. The majority of both 
phenotypes of DA neurons that continued to proliferate in the graft after transplantation were found 
in the periphery of all grafts. Significant differences between the groups are depicted on the graph. 
Data presented as group means ± SEM; significance levels: * p<0.05, ** p<0.01, *** p<0.001.  
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5.4. Discussion 
This study examined the A9 type and A10 type DA precursor cell proliferation 
and subsequent differentiation into functional DA neurons within the environment of 
intrastriatal grafts derived from E12 and E14 rat VM. Both donor ages lie within the 2-3 
day period of embryonic development when maximal neurogenesis of SNpc DA 
neurons occurs. However, there is some discrepancy in the evidence of the day of 
embryogenesis on which the generation of midbrain DA neurons is at its height.  
The earliest ontological studies using catecholamine fluorescence revealed that 
DA neurons in the rat VM start to appear in E10-11, 7mm embryos, rapidly increase in 
numbers at E12-13 and continue to increase in numbers at E15-16 (Olson and Seiger, 
1972, Seiger and Olson, 1973). Another study showed that TH-ir neurons with a few 
thin processes are detectable in the developing VM at E12.5, in 9 mm embryos, greatly 
increase in numbers by E13.5, in 11 mm embryos, exhibit an even more extensive 
distribution and project axons to the caudate-putamen by E14.5, in 15 mm embryos 
(Specht et al., 1981). Note that according to the most recent staging scale a CRL of 7 
mm corresponds to E12.5 rat embryos, 9 mm – E13, 11mm – E14, 15 mm – E16 
(Torres et al., 2008b). First examination of cell birth using tritiated thymidine (which 
incorporates into cell DNA during mitosis when injected into pregnant dams) provided 
evidence that neurons in the SNpc are born at E13-15 and neurons in the VTA are born 
slightly later, at E13-16 (Altman and Bayer, 1981, Marchand and Poirier, 1983). 
Another independent study mainly supported these results and showed that the 
generation of SNpc neurons occurs at E12-15 (Marchand and Poirier, 1983). Double 
labelling of BrdU-labelled neurons with TH produced similar results and showed that 
DA neurons in the SNpc develop between E12 and E16, rapidly increasing in numbers 
from E13 onwards to a maximum at E14 and E15 [with the day after overnight mating 
designated as E1 (Sinclair et al., 1999)]. Using a similar technique, a more recent study 
provided evidence that the peak neurogenesis of DA neurons occurs earlier  than at E14, 
in fact, the majority of DA neurons in the SNpc make their final division at E12 (Gates 
et al., 2006). However, in this experiment, the mating session was conducted for 2 hours 
in the evening and the following day was designated as E0. Thus, E12 as designated in 
this study most likely corresponds to E12.5 if the nomenclature is adjusted according to 
our breeding protocol (Chapter 2.2). Clearly, laboratory practise significantly varies in 
the aforementioned studies. There are differences in the duration of mating sessions 
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(from 2 hours to overnight mating) and in the methods used to designate embryonic age 
(day of plugging varied from E0 to E1). Therefore, the days of embryonic neurogenesis 
reported in these studies as the peak of DA neuron birth in the VM might be off by 12-
24 hours due to variability in the methods of reporting.        
In the present study, the animals were mated for a maximum of 3 hours and the 
day of mating was designated as E0. Previous research in our lab shows that about 10% 
of TH-ir neurons in the SNpc incorporated BrdU when pregnant dams were injected 
with the compound at E12 while more than 16% co-labelled with BrdU at E14 
(Weyrauch, 2009). This evidence suggests that the peak neurogenesis of DA neurons in 
the SNpc occurs after E12 and possibly closer to E14 in embryos produced by our 
standard breeding protocol and that E12 VM mostly contains undifferentiated DA 
precursor cells at the time of transplantation. 
The BrdU dose of 120mg/kg injected i.p. produced reliable strong labelling of 
mitotic cells in grafts derived from E12 and E14 rat VMs. There were no differences in 
DA neuron yields or the functionality of the grafts between BrdU-treated animals and 
controls. These results corroborate previous findings of no toxic effects of BrdU doses 
>100mg/kg on foetal graft maturation and integration into the host striatum (Weyrauch, 
2009, Bye et al., 2012).  
Figure 5.3C shows both strong and pale BrdU-ir staining of cell nuclei in grafts 
in the E12 group. One possible explanation of different intensity of BrdU staining is that 
strongly stained cells most likely divided only once when they incorporated the 
compound. Paler staining, on the other hand, might be indicative of the second and third 
generation descendants of the originally marked precursors. BrdU signal intensity is 
reduced with each cell division and disappears after 4 days of continued cell 
proliferation (Dayer et al., 2003). Also, it could be that glial BrdU nucleic staining is 
stronger than neuronal nucleic staining due to a higher density of chromatin in the 
nuclei of glial cells. Both haematoxylin and Nissl stains mark glial cells with a higher 
intensity than neurons. Similarly in fluorescent IHC, BrdU signal in the majority of 
BrdU-ir/TH-ir neurons was weaker than in the surrounding single labelled BrdU-ir 
cells. Furthermore, depending on the stage of the S-phase at the time of BrdU injection, 
the staining in the cell nucleus was either diffused or punctate. Punctate staining 
represents the end of the S-phase when chromatin replication occurs (Cameron and 
McKay, 2001). 
Labelling mitotic cells with BrdU has a number of limitations. Cameron and 
McKay (2001) have shown that only a high dose of BrdU (300 mg/kg) reliably labels all 
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cells in the S-phase in the adult rat dentate gyrus while lower doses label only a fraction 
of cells. Also, high doses of BrdU have been suggested for long-term labelling of 
dividing cells in adult animals (Dayer et al., 2003, McDonald and Wojtowicz, 2005, 
Wojtowicz and Kee, 2006). However, doses as low as 50mg/kg have been demonstrated 
to be toxic for embryos and cause developmental abnormalities when administered into 
pregnant dams (Kolb et al., 1999). Hence, high doses of BrdU while harmless to 
neurogenesis in the adult dendate gyrus might be toxic to the embryonic neurons in the 
grafts. Additionally, BrdU is quickly metabolised to half its concentration within an 
hour after administration which highlights the desirability of using a higher dose (Kriss 
and Revesz, 1962, Packard et al., 1973). This illustrates a classic challenge, which is a 
compromise between BrdU signal strength and toxicity when selecting the dose to be 
administered. As mentioned in Chapter 5.1, the S-phase equates to one third or half of 
the 12-14 hour cell cycle of progenitor cells (Hayes and Nowakowski, 2000, Hayes and 
Nowakowski, 2002). Hence, up to 4 injections of BrdU might be required in order to 
label all dividing cells within a 24 hour period. Thus, results presented here likely 
account for only a fraction of the cell populations in the grafts that were born within the 
4-10 hour period after transplantation.  
There was a high level of cell proliferation as early as 3-4 hours after 
transplantation in grafts derived from E12 VM and a great number of cell precursors 
subsequently differentiated into mature cells in the grafts as revealed by a high yield of 
BrdU-ir cells (Figure 5.4A). These results are comparable to the numbers of BrdU-ir 
cells found in E12 VM grafts when animals received BrdU injections either 1 or 2 days 
post-transplantation (Weyrauch, 2009). This provides evidence that E12 VM contains a 
large population of precursor cells that continue to proliferate in the host over a course 
of a few days post-grafting. As seen in Chapter 4, grafts derived from E12 and E14 
VMs yield similar numbers of neurons despite the fact that E12 VM contains 5-fold 
fewer cells at the time of transplantation than E14 VM. Thus, post-grafting proliferation 
of precursor cells in the E12 group, at least in part, might account for that. The number 
of BrdU-ir cells in grafts derived from E14 VM was 2.6-fold lower than previously 
reported for E14 grafts at the same time point of BrdU injection post-transplantation 
(Sinclair et al., 1999). However, Sinclair et al. injected BrdU into the lateral ventricle 
adjacent to the grafted striatum while the compound was injected i.p. in the current 
study. Intracerebral delivery might give BrdU a better access to the grafted cells and 
explain a higher yield of BrdU-ir neurons in the grafts.  
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 Grafts in both donor age groups were found to be functional as indicated by 
drug-induced rotations (Figure 5.1) and a correspondingly high yield of DA neurons 
(Figure 5.2B). Grafts in the E12 group yielded more DA neurons than grafts in the E14 
group, this replicates previous findings (Chapters 3 and 4; Torres et al., 2007). More 
DA precursor cells were proliferating at the time of BrdU injection 4 hours after 
transplantation and subsequently were capable of differentiating into DA neurons in 
grafts in the E12 group than E14 group (Figure 5.4B). A higher percentage of TH-ir 
neurons that co-labelled with BrdU in grafts in the E12 group (3.2%) than E14 group 
(1.6%) suggests that post-grafting proliferation of DA precursor cells contribute to a 
higher yield of DA neurons in grafts derived from E12 VM (Figure 5.4C). These results 
complement previous findings in E12 grafts that revealed that a small percentage of DA 
neurons in mature grafts were proliferating DA precursor cells as late as 1 and 2 days 
after transplantation (Weyrauch, 2009). Also, a small percentage of E14 DA neurons 
was reported to incorporate BrdU 2 hours post-grafting while virtually no proliferating 
DA precursor cells were found 1 and 2 days after transplantation (Sinclair et al., 1999). 
Combined together, these results describe modest levels of DA neuron birth in the host 
over the course of a few days, in grafts derived from younger as compared to older 
donor tissue, congruent to normal development where SNpc DA neurogenesis occurs 
sometime between E12.5-E14.  
The percentages of TH-ir neurons that co-labelled with BrdU in the grafts in 
both donor age groups were considerably lower than those found in a normally 
developed SNpc when pregnant dams were injected with BrdU at E12 and E14 (Sinclair 
et al., 1999, Gates et al., 2006, Weyrauch, 2009). Several factors have been identified to 
have an impact on E14 VM cell survival during cell suspension preparation (30% cell 
death) and within first week after surgery (Barker et al., 1995, Fawcett et al., 1995). It is 
possible that especially young precursor cells are vulnerable to mechanical and 
chemical dissociation of the tissue, hypoxia and hypoglycaemia associated with the 
transplantation process, however, this has not yet been addressed experimentally. 
As shown in Figure 5.6, grafts derived from E12 VM yielded higher numbers of 
both the A9 type and A10 type DA neurons than grafts in the E14 group, a finding that 
corroborates our previous work (Chapters 3 and 4). In agreement with results described 
in Chapter 3, grafts in the E12 group were enriched with the A9 type DA neurons as 
compared to grafts in the E14 group. Small numbers of both A9 type and A10 type DA 
neurons born after transplantation were found in all grafts indicating that at least a 
subpopulation of mitotic DA precursor cells are committed to their fate and the graft in 
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combination with the host striatum provide the necessary environment for precursor 
cells to follow their correct developmental pathway (Figure 5.7A). Only proliferation of 
A9 type DA precursor cells in grafts in the E12 group contributed significantly more 
than others to the resulting TH-ir cell yield (Figure 5.8A). Figure 5.8B shows that 
mitotic population of TH-ir is enriched with A9 type DA precursor cells in grafts in the 
E12 group while the ratio is shifted towards the A10 type DA precursor cells in grafts in 
the E14 group. These results support previous research, which suggests that SNpc DA 
neuron birth precedes VTA DA neuron birth in the normal developing midbrain 
(Altman and Bayer, 1981). As shown in Figure 5.9A, the enriched yield of A9 type DA 
neurons in the E12 grafts is the result not only of phenotypic maturation of post-mitotic 
neurons but also to some extent of cell birth in the host. However, post-grafting 
proliferation of A10 type DA precursor cells does not contribute to a higher yield of 
these neurons in mature grafts derived from E12 VM as compared to grafts from older 
donor tissue. Previous research in a mouse model of PD demonstrated similar trends of 
increased levels of A9 type DA neuron cell birth in grafts derived from E10 mouse VM 
and, conversely, increased A10 type DA neuron birth in E12.5 grafts (Bye et al., 2012).  
The yield of BrdU-ir A9 type and A10 type DA neurons in the centre of grafts 
was significantly lower than in the periphery of grafts in both donor age groups. As 
shown in Chapters 3 and 4, the numbers of DA neurons were lower in the centre than 
periphery of the graft in both donor age groups. Although not quantified, the 
distribution of BrdU-ir cells appeared to be homogeneous within the graft in both donor 
age groups. This suggests that either the survival of young mitotic DA precursor cells is 
promoted at the periphery of the grafts, or impaired in the centre of grafts, or that whilst 
still at an early stage of development, young DA precursors might be able to migrate to 
the periphery of grafts to make functional connections with the host striatum.  
Conclusion 
The aim of this chapter to determine levels of the A9 type and A10 type DA 
neuron birth in the grafts derived from E12 and E14 VMs has been achieved. Younger 
donor tissue contained bigger subpopulations of DA progenitors that continued to divide 
in the host striatum. Current evidence suggests that younger donor tissue grafts enrich 
with the A9 type DA neurons as compared to grafts in the E14 group due to, at least in 
part, a higher level of post-grafting proliferation of the A9 type DA precursor cells. 
Also, the majority of DA neurons born post-grafting were found in the periphery of 
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grafts suggesting that the proximity to the functional targets might be required for 
mitotic DA precursor cells to survive and differentiate into mature neurons. Although 
current findings sufficiently describe relative contributions of the A9 type and A10 type 
DA neuron birth in the grafts towards the DA neuron yields in both donor age groups, 
the results presented here might still account for only a fraction of actual populations of 
mitotic cells due to limitations of BrdU labelling. We have demonstrated here that E12 
VM tissue is a better candidate for cell transplantation therapy in a rat model of PD. 
 
 
117 
 
 
 
Chapter 6. General Discussion 
 
Summary 
The work discussed in this thesis adds further knowledge regarding the survival 
of embryonic DA grafts in the rat model of PD in terms of the populations of cells 
involved, their distribution within the grafts and how these are affected by the donor age 
and the host environment in to which they are implanted. 
 The current data further underline the impact of the donor age on DA neuron 
yields in the grafts (Torres et al., 2007, Torres et al., 2008a, Bye et al., 2012), and 
reinforce the notion that harvesting embryonic VM tissue before the peak of DA 
neurogenesis yields more DA cells in the grafts and, more importantly, also more A9 
type DA neurons, which are an important determinant for functional recovery (Chapters 
3, 4, and 5). 
A9 type DA neurons were found to be influenced both by the environment 
within the graft and by the host environment in the transplantation site to a higher extent 
than the A10 type DA neurons (Chapters 3 and 4). The present results suggest that 
differentiation of DA neural precursor cells rather than their survival might be affected 
by the afferent DA innervation of the transplantation site (Chapter 4). 
DA neural progenitors cells procured from rat embryos at E12 were shown to 
have a greater potential to proliferate post-graft and differentiate into mature DA 
neurons as compared to embryos at E14 (Chapter 5). In vivo proliferation of younger 
precursor cells significantly contributed to the higher yields of the A9 type DA neurons 
in the grafts. With this improved yield of the A9 type DA neurons fewer human donors 
might suffice to produce functional grafts in PD patients.   
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Improvement of the functional efficacy of the cell replacement therapy for PD is 
still a major challenge that needs to be overcome before this treatment can be brought 
into the clinic. The aim of this PhD thesis was to identify some of the critical factors 
that influence the functionally important A9 type DA neuron component in VM grafts 
in the 6-OHDA lesion rat model. VM grafts derived from E12 rat embryos have 
previously been shown to significantly improve DA neuron yield but not to improve 
behavioural recovery of lesion-induced deficits over and above that achieved using 
standard E14 VM tissue. The first part of this thesis was intended to measure the impact 
of the donor age on the A9 type and A10 type DA neuron subpopulations in intrastriatal 
VM grafts (Chapter 3). The present results show that there is enrichment for the A9 type 
DA neurons in grafts derived from younger embryonic VM tissue, and that this might 
be the result of target-specific cues in the striatum which favour the survival of this DA 
neuron subpopulation and/or enhance differentiation of the SNpc phenotype in 
implanted DA neural precursor cells. The second study was designed to address the 
question of the commitment of DA neural precursor cells to the SNpc and VTA fate and 
to investigate whether distinct DA and NA innervation of the transplantation site 
influenced the DA neuronal composition of the grafts (Chapter 4). The last part of this 
thesis aimed to determine whether the enrichment of DA neurons of the SNpc 
phenotype observed in younger tissue grafts is due to increased proliferation or 
improved survival of the A9 type DA neural progenitor cells post-transplantation 
(Chapter 5). An unexpected pattern emerged from all three studies suggesting that the 
E12 graft enrichment for the A9 type DA neurons might be influenced by the amount of 
VM tissue implanted.   
6.1 Benefits of using younger donor tissue for transplantation 
The work presented here and previous studies in the literature (Torres et al., 
2007, Torres et al., 2008a) indicate that VM tissue derived from rat embryos at E12 
significantly improves DA neuron yield in the grafts compared to tissue obtained at 
E14. It may be that immature E12 DA neural precursor cells survive the transplantation 
procedure better than newly born (post-mitotic) DA neurons because they lack 
extensive neurites (Gates et al., 2004), however, the exact reasons still remain unknown. 
Factors influencing the survival of mesencephalic DA neurons, such as tissue 
dissociation, cool storage, in vitro culture prior to transplantation, have been studied in 
detail in the past, however none of these studies included VM tissue derived as early as 
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E12 (Bjorklund et al., 1980b, Brundin et al., 1985a, Brundin et al., 1985b, Nikkhah et 
al., 1995). A growing body of evidence indicates that undifferentiated DA neural 
precursor cells rely on intrinsic signals present within the transplanted VM to follow the 
correct developmental pathway. The peak contribution of Shh-expressing cells in the 
VM floor plate to DA neurons was shown to occur at E10.5 in mice (considered to be 
equivalent to E12 in rats), a time point of most extensive labelling of Shh-expressing 
cells in the Lmx1a-positive putative DA precursor domain (Blaess et al., 2011), 
suggesting that the signalling activity within the developing VM that directs DA neuron 
specification might be at its highest at this time point. Previous studies, which used rat 
E12 VM tissue, have shown that the presence of Shh and a transforming growth factor 
TGF-β were required for DA neuron differentiation in vitro (Farkas et al., 2003) and 
that adenoviral-vector-delivered Shh improved (3-fold) the yield of DA neurons in 
grafts (Torres et al., 2005). Another study demonstrated that purifying mouse DA neural 
precursor cells at E10.5 and transplanting them into the DA-depleted striatum results in 
poor graft survival and low DA neuron yields (Jonsson et al., 2009). This indicates that 
other neural progenitor cells and glia present in the VM floor plate might be crucial for 
final differentiation of DA neurons and, although the cytoarchitecture of the VM is lost 
during cell suspension preparation, these cells are still capable of inducing DA fate in 
neural precursor cells in the graft.   
DA neuron subtypes in the grafts, particularly the nigral A9 type, have been the 
focus of DA cell transplantation research for the last few years. Current work 
demonstrates, for the first time, that grafts derived from rat E12 VM tissue improve 
yields of both the A9 type (Girk2-ir) and A10 type (calbindin-ir) DA neurons. Previous 
studies have demonstrated that VM donor tissue generated larger grafts, presumably due 
to increased survival (Freeman et al., 1995b, Sinclair et al., 1999, Hahn et al., 2009). 
However, recent studies have demonstrated that transplanted E12 VM tissue contains a 
mixture of both differentiated DA neurons, that have already undergone their final 
mitosis, and DA neural progenitor cells that continue to proliferate in the host and 
mature into DA neurons after transplantation (Weyrauch, 2009). Grafts derived from 
E10 mice donor tissue (equivalent to E11.5 in rats) have been shown to be enriched 
with mitotic DA neuroblasts, which contribute to a higher yield of the A9 type DA 
neurons in the grafts (Bye et al., 2012). Similarly, the work carried out in Chapter 5 
demonstrated that a substantial increase in E12 VM-derived mitotic cells soon after 
transplantation significantly contributes to larger grafts, and that improved enrichment 
for the DA neurons of the SNpc phenotype in grafts derived from younger rat embryos 
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results in part due to a higher level of the A9 type DA neuron birth post-transplantation.     
Also, when VMs are dissociated into a single cell suspension and the equivalent of one 
VM is transplanted into the striatum (Chapters 3 and 5), a higher enrichment for the 
functionally important A9 type DA neurons is observed in grafts derived from E12 
embryos than E14 embryos (note that, no such difference was observed when the 
equivalent of ½ VM was transplanted into the striatum as described in Chapter 4). 
Smaller populations of transplanted cells might be unable to provide sufficient levels of 
developmental signalling in vivo to direct DA neural precursor cells towards the correct 
pathway. At this stage, it is not clear whether this drop in the enrichment of the grafts 
for the A9 type DA neurons can be attributed to different experimental conditions and 
future studies where even smaller proportions of the VM, e.g. ⅓ and ¼, are transplanted 
into the striatum are required to address this question.  
Similar findings have been reported for grafts derived from mouse VM, where 
younger donor tissue improved enrichment of grafts for DA neurons belonging to the 
SNpc phenotype (Bye et al., 2012). The same study also reported that grafts derived 
from E12 mouse VM (considered to be equivalent to E13.5 in rats) contained a higher 
proportion of the A10 type DA neurons than grafts from the E10 group. However, 
increased proportions of DA neurons belonging to the VTA phenotype in grafts in the 
E14 group were not observed in any of the studies described here. This is most likely 
due to a combined effect of the 0.5 day difference between time points when embryos 
were harvested, and between-species differences in embryonic developmental stages 
(such that ages E12 in mice and E13.5 in rats are not truly identical) and not due to 
Girk2 and calbindin antibodies being unreliable markers of two DA neuron phenotypes 
in rats, as they were reported to label separate DA neuron populations in the SNpc and 
the VTA in mice and rats in an identical manner (Thompson et al., 2005). However, 
recent studies have suggested that high levels of Girk2 protein can be detected also in 
DA neurons located in the dorsal tier of the SNpc and in a proportion of DA neurons in 
the VTA in mice and humans (Reyes et al., 2012). Nevertheless, coexpression of 
calbindin in TH-ir neurons was found to be more restricted to the VTA regions and 
these two proteins were rarely found to be expressed together in DA neurons. Therefore, 
Girk2 and calbindin are still considered to be largely confined to two different 
populations of DA neurons.  
E12 and E14 VM tissue, especially E12, contains a mix of fully developed DA 
neurons and undifferentiated DA neural precursor cells (Gates et al., 2006) that use both 
intrinsic cues present within the transplanted graft and target-specific cues in host 
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environment to direct their differentiation towards the correct DA phenotype as 
demonstrated in Chapter 4. In both donor age groups, fate specification of the A9 type 
DA neurons was more influenced by the host environment than that of the A10 type 
neurons, despite the fact that previous studies have shown that, in normal development, 
DA neurons in the SNpc complete differentiation process before DA neurons in the 
VTA (Bye et al., 2012). A10 type DA neural precursor cells and neurons derived from 
either E12 or E14 VM tissue remained committed to the VTA phenotype even when 
transplanted into the hippocampus, a site rich in NA innervation. A9 type DA neural 
precursors, on the other hand, were less likely to follow the correct developmental 
pathway in the absence of functional connections as evidenced by a greater proportion 
of TH-ir neurons that were negative for Girk2. When grafted into the striatum, A9 type 
DA neurons had a direct access to functional targets; however, while the target striatum 
remained in close proximity to neurons transplanted into the adjacent N.Acc, the access 
to functional targets was greatly reduced for grafts in the PFC and unavailable for 
transplants in the hippocampus. Also, the striatum is not only the correct target area but 
it is lesioned, and while the N.Acc and the PFC are also partially depleted of DA, the 
hippocampus is not. Although previous studies have suggested that DA grafts survive 
equally well both in the intact and lesioned striatal environment (Schmidt et al., 1981, 
Dunnett et al., 1988), afferent connections to the grafts in adult recipients are reportedly 
poor unless the host systems are deprived of their normal synaptic targets. This suggest 
that, the level of DA depletion in either A9 (striatum) or A10 (N.Acc) input nuclei in 
the basal ganglia might influence the preferential yield of DA neuron phenotypes in the 
grafts, an issue which has not yet been investigated experimentally. These findings have 
important implications for cell therapies first because they further highlight how crucial 
it is to choose the correct transplantation target to achieve optimal cell populations in 
the graft, and second because they demonstrate that developing neurons in the transplant 
use cues in the surrounding environment to complete differentiation. Indeed, during 
normal nervous system development, target tissues secrete trophic factors that attract 
axonal growth and support survival of neurons innervating the target (Hendry, 1975, 
Landmesser, 1978). Several studies have investigated this neuron-target interaction in 
the past and have demonstrated that when transplanted in the vicinity of the DA-
depleted striatum, e.g. into the adjacent cortex or ventricle, grafts derived from human 
foetal VM tissue exhibited a target specific TH-ir fibre outgrowth (Stromberg et al., 
1992). Another study has shown that DA neurons transplanted into the parietal cortex, 
which normally receives no DA innervation, survived in abundance but exhibited very 
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sparse axonal growth to the immediate vicinity to the transplantation site (Schmidt et 
al., 1981). Similarly, present findings demonstrate that, when compared to grafts in to 
the striatum, in grafts in to the hippocampus, in the absence of rich midbrain-derived 
innervation, a great proportion of DA neurons were negative for either Girk2 or 
calbindin, indicating that, in the absence of functional connections, they may have 
silenced their A9 and A10 phenotypes (Chapter 4). Moreover, neuron responsiveness to 
guidance cues was shown to decrease with donor age (Van den Heuvel and Pasterkamp, 
2008), a finding corroborated in the present study: a change from the A9 type to the 
A10 type afferent innervation to the transplantation site resulted in a significant 
decrease in the proportion of the A9 type DA neurons between grafts in the striatum and 
N.Acc in the E12 group but not E14 group. Thus, VM tissue derived from younger 
donor age embryos contains proliferating DA neural precursor cells that are able to use 
environmental cues in the striatum to differentiate into the A9 type DA neurons and 
produces larger grafts that might improve DA cell therapy for PD.  
A lot of research has been directed towards purification of A9 type DA neurons 
for transplantation purposes, since this component of the grafts is an important 
determinant for behavioural recovery (Mendez et al., 2005, Thompson et al., 2005, 
Grealish et al., 2010). Such studies have shown that reinnervation of the DA-depleted 
striatum is derived almost exclusively from the A9 type DA neurons in the grafts and 
that almost a complete elimination of the nigral DA neuron population from the graft 
with sparing of the A10 type DA neuron component results in partial behavioural 
recovery of lesion-induced deficits (Grealish et al., 2010). However, purification of the 
A9 type DA neuron population has proven to be a challenging task. It is possible to 
isolate the floor plate domain that gives rise to both subtypes of midbrain DA neurons 
based on the expression or lack of expression of Ngn2 depending on the developmental 
stage and produce small grafts that still induce behavioural recovery but these grafts still 
contain a mixed population of the A9 and A10 type DA neurons (Thompson et al., 
2006, Jonsson et al., 2009). The absence of Corin expression at E10.5 in mice was used 
to isolate the A9 type DA neural progenitors but in vivo survival of these grafts was 
poor and only a trend towards behavioural recovery was observed (Jonsson et al., 2009). 
Isolated A9 type neural progenitor cells failed to differentiate in vivo in the absence of 
other cell types normally present in the developing VM suggesting that isolated cell 
populations should be expanded prior to implantation to boost the A9 type DA neuron 
yield in the grafts. During normal development, DA neurons rely on both intrinsic and 
external signals for fate induction, final differentiation, as well as axonal outgrowth, and 
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since unsorted VM tissue produces good grafts that achieve functional recovery, cell 
sorting of primary tissue grafts might not be required for practical applications.  
6.2 Implications for foetal cell transplantation therapy  
Two studies have reported different results regarding improved behavioural 
recovery offered by younger donor grafts. The first study demonstrated that despite 
producing higher yields of DA neurons, grafts derived from E12 rat VM tissue did not 
confer behavioural recovery of beyond the levels that can be achieved by standard E14 
VM-derived transplants (Torres et al., 2008a). Another study has reported that younger 
donor tissue grafts promoted restoration of function in apomorphine-induced rotation 
test and stepping test (Hahn et al., 2009). However, due to different transplantation 
conditions, the yield of DA neurons in grafts in the second study was much lower (E12: 
1500; E14: 846 DA neurons) than in the study conducted by Torres and colleagues 
(E12: 26,000; E14: 4,500 DA neurons) suggesting that differences in behavioural 
recovery seen were not truly representative of the impact of the donor age, but rather 
due to low numbers of DA neurons in the grafts. The experiments described in this 
thesis suggest that the enrichment of E12 VM-derived intrastriatal grafts for the A9 type 
DA neurons is influenced by the transplantation conditions. However, in all three of the 
present studies, a significantly higher yield of DA neurons of the SNpc phenotype was 
observed in intrastriatal grafts derived from younger donor tissue. Also, all grafts were 
enriched for the A9 type DA neurons, with the yield of these neurons being at least 2-
fold higher than the yield of the A10 type DA neurons regardless of the donor age 
group. Thus, despite facilitating higher total numbers of DA neurons (Torres et al., 
2008a) and functionally important A9 type DA neurons (Chapters 3, 4, and 5) grafts 
derived from younger VM tissue fail to enhance amelioration of lesion-induced deficits. 
This suggests that, even when using the most clinically relevant multiple placements of 
intrastriatal grafts, there is a limit to the behavioural recovery that can be achieved by 
tonic DA supply and reinnervation of the striatum provided by the transplant. Recovery 
of finer motor skills will most likely require a more global restoration of the basal 
ganglia circuitry. Indeed, simultaneous grafts in the striatum, SNpc and the STN 
restored forelimb function significantly better than grafts in the striatum alone (Mukhida 
et al., 2001, Mukhida et al., 2008). More global amelioration of symptoms induced by 
the loss of DA neurotransmission in the nigrostriatal pathway may require restoration of 
DA supply to the striatum plus either restoration of dopaminergic control in the SNpc 
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and the STN (Mukhida et al., 2001) or inhibition of the pathological overactivity in the 
SNpc and the STN (Mukhida et al., 2008). 
The other limiting factor to clinical application of the transplantation cell 
therapy for PD is major cell loss post-grafting, such that 90-95% of the DA cells 
implanted are lost post-implantation. As a result, 6 to 8 donor embryos per unilateral 
transplant are required. As younger donor tissue grafts in both rats and mice produce 
significantly higher DA neuron yields with the main component of DA neuron 
population being of the SNpc phenotype, it ought to be possible to achieve a similar 
improvement of the human foetal transplantation therapy by similar use of younger DA 
neural precursor cells. If the correct human embryonic age could be identified, then 
clinical improvement in PD patients might be effected with fewer donor embryos. 
Based on the Carnegie staging scale and ontogeny studies of the VM (Nelander et al., 
2009) the human equivalent of rat donor age should occur somewhere around 5 weeks 
post-conception, before there is appreciable TH expression in the VM, similar to what is 
seen in rat E12 and mouse E10.5 VM. Previous clinical trials have all used older donor 
embryos, aged 6 – 9 weeks post-conception equivalent to E14-15 rat embryos. Recent in 
vitro studies of DA neuron yields in VM cultures derived from medical terminations of 
pregnancies (MTOP), a method that is increasingly replacing surgical terminations of 
pregnancies in the UK, demonstrated that donor embryos that produced the highest 
numbers of DA neurons had CRLs of 18 – 27 mm, corresponding to the age of 
approximately 7 – 8 weeks post-conception (Weyrauch, 2009). However, the range of 
donor ages investigated in this study did not include ages younger than 6 weeks. Even if 
the ‘ideal’ donor age could be identified, the very limited human foetal tissue supply 
would simply increase the logistic challenges involved in sourcing tissue for human use. 
Thus whilst it is academically interesting to determine at which stage human foetal DA 
neural precursor cells might be more efficient in producing better grafts than newly 
differentiated DA neurons, if this donor age is younger or borderline with those 
currently supplied by the clinic, from 6 to 12 weeks post-conception (Kelly et al., 2011), 
procurement may prove impractical for clinical applications. Nevertheless, if implanting 
VM tissue obtained before the peak of DA neurogenesis could yield sufficiently high 
DA neuron numbers and greater yields of A9 type DA neurons, then a single embryo 
might suffice to transplant one patient unilaterally, and despite the logistic challenges 
this could be an important advance.   
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6.3 Implications beyond foetal transplantation 
The current findings also have implications beyond foetal transplantation. 
Numerous efforts have been made to generate large pools of VM DA neurons for cell 
transplantation therapy including the expansion of foetal tissue (Parish et al., 2008, 
Ribeiro et al., 2013) and the generation VM DA neurons from PSCs (Bjorklund et al., 
2002, Kriks et al., 2011). While this has been successfully achieved in a number of 
instances in vitro, poor graft survival and a lack of functional input of these therapies 
are generally observed in vivo. In agreement with recent studies conducted in mice (Bye 
et al., 2012), the present findings demonstrate that higher yields of functionally 
important A9 type DA neurons are produced by intrastriatal grafts derived from 
younger VM tissue, which contains proliferating DA neural precursor cells in the floor 
plate. This suggests that a combination of VM-derived developmental signals and 
striatum-derived target specific cues is sufficient to guide mitotic DA progenitors down 
their correct phenotype. Also, the yield of A9 type DA neurons falls by two thirds 
following implantation into the hippocampus, indicating that VM-like environment in 
the graft is able to support the A9 phenotype in a great number of DA neurons even in 
the absence of normally present innervation targets. The generally low DA neuron 
yields observed in expanded foetal tissue-derived grafts or in PSCs-derived grafts might 
be due to incomplete specification of these cells as a result of in vitro isolation from the 
normal embryonic environment prior to transplantation. Indeed, induction of the floor 
plate phenotype in hESCs prior to their differentiation into Nurr1-expressing DA 
neurons effectively produces engraftable TH-ir/FoxA2-ir neurons that mature into the 
A9 type and A10 type DA neurons in the host (Kriks et al., 2011). Identification of the 
region in the developing midbrain that gives rise exclusively to the A9 type neurons is 
of particular interest so that this region can be expanded in vitro prior to transplantation. 
Although, some progress has been made in this area, expansion of isolated VM DA 
progenitors and subsequent grafting have not yet been tested (Jonsson et al., 2009). If 
applicable in an ESC setting, these sorting tools can be used to generate well-
characterised stem cell-derived VM DA neural progenitors free of potentially 
tumorigenic cell types for transplantation therapy for PD. 
6.4 Conclusion 
The work presented in this thesis has demonstrated further the importance of 
deriving rat foetal VM tissue at a younger donor age (E12), which generates increased 
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yields of A9 type DA neurons when transplanted into the right functional target. 
However, it is still not clear whether there is an equivalent human embryonic donor age 
that could be used to reproduce the present findings, and improve the DA neuron 
survival and functional outcome of cell transplantation in PD patients. ESC-derived 
grafts, on the other hand, might need to be utilised at an earlier developmental stage to 
improve the therapy and bring it closer to the clinic. Global functional outcome is 
dependent on more than just restoration of DA supply to the putamen and caudate 
nucleus and additional grafts into the STN should be considered for the restoration of 
the sensorimotor function in patients. PD is a complex heterogeneous progressive 
disorder and no currently available or ‘in-development’ treatments are able to either 
cure it or single-handedly address all the symptoms. There may be no universal solution 
to the treatment of PD.   
 
 
127 
 
List of References 
 
AARSLAND, D., BRONNICK, K., EHRT, U., DE DEYN, P. P., TEKIN, S., EMRE, 
M. & CUMMINGS, J. L. 2007. Neuropsychiatric symptoms in patients with 
Parkinson's disease and dementia: frequency, profile and associated care giver 
stress. Journal of Neurology Neurosurgery and Psychiatry, 78, 36-42. 
ABERCROMBIE, M. 1946. Estimation of nuclear population from microtome sections. 
Anatomical Record, 94, 239-247. 
AGRAWAL, A. K., CHATURVEDI, R. K., SHUKLA, S., SETH, K., CHAUHAN, S., 
AHMAD, A. & SETH, P. K. 2004. Restorative potential of dopaminergic grafts 
in presence of antioxidants in rat model of Parkinson's disease. Journal of 
Chemical Neuroanatomy, 28, 253-264. 
AHLSKOG, J. E. & MUENTER, M. D. 2001. Frequency of levodopa-related 
dyskinesias and motor fluctuations as estimated from the cumulative literature. 
Movement Disorders, 16, 448-458. 
AKAO, Y., MARUYAMA, W., YI, H., SHAMOTO-NAGAI, M., YOUDIM, M. B. H. 
& NAOI, M. 2002. An anti-Parkinson's disease drug, N-propargyl-1(R)-
aminoindan (rasagiline), enhances expression of anti-apoptotic Bcl-2 in human 
dopaminergic SH-SY5Y cells. Neuroscience Letters, 326, 105-108. 
ALAM, M., MAYERHOFER, A. & SCHMIDT, W. J. 2004. The neurobehavioral 
changes induced by bilateral rotenone lesion in medial forebrain bundle of rats 
are reversed by L-DOPA. Behavioural Brain Research, 151, 117-124. 
ALBIN, R. L., YOUNG, A. B. & PENNEY, J. B. 1989. The functional anatomy of 
basal ganglia disorders. Trends in Neurosciences, 12, 366-375. 
ALMQVIST, P. M., AKESSON, E., WAHLBERG, L. U., PSCHERA, H., SEIGER, A. 
& SUNDSTROM, E. 1996. First trimester development of the human 
nigrostriatal dopamine system. Experimental Neurology, 139, 227-237. 
ALTMAN, J. & BAYER, S. A. 1981. Development of the brain-stem in the rat .5. 
Thymidine-radiographic study of the time of origin of neurons in the midbrain 
tegmentum. Journal of Comparative Neurology, 198, 677-716. 
ANDERSON, L. & CALDWELL, M. A. 2007. Human neural progenitor cell 
transplants into the subthalamic nucleus lead to functional recovery in a rat 
model of Parkinson's disease. Neurobiology of Disease, 27, 133-140. 
ANDERSSON, E., TRYGGVASON, U., DENG, Q. L., FRILING, S., ALEKSEENKO, 
Z., ROBERT, B., PERLMANN, T. & ERICSON, J. 2006. Identification of 
intrinsic determinants of midbrain dopamine neurons. Cell, 124, 393-405. 
ANNETT, L. E., TORRES, E. M., CLARKE, D. J., ISHIDA, Y., BARKER, R. A., 
RIDLEY, R. M., BAKER, H. F. & DUNNETT, S. B. 1997. Survival of nigral 
grafts within the striatum of marmosets with 6-OHDA lesions depends critically 
on donor embryo age. Cell Transplant, 6, 557-69. 
ANTONINI, A., ISAIAS, I. U., CANESI, M., ZIBETTI, M., MANCINI, F., 
MANFREDI, L., DAL FANTE, M., LOPIANO, L. & PEZZOLI, G. 2007. 
Duodenal levodopa infusion for advanced Parkinson's disease: 12-month 
treatment outcome. Movement Disorders, 22, 1145-1149. 
ARIMA, K., UEDA, K., SUNOHARA, N., ARAKAWA, K., HIRAI, S., 
NAKAMURA, M., TONOZUKA-UEHARA, H. & KAWAI, M. 1998. 
NACP/alpha-synuclein immunoreactivity in fibrillary components of neuronal 
and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple 
system atrophy. Acta Neuropathologica, 96, 439-444. 
128 
 
BABA, M., NAKAJO, S., TU, P. H., TOMITA, T., NAKAYA, K., LEE, V. M. Y., 
TROJANOWSKI, J. Q. & IWATSUBO, T. 1998. Aggregation of alpha-
synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with 
lewy bodies. American Journal of Pathology, 152, 879-884. 
BACK, S., PERANEN, J., GALLI, E., PULKKILA, P., LONKA-NEVALAITA, L., 
TAMMINEN, T., VOUTILAINEN, M. H., RAASMAJA, A., SAARMA, M., 
MANNISTO, P. T. & TUOMINEN, R. K. 2013. Gene therapy with AAV2-
CDNF provides functional benefits in a rat model of Parkinson's disease. Brain 
and behavior, 3, 75-88. 
BACKLUND, E. O., GRANBERG, P. O., HAMBERGER, B., KNUTSSON, E., 
MARTENSSON, A., SEDVALL, G., SEIGER, A. & OLSON, L. 1985. 
Transplantation of adrenal-medullary tissue to striatum in parkinsonism - 1st 
clinical-trials. Journal of Neurosurgery, 62, 169-173. 
BAGHERI, H., DAMASE-MICHEL, C., LAPEYRE-MESTRE, M., CISMONDO, S., 
O'CONNELL, D., SENARD, J. M., RASCOL, O. & MONTASTRUC, J. L. 
1999. A study of salivary secretion in Parkinson's disease. Clinical 
Neuropharmacology, 22, 213-215. 
BAI, C. B., AUERBACH, W., LEE, J. S., STEPHEN, D. & JOYNER, A. L. 2002. Gli2, 
but not Gli1, is required for initial Shh signaling and ectopic activation of the 
Shh pathway. Development, 129, 4753-4761. 
BAKER, K. A., SADI, D., HONG, M. & MENDEZ, I. 2000. Simultaneous intrastriatal 
and intranigral dopaminergic grafts in the Parkinsonian rat model: Role of the 
intranigral graft. Journal of Comparative Neurology, 426, 106-116. 
BARKER, R. A., DUNNETT, S. B., FAISSNER, A. & FAWCETT, J. W. 1996. The 
time course of loss of dopaminergic neurons and the gliotic reaction surrounding 
grafts of embryonic mesencephalon to the striatum. Experimental Neurology, 
141, 79-93. 
BARKER, R. A., FRICKER, R. A., ABROUS, D. N., FAWCETT, J. & DUNNETT, S. 
B. 1995. A comparative-study of preparation techniques for improving the 
viability of nigral grafts using vital stains, in-vitro cultures, and in-vivo grafts. 
Cell Transplantation, 4, 173-200. 
BAYER, S. A., WILLS, K. V., TRIARHOU, L. C. & GHETTI, B. 1995. Time of 
neuron origin and gradients of neurogenesis in midbrain dopaminergic-neurons 
in the mouse. Experimental Brain Research, 105, 191-199. 
BENABID, A. L., BENAZZOUZ, A., GAO, D. M., HOFFMANN, D., LIMOUSIN, P., 
KOUDSIE, A., KRACK, P. & POLLAK, P. 1999. Chronic electrical stimulation 
of the ventralis intermedius nucleus of the thalamus and of other nuclei as a 
treatment for Parkinson's disease. Techniques in Neurosurgery, 5, 5-30. 
BENABID, A. L., POLLAK, P., LOUVEAU, A., HENRY, S. & DEROUGEMONT, J. 
1987. Combined (thalamotomy and stimulation) stereotactic surgery of the VIM 
thalamic nucleus for bilateral Parkinson disease. Applied Neurophysiology, 50, 
344-346. 
BENNETT, D. A., BECKETT, L. A., MURRAY, A. M., SHANNON, K. M., GOETZ, 
C. G., PILGRIM, D. M. & EVANS, D. A. 1996. Prevalence of Parkinsonian 
signs and associated mortality in a community population of older people. New 
England Journal of Medicine, 334, 71-76. 
BERARDELLI, A., ROTHWELL, J. C., THOMPSON, P. D. & HALLET, M. 2001. 
Pathophysiology of bradykinesia in Parkinson's disease. Brain, 124, 2131-2146. 
BERGMAN, H., WICHMANN, T. & DELONG, M. R. 1990. Reversal of experimental 
parkinsonism by lesions of the subthalamic nucleus. Science, 249, 1436-1438. 
129 
 
BETARBET, R., SHERER, T. B., DI MONTE, D. A. & GREENAMYRE, J. T. 2002. 
Mechanistic approaches to Parkinson's disease pathogenesis. Brain Pathology, 
12, 499-510. 
BETARBET, R., SHERER, T. B., MACKENZIE, G., GARCIA-OSUNA, M., PANOV, 
A. V. & GREENAMYRE, J. T. 2000. Chronic systemic pesticide exposure 
reproduces features of Parkinson's disease. Nature Neuroscience, 3, 1301-1306. 
BETARBET, R., TURNER, R., CHOCKKAN, V., DELONG, M. R., ALLERS, K. A., 
WALTERS, J., LEVEY, A. I. & GREENAMYRE, J. T. 1997. Dopaminergic 
neurons intrinsic to the primate striatum. Journal of Neuroscience, 17, 6761-
6768. 
BEZARD, E., IMBERT, C., DELOIRE, X., BIOULAC, B. & GROSS, C. E. 1997. A 
chronic MPTP model reproducing the slow evolution of Parkinson's disease: 
evolution of motor symptoms in the monkey. Brain Research, 766, 107-112. 
BEZARD, E., IMBERT, C. & GROSS, C. E. 1998. Experimental models of Parkinson's 
disease: From the static to the dynamic. Reviews in the Neurosciences, 9, 71-90. 
BIRKMAYER, W. & HORNYKIEWICZ, O. 1961. The L-3,4-dioxyphenylalanine 
(DOPA)-effect in Parkinson-akinesia. Wiener klinische Wochenschrift, 73, 787-
8. 
BJORKLUND, A., DUNNETT, S. B., STENEVI, U., LEWIS, M. E. & IVERSEN, S. 
D. 1980a. Re-innervation of the denervated striatum by substantia nigra 
transplants - functional consequences as revealed by pharmacological and 
sensorimotor testing. Brain Research, 199, 307-333. 
BJORKLUND, A., NILSSON, O. G. & KALEN, P. 1990. Reafferentation of the 
subcortically denervated hippocampus as a model for transplant-induced 
functional recovery in the CNS. Progress in Brain Research, 83. 
BJORKLUND, A., SCHMIDT, R. H. & STENEVI, U. 1980b. Functional re-innervation 
of the neostriatum in the adult-rat by use of intraparenchymal grafting of 
dissociated cell-suspensions from the substantia nigra. Cell and Tissue Research, 
212, 39-45. 
BJORKLUND, A. & STENEVI, U. 1979. Reconstruction of the nigrostriatal dopamine 
pathway by intra-cerebral nigral transplants. Brain Research, 177, 555-560. 
BJORKLUND, A. & STENEVI, U. 1981. Invivo evidence for a hippocampal 
adrenergic neuronotrophic factor specifically released on septal deafferentation. 
Brain Research, 229. 
BJORKLUND, A., STENEVI, U., SCHMIDT, R. H., DUNNETT, S. B. & GAGE, F. 
H. 1983a. Intracerebral grafting of neuronal cell suspensions. I. Introduction and 
general methods of preparation. Acta physiologica Scandinavica. 
Supplementum, 522, 1-7. 
BJORKLUND, A., STENEVI, U., SCHMIDT, R. H., DUNNETT, S. B. & GAGE, F. 
H. 1983b. Intracerebral grafting of neuronal cell suspensions. II. Survival and 
growth of nigral cell suspensions implanted in different brain sites. Acta 
physiologica Scandinavica. Supplementum, 522, 9-18. 
BJORKLUND, A., STENEVI, U. & SVENDGAARD, N. A. 1976. Growth of 
transplanted monoaminergic neurons into adult hippocampus along perforant 
path. Nature, 262. 
BJORKLUND, L. M., SANCHEZ-PERNAUTE, R., CHUNG, S. M., ANDERSSON, 
T., CHEN, I. Y. C., MCNAUGHT, K. S., BROWNELL, A. L., JENKINS, B. 
G., WAHLESTEDT, C., KIM, K. S. & ISACSON, O. 2002. Embryonic stem 
cells develop into functional dopaminergic neurons after transplantation in a 
Parkinson rat model. Proceedings of the National Academy of Sciences of the 
United States of America, 99, 2344-2349. 
130 
 
BLAESS, S., BODEA, G. O., KABANOVA, A., CHANET, S., MUGNIERY, E., 
DEROUICHE, A., STEPHEN, D. & JOYNER, A. L. 2011. Temporal-spatial 
changes in Sonic Hedgehog expression and signaling reveal different potentials 
of ventral mesencephalic progenitors to populate distinct ventral midbrain 
nuclei. Neural Development, 6. 
BLANDINI, F., ARMENTERO, M.-T. & MARTIGNONI, E. 2008. The 6-
hydroxydopamine model: news from the past. Parkinsonism & related 
disorders, 14 Suppl 2, S124-9. 
BLESA, J., JURI, C., COLLANTES, M., PENUELAS, I., PRIETO, E., IGLESIAS, E., 
MARTI-CLIMENT, J., ARBIZU, J., ZUBIETA, J. L., CRUZ RODRIGUEZ-
OROZ, M., GARCIA-GARCIA, D., RICHTER, J. A., CAVADA, C. & 
OBESO, J. A. 2010. Progression of dopaminergic depletion in a model of 
MPTP-induced Parkinsonism in non-human primates. An F-18-DOPA and C-
11-DTBZ PET study. Neurobiology of Disease, 38, 456-463. 
BLESA, J., PHANI, S., JACKSON-LEWIS, V. & PRZEDBORSKI, S. 2012. Classic 
and New Animal Models of Parkinson's Disease. Journal of Biomedicine and 
Biotechnology. 
BLOCH, A., PROBST, A., BISSIG, H., ADAMS, H. & TOLNAY, M. 2006. alpha-
Synuclein pathology of the spinal and peripheral autonomic nervous system in 
neurologically unimpaired elderly subjects. Neuropathology and Applied 
Neurobiology, 32, 284-295. 
BOER, G. J. 1994. Ethical guidelines for the use of human embryonic   or fetal tissue 
for experimental and clinical neurotransplantation and   research. Journal of 
Neurology, 242, 1-13. 
BONIFATI, V., RIZZU, P., VAN BAREN, M. J., SCHAAP, O., BREEDVELD, G. J., 
KRIEGER, E., DEKKER, M. C. J., SQUITIERI, F., IBANEZ, P., JOOSSE, M., 
VAN DONGEN, J. W., VANACORE, N., VAN SWIETEN, J. C., BRICE, A., 
MECO, G., VAN DUIJN, C. M., OOSTRA, B. A. & HEUTINK, P. 2003. 
Mutations in the DJ-1 gene associated with autosomal recessive early-onset 
parkinsonism. Science, 299, 256-259. 
BONILLA, S., HALL, A. C., PINTO, L., ATTARDO, A., GOTZ, M., HUTTNER, W. 
B. & ARENAS, E. 2008. Identification of midbrain floor plate radial glia-like 
cells as dopaminergic progenitors. Glia, 56, 809-820. 
BONUCCELLI, U., DEL DOTTO, P. & RASCOL, O. 2009. Role of dopamine receptor 
agonists in the treatment of early Parkinson's disease. Parkinsonism & related 
disorders, 15 Suppl 4, S44-53. 
BOREK, L. L., KOHN, R. & FRIEDMAN, J. H. 2007. Phenomenology of dreams in 
Parkinson's disease. Movement Disorders, 22, 198-202. 
BOREL, J. F., FEURER, C., GUBLER, H. U. & STAHELIN, H. 1976. Biological 
effects of Cyclosporin-a - new antilymphocytic agent. Agents and Actions, 6, 
468-475. 
BOWER, J. H., MARAGANORE, D. M., MCDONNELL, S. K. & ROCCA, W. A. 
1999. Incidence and distribution of parkinsonism in Olmsted County, 
Minnesota, 1976-1990. Neurology, 52, 1214-1220. 
BRAAK, H., DEL TREDICI, K., RUB, U., DE VOS, R. A. I., STEUR, E. & BRAAK, 
E. 2003. Staging of brain pathology related to sporadic Parkinson's disease. 
Neurobiology of Aging, 24, 197-211. 
BREESE, G. R. & TRAYLOR, T. D. 1971. Depletion of brain noradrenaline and 
dopamine by 6-hydroxydopamine. British Journal of Pharmacology, 42, 88-&. 
BREYSSE, N., CARLSSON, T., WINKLER, C., BJORKLUND, A. & KIRIK, D. 2007. 
The functional impact of the intrastriatal dopamine neuron grafts in parkinsonian 
rats is reduced with advancing disease. Journal of Neuroscience, 27, 5849-5856. 
131 
 
BRODSKY, H., VUONG, K. D., THOMAS, M. & JANKOVIC, J. 2004. Glabellar and 
palmomental reflexes in parkinsonian disorders. Neurology, 63, 1096-1098. 
BROOKS, A. I., CHADWICK, C. A., GELBARD, H. A., CORY-SLECHTA, D. A. & 
FEDEROFF, H. J. 1999. Paraquat elicited neurobehavioral syndrome caused by 
dopaminergic neuron loss. Brain Research, 823, 1-10. 
BROTCHIE, J. M., MITCHELL, I. J., SAMBROOK, M. A. & CROSSMAN, A. R. 
1991. Alleviation of parkinsonism by antagonism of excitatory amino-acid 
transmission in the medial segment of the globus-pallidus in rat and primate. 
Movement Disorders, 6, 133-138. 
BRUNDIN, P., BARBIN, G., ISACSON, O., MALLAT, M., CHAMAK, B., 
PROCHIANTZ, A., GAGE, F. H. & BJORKLUND, A. 1985a. Survival of 
intracerebrally grafted rat dopamine neurons previously cultured invitro. 
Neuroscience Letters, 61, 79-84. 
BRUNDIN, P., BARBIN, G., STRECKER, R. E., ISACSON, O., PROCHIANTZ, A. & 
BJORKLUND, A. 1988. Survival and function of dissociated rat dopamine 
neurons grafted at different developmental stages or after being cultured invitro. 
Developmental Brain Research, 39, 233-243. 
BRUNDIN, P., ISACSON, O. & BJORKLUND, A. 1985b. Monitoring of cell viability 
in suspensions of embryonic CNS tissue and its use as a criterion for 
intracerebral graft-survival. Brain Research, 331, 251-259. 
BRUNDIN, P., KARLSSON, J., EMGARD, M., SCHIERLE, G. S. K., HANSSON, O., 
PETERSEN, A. & CASTILHO, R. F. 2000a. Improving the survival of grafted 
dopaminergic neurons: A review over current approaches. Cell Transplantation, 
9, 179-195. 
BRUNDIN, P., POGARELL, O., HAGELL, P., PICCINI, P., WIDNER, H., SCHRAG, 
A., KUPSCH, A., CRABB, L., ODIN, P., GUSTAVII, B., BJORKLUND, A., 
BROOKS, D. J., MARSDEN, C. D., OERTEL, W. H., QUINN, N. P., 
REHNCRONA, S. & LINDVALL, O. 2000b. Bilateral caudate and putamen 
grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's 
disease. Brain, 123, 1380-1390. 
BURNS, R. S., CHIUEH, C. C., MARKEY, S. P., EBERT, M. H., JACOBOWITZ, D. 
M. & KOPIN, I. J. 1983. A primate model of parkinsonism - selective 
destruction of dopaminergic-neurons in the pars compacta of the substantia nigra 
by n-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proceedings of the National 
Academy of Sciences of the United States of America-Biological Sciences, 80, 
4546-4550. 
BURNSTEIN, R. M., FOLTYNIE, T., HE, X. L., MENON, D. K., SVENDSEN, C. N. 
& CALDWELL, M. A. 2004. Differentiation and migration of long term 
expanded human neural progenitors in a partial lesion model of Parkinson's 
disease. International Journal of Biochemistry & Cell Biology, 36, 702-713. 
BYE, C. R., THOMPSON, L. H. & PARISH, C. L. 2012. Birth dating of midbrain 
dopamine neurons identifies A9 enriched tissue for transplantation into 
Parkinsonian mice. Experimental Neurology, 236. 
CALDWELL, M. A., HE, X., WILKIE, N., POLLACK, S., MARSHALL, G., 
WAFFORD, K. A. & SVENDSEN, C. N. 2001. Growth factors regulate the 
survival and fate of cells derived from human neurospheres. Nat Biotechnol, 19, 
475-9. 
CAMERON, H. A. & MCKAY, R. D. G. 2001. Adult neurogenesis produces a large 
pool of new granule cells in the dentate gyrus. Journal of Comparative 
Neurology, 435, 406-417. 
132 
 
CANNON, J. R., TAPIAS, V., NA, H. M., HONICK, A. S., DROLET, R. E. & 
GREENAMYRE, J. T. 2009. A highly reproducible rotenone model of 
Parkinson's disease. Neurobiology of Disease, 34, 279-290. 
CAPARROS-LEFEBVRE, D., BLOND, S., FELTIN, M. P., POLLAK, P. & 
BENABID, A. L. 1999. Improvement of levodopa induced dyskinesias by 
thalamic deep brain stimulation is related to slight variation in electrode 
placement: possible involvement of the centre median and parafascicularis 
complex. Journal of Neurology Neurosurgery and Psychiatry, 67, 308-314. 
CARLSSON, A., FALCK, B. & HILLARP, N. A. 1962. Cellular localization of brain 
monoamines. Acta physiologica Scandinavica. Supplementum, 56, 1-28. 
CARLSSON, A., LINDQVIST, M. & MAGNUSSON, T. 1957. 3,4-
dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. 
Nature, 180, 1200. 
CARLSSON, M. & CARLSSON, A. 1989. The NMDA antagonist MK-801 causes 
marked locomotor stimulation in monoamine-depleted mice. Journal of Neural 
Transmission, 75, 221-226. 
CARLSSON, T., CARTA, M., WINKLER, C., BJORKLUND, A. & KIRIK, D. 2007. 
Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat 
model of Parkinson's disease. Journal of Neuroscience, 27, 8011-8022. 
CARPENTER, M. K., CUI, X., HU, Z. Y., JACKSON, J., SHERMAN, S., SEIGER, A. 
& WAHLBERG, L. U. 1999. In vitro expansion of a multipotent population of 
human neural progenitor cells. Experimental Neurology, 158, 265-278. 
CARTA, M., CARLSSON, T., KIRIK, D. & BJORKLUND, A. 2007. Dopamine 
released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in 
Parkinsonian rats. Brain, 130, 1819-1833. 
CASSARINO, D. S., FALL, C. P., SWERDLOW, R. H., SMITH, T. S., HALVORSEN, 
E. M., MILLER, S. W., PARKS, J. P., PARKER, W. D. & BENNETT, J. P. 
1997. Elevated reactive oxygen species and antioxidant enzyme activities in 
animal and cellular models of Parkinson's disease. Biochimica Et Biophysica 
Acta-Molecular Basis of Disease, 1362, 77-86. 
CAYUSO, J., ULLOA, F., COX, B., BRISCOE, J. & MARTI, E. 2006. The Sonic 
hedgehog pathway independently controls the patterning, proliferation and 
survival of neuroepithelial cells by regulating Gli activity. Development, 133, 
517-528. 
CHAMLEY, J. H. & DOWEL, J. J. 1975. Specificity of nerve-fiber attraction to 
autonomic effector organs in tissue-culture. Experimental Cell Research, 90. 
CHANG, J. Y., SHI, L. H., LUO, F., ZHANG, W. M. & WOODWARD, D. J. 2007. 
Studies of the neural mechanisms of deep brain stimulation in rodent models of 
Parkinson's disease. Neuroscience and Biobehavioral Reviews, 31, 643-657. 
CHARTIER-HARLIN, M.-C., DACHSEL, J. C., VILARINO-GUEELL, C., 
LINCOLN, S. J., LEPRETRE, F., HULIHAN, M. M., KACHERGUS, J., 
MILNERWOOD, A. J., TAPIA, L., SONG, M.-S., LE RHUN, E., MUTEZ, E., 
LARVOR, L., DUFLOT, A., VANBESIEN-MAILLIOT, C., KREISLER, A., 
ROSS, O. A., NISHIOKA, K., SOTO-ORTOLAZA, A. I., COBB, S. A., 
MELROSE, H. L., BEHROUZ, B., KEELING, B. H., BACON, J. A., 
HENTATI, E., WILLIAMS, L., YANAGIYA, A., SONENBERG, N., 
LOCKHART, P. J., ZUBAIR, A. C., UITTI, R. J., AASLY, J. O., 
KRYGOWSKA-WAJS, A., OPALA, G., WSZOLEK, Z. K., FRIGERIO, R., 
MARAGANORE, D. M., GOSAL, D., LYNCH, T., HUTCHINSON, M., 
BENTIVOGLIO, A. R., VALENTE, E. M., NICHOLSO, W. C., PANKRATZ, 
N., FOROUD, T., GIBSON, R. A., HENTATI, F., DICKSON, D. W., DESTEE, 
133 
 
A. & FARRER, M. J. 2011. Translation Initiator EIF4G1 Mutations in Familial 
Parkinson Disease. American Journal of Human Genetics, 89, 398-406. 
CHATURVEDI, R. K., SHUKLA, S., SETH, K. & AGRAWAL, A. K. 2006. Nerve 
growth factor increases survival of dopaminergic graft, rescue nigral 
dopaminergic neurons and restores functional deficits in rat model of 
Parkinson's disease. Neuroscience Letters, 398, 44-49. 
CHAUDHURI, K. R., ODIN, P., ANTONINI, A. & MARTINEZ-MARTIN, P. 2011. 
Parkinson's disease: The non-motor issues. Parkinsonism & Related Disorders, 
17, 717-723. 
CHAUDHURI, K. R. & SCHAPIRA, A. H. V. 2009. Non-motor symptoms of 
Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet 
Neurology, 8, 464-474. 
CHIUEH, C. C., MARKEY, S. P., BURNS, R. S., JOHANNESSEN, J. N., PERT, A. & 
KOPIN, I. J. 1984. Neurochemical and behavioral-effects of systemic and 
intranigral administration of n-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the 
rat. European Journal of Pharmacology, 100, 189-194. 
CHO, M. S., LEE, Y.-E., KIM, J. Y., CHUNG, S., CHO, Y. H., KIM, D.-S., KANG, S.-
M., LEE, H., KIM, M.-H., KIM, J.-H., LEEM, J. W., OH, S. K., CHOI, Y. M., 
HWANG, D.-Y., CHANG, A. W. & KIM, D.-W. 2008. Highly efficient and 
large-scale generation of functional dopamine neurons from human embryonic 
stem cells. Proceedings of the National Academy of Sciences of the United 
States of America, 105, 3392-3397. 
CHU, Y. P., KOMPOLITI, K., COCHRAN, E. J., MUFSON, E. J. & KORDOWER, J. 
H. 2002. Age-related decreases in Nurr1 immunoreactivity in the human 
substantia nigra. Journal of Comparative Neurology, 450, 203-214. 
CHUNG, C. Y., SEO, H., SONNTAG, K. C., BROOKS, A., LIN, L. & ISACSON, O. 
2005. Cell type-specific gene expression of midbrain dopaminergic neurons 
reveals molecules involved in their vulnerability and protection. Human 
Molecular Genetics, 14, 1709-1725. 
CLARKE, D. J., BRUNDIN, P., STRECKER, R. E., NILSSON, O. G., BJORKLUND, 
A. & LINDVALL, O. 1988. Human-fetal dopamine neurons grafted in a rat 
model of Parkinsons-disease - ultrastructural evidence for synapse formation 
using tyrosine-hydroxylase immunocytochemistry. Experimental Brain 
Research, 73, 115-126. 
CLARKE, D. J., NILSSON, O. G., BRUNDIN, P. & BJORKLUND, A. 1990. Synaptic 
connections formed by grafts of   different types of cholinergic neurons in the 
host hippocampus. Experimental Neurology, 107. 
COLLIER, T. J., KANAAN, N. M. & KORDOWER, J. H. 2011. Ageing as a primary 
risk factor for Parkinson's disease: evidence from studies of non-human 
primates. Nature Reviews Neuroscience, 12, 359-366. 
COLLIER, T. J. & SORTWELL, C. E. 1999. Therapeutic potential of nerve growth 
factors in Parkinson's disease. Drugs & Aging, 14, 261-287. 
COLLIER, T. J., SORTWELL, C. E., ELSWORTH, J. D., TAYLOR, J. R., ROTH, R. 
H., SLADEK, J. R., JR. & REDMOND, D. E., JR. 2002. Embryonic ventral 
mesencephalic grafts to the substantia nigra of MPTP-treated monkeys: 
feasibility relevant to multiple-target grafting as a therapy for Parkinson's 
disease. J Comp Neurol, 442, 320-30. 
COOPER, J. A., SAGAR, H. J., TIDSWELL, P. & JORDAN, N. 1994. Slowed central 
processing in simple and go no-go reaction-time tasks in Parkinsons-disease. 
Brain, 117, 517-529. 
134 
 
COTZIAS, G. C., PAPAVASI.PS & GELLENE, R. 1969. Modification of 
parkinsonism - chronic treatment with L-DOPA. New England Journal of 
Medicine, 280, 337-&. 
COUGHLIN, M. D., DIBNER, M. D., BOYER, D. M. & BLACK, I. B. 1978. Factors 
regulating development of an embryonic mouse sympathetic-ganglion. 
Developmental Biology, 66. 
DAHLSTROM, A. & FUXE, K. 1964. Localization of monoamines in lower brain 
stem. Experientia, 20, 398-399. 
DAUER, W., KHOLODILOV, N., VILA, M., TRILLAT, A. C., GOODCHILD, R., 
LARSEN, K. E., STAAL, R., TIEU, K., SCHMITZ, Y., YUAN, C. A., 
ROCHA, M., JACKSON-LEWIS, V., HERSCH, S., SULZER, D., 
PRZEDBORSKI, S., BURKE, R. & HEN, R. 2002. Resistance of alpha-
synuclein null mice to the parkinsonian neurotoxin MPTP. Proceedings of the 
National Academy of Sciences of the United States of America, 99, 14524-
14529. 
DAVIS, G. C., WILLIAMS, A. C., MARKEY, S. P., EBERT, M. H., CAINE, E. D., 
REICHERT, C. M. & KOPIN, I. J. 1979. Chronic parkinsonism secondary to 
intravenous-injection of meperidine analogs. Psychiatry Research, 1, 249-254. 
DAWSON, T. M., KO, H. S. & DAWSON, V. L. 2010. Genetic Animal Models of 
Parkinson's Disease. Neuron, 66, 646-661. 
DAY, M., WANG, Z. F., DING, J., AN, X. H., INGHAM, C. A., SHERING, A. F., 
WOKOSIN, D., ILIJIC, E., SUN, Z. X., SAMPSON, A. R., MUGNAINI, E., 
DEUTCH, A. Y., SESACK, S. R., ARBUTHNOTT, G. W. & SURMEIER, D. 
J. 2006. Selective elimination of glutamatergic synapses on striatopallidal 
neurons in Parkinson disease models. Nature Neuroscience, 9, 251-259. 
DAYER, A. G., FORD, A. A., CLEAVER, K. M., YASSAEE, M. & CAMERON, H. 
A. 2003. Short-term and long-term survival of new neurons in the rat dentate 
gyrus. Journal of Comparative Neurology, 460, 563-572. 
DEHAY, B., MARTINEZ-VICENTE, M., CALDWELL, G. A., CALDWELL, K. A., 
YUE, Z., COOKSON, M. R., KLEIN, C., VILA, M. & BEZARD, E. 2013. 
Lysosomal impairment in Parkinson's disease. Movement Disorders, 28, 725-
732. 
DENIAU, J. M. & CHEVALIER, G. 1985. Disinhibition as a basic process in the 
expression of striatal functions .2. The striato-nigral influence on 
thalamocortical cells of the ventromedial thalamic nucleus. Brain Research, 334, 
227-233. 
DERIJK, M. C., BRETELER, M. M. B., GRAVELAND, G. A., OTT, A., GROBBEE, 
D. E., VANDERMECHE, F. G. A. & HOFMAN, A. 1995. Prevalence of 
Parkinson's disease in the elderly: The Rotterdam study. Neurology, 45, 2143-
2146. 
DEXTER, D. T., CARTER, C. J., WELLS, F. R., JAVOYAGID, F., AGID, Y., LEES, 
A., JENNER, P. & MARSDEN, C. D. 1989. Basal lipid-peroxidation in 
substantia nigra is increased in Parkinsons-disease. Journal of Neurochemistry, 
52, 381-389. 
DI FONZO, A., ROHE, C. F., FERREIRA, R. J., CHIEN, H. F., VACCA, L., 
STOCCHI, F., GUEDES, L., FABRIZIO, E., MANFREDI, M., VANACORE, 
N., GOLDWURM, S., BREEDVELD, G., SAMPAIO, C., MECO, G., 
BARBOSA, E., OOSTRA, B. A., BONIFATI, V. & ITALIAN PARKINSON 
GENETICS, N. 2005. A frequent LRRK2 gene mutation associated with 
autosomal dominant Parkinson's disease. Lancet, 365, 412-415. 
DI MONTE, D. A., MCCORMACK, A., PETZINGER, G., JANSON, A. M., QUIK, M. 
& LANGSTON, W. J. 2000. Relationship among nigrostriatal denervation, 
135 
 
parkinsonism, and dyskinesias in the MPTP primate model. Movement 
Disorders, 15, 459-466. 
DOUCET, G., MURATA, Y., BRUNDIN, P., BOSLER, O., MONS, N., GEFFARD, 
M., OUIMET, C. C. & BJORKLUND, A. 1989. Host afferents into intrastriatal 
transplants of fetal ventral mesencephalon. Experimental Neurology, 106, 1-19. 
DOUDET, D., GROSS, C., LEBRUNGRANDIE, P. & BIOULAC, B. 1985. MPTP 
primate model of Parkinsons-disease - a mechanographic and electromyographic 
study. Brain Research, 335, 194-198. 
DOWD, E. & DUNNETT, S. B. 2004. Deficits in a lateralized associative learning task 
in dopamine-depleted rats with functional recovery by dopamine-rich 
transplants. European Journal of Neuroscience, 20, 1953-1959. 
DOWD, E. & DUNNETT, S. B. 2005a. Comparison of 6-hydroxydopamine-induced 
medial forebrain bundle and nigrostriatal terminal lesions in a lateralised nose-
poking task in rats. Behavioural Brain Research, 159, 153-161. 
DOWD, E. & DUNNETT, S. B. 2005b. Comparison of 6-hydroxydopamine-induced 
medial forebrain bundle and nigrostriatal terminal lesions in rats using a 
lateralised nose-poking task with low stimulus-response compatibility. 
Behavioural Brain Research, 165, 181-186. 
DUNN, E. H. 1917. Primary and secondary findings in a series of attempts to transplant 
cerebral cortex in the albino rat. Journal of Comparative Neurology, 27, 565-
582. 
DUNNETT, S. B. & BJORKLUND, A. 1992. Staging and dissection of rat embryos. In: 
DUNNETT, S. B. & BJORKLUND, A. (eds.) Neural Transplantation: A 
Practical Approach. Oxford: IRL. 
DUNNETT, S. B. & BJORKLUND, A. 1997. Basic neural transplantation techniques. 
I.Dissociated cell suspension grafts of embryonic ventral mesencephalon in the 
adult rat brain., Brain Res Protoc. 
DUNNETT, S. B., BJORKLUND, A., SCHMIDT, R. H., STENEVI, U. & IVERSEN, 
S. D. 1983. Intracerebral grafting of neuronal cell suspensions. IV. Behavioural 
recovery in rats with unilateral 6-OHDA lesions following implantation of nigral 
cell suspensions in different forebrain sites. Acta Physiol Scand Suppl, 522, 29-
37. 
DUNNETT, S. B., HERNANDEZ, T. D., SUMMERFIELD, A., JONES, G. H. & 
ARBUTHNOTT, G. 1988. Graft-derived recovery from 6-OHDA lesions: 
specificity of ventral mesencephalic graft tissues. Exp Brain Res, 71, 411-24. 
DUNNETT, S. B., ROGERS, D. C. & RICHARDS, S. J. 1989. Nigrostriatal 
reconstruction after 6-OHDA lesions in rats - combination of dopamine-rich 
nigral grafts and nigrostriatal bridge grafts. Experimental Brain Research, 75, 
523-535. 
ELAHI, B., PHIELIPP, N. & CHEN, R. 2012. N-Methyl-D-Aspartate Antagonists in 
Levodopa Induced Dyskinesia: A Meta-Analysis. Canadian Journal of 
Neurological Sciences, 39, 465-472. 
ELBAZ, A. & MOISAN, F. 2008. Update in the epidemiology of Parkinson's disease. 
Current Opinion in Neurology, 21, 454-460. 
EMBORG, M. E., MA, S. Y., MUFSON, E. J., LEVEY, A. I., TAYLOR, M. D., 
BROWN, W. D., HOLDEN, J. E. & KORDOWER, J. H. 1998. Age-related 
declines in nigral neuronal function correlate with motor impairments in rhesus 
monkeys. Journal of Comparative Neurology, 401, 253-265. 
ENGLUND, U., BJORKLUND, A. & WICTORIN, K. 2002. Migration patterns and 
phenotypic differentiation of long-term expanded human neural progenitor cells 
after transplantation into the adult rat brain. Developmental Brain Research, 
134, 123-141. 
136 
 
ERIKSSON, T., GRANERUS, A. K., LINDE, A. & CARLSSON, A. 1988. On-off 
phenomenon in Parkinsons-disease - relationship between DOPA and other large 
neutral amino-acids in plasma. Neurology, 38, 1245-1248. 
EULITZ, D., PRUSS, H., DERST, C. & VEH, R. W. 2007. Heterogeneous distribution 
of Kir3 potassium channel proteins within dopaminergic neurons in the 
mesencephalon of the rat brain. Cellular and Molecular Neurobiology, 27, 285-
302. 
FAHN, S. 2009. Parkinson's disease and related disorders. In: HALTER, J., 
OUSLANDER, J., TINETTI, M., STUDENSKI, S., HIGH, K. & ASTHANA, S. 
(eds.) Hazzard's geriatric medicine and gerontology. Part IV Organ systems and 
diseases. 6 ed. USA: McGraw-Hill Medical. 
FALCK, B., THIEME, G., HILLARP, N. A. & TORP, A. 1962. Fluorescence of 
catechol amines and related compounds condensed with formaldehyde. Journal 
of Histochemistry & Cytochemistry, 10, 348-354. 
FALLON, J. H. & LOUGHLIN, S. E. 1982. Monoamine innervation of the forebrain - 
collateralization. Brain Research Bulletin, 9, 295-307. 
FARKAS, L. M., DUNKER, N., ROUSSA, E., UNSICKER, K. & KRIEGLSTEIN, K. 
2003. Transforming growth factor-beta s are essential for the development of 
midbrain dopaminergic neurons in vitro and in vivo. Journal of Neuroscience, 
23, 5178-5186. 
FAWCETT, J. W., BARKER, R. A. & DUNNETT, S. B. 1995. Dopaminergic neuronal 
survival and the effects of BFGF in explant, 3-dimensional and monolayer-
cultures of embryonic rat ventral mesencephalon. Experimental Brain Research, 
106, 275-282. 
FEANY, M. B. & BENDER, W. W. 2000. A Drosophila model of Parkinson's disease. 
Nature, 404, 394-398. 
FERNANDEZ, H. H. & LAPANE, K. L. 2002. Predictors of mortality among nursing 
home residents with a diagnosis of Parkinson's disease. Medical science monitor 
: international medical journal of experimental and clinical research, 8, CR241-
6. 
FERRANTE, R. J., SCHULZ, J. B., KOWALL, N. W. & BEAL, M. F. 1997. Systemic 
administration of rotenone produces selective damage in the striatum and globus 
pallidus, but not in the substantia nigra. Brain Research, 753, 157-162. 
FOLEY, P., GERLACH, M., DOUBLE, K. L. & RIEDERER, P. 2004. Dopamine 
receptor agonists in the therapy of Parkinson's disease. Journal of Neural 
Transmission, 111, 1375-1446. 
FORNO, L. S., DELANNEY, L. E., IRWIN, I. & LANGSTON, J. W. 1993. Similarities 
and differences between MPTP-induced parkinsonism and Parkinsons-disease - 
neuropathologic considerations. Parkinsons Disease : from Basic Research to 
Treatment, 60, 600-608. 
FREED, C. R., BREEZE, R. E., ROSENBERG, N. L., SCHNECK, S. A., KRIEK, E., 
QI, J. X., LONE, T., ZHANG, Y. B., SNYDER, J. A., WELLS, T. H., RAMIG, 
L. O., THOMPSON, L., MAZZIOTTA, J. C., HUANG, S. C., GRAFTON, S. 
T., BROOKS, D., SAWLE, G., SCHROTER, G. & ANSARI, A. A. 1992. 
Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 
months after transplantation for Parkinsons-disease. New England Journal of 
Medicine, 327, 1549-1555. 
FREED, C. R., GREENE, P. E., BREEZE, R. E., TSAI, W. Y., DUMOUCHEL, W., 
KAO, R., DILLON, S., WINFIELD, H., CULVER, S., TROJANOWSKI, J. Q., 
EIDELBERG, D. & FAHN, S. 2001. Transplantation of embryonic dopamine 
neurons for severe Parkinson's disease. New England Journal of Medicine, 344, 
710-719. 
137 
 
FREEMAN, T. B., OLANOW, C. W., HAUSER, R. A., NAUERT, G. M., SMITH, D. 
A., BORLONGAN, C. V., SANBERG, P. R., HOLT, D. A., KORDOWER, J. 
H., VINGERHOETS, J. G., SNOW, B. J., CALNE, D. & GAUGER, L. I. 
1995a. Bilateral fetal nigral transplantation into the postcommissural putamen in 
Parkinsons-disease. Annals of Neurology, 38, 379-388. 
FREEMAN, T. B., SANBERG, P. R., NAUERT, G. M., BOSS, B. D., SPECTOR, D., 
OLANOW, C. W. & KORDOWER, J. H. 1995b. The influence of donor age on 
the survival of solid and suspension intraparenchymal human embryonic nigral 
grafts. Cell Transplantation, 4, 141-154. 
FREEMAN, T. B., SPENCE, M. S., BOSS, B. D., SPECTOR, D. H., STRECKER, R. 
E., OLANOW, C. W. & KORDOWER, J. H. 1991. Development of 
dopaminergic-neurons in the human substantia-nigra. Experimental Neurology, 
113, 344-353. 
FREUND, T. F., BOLAM, J. P., BJORKLUND, A., STENEVI, U., DUNNETT, S. B., 
POWELL, J. F. & SMITH, A. D. 1985. Efferent synaptic connections of grafted 
dopaminergic-neurons reinnervating the host neostriatum - a tyrosine-
hydroxylase immunocytochemical study. Journal of Neuroscience, 5, 603-616. 
FRICKER, R. A., CARPENTER, M. K., WINKLER, C., GRECO, C., GATES, M. A. 
& BJORKLUND, A. 1999. Site-specific migration and neuronal differentiation 
of human neural progenitor cells after transplantation in the adult rat brain. J 
Neurosci, 19, 5990-6005. 
FUNAYAMA, M., HASEGAWA, K., KOWA, H., SAITO, M., TSUJI, S. & OBATA, 
F. 2002. A new locus for Parkinson's disease (PARK8) maps to chromosome 
12p11.2-q13.1. Annals of Neurology, 51, 296-301. 
GALVIN, J. E., POLLACK, J. & MORRIS, J. C. 2006. Clinical phenotype of Parkinson 
disease dementia. Neurology, 67, 1605-1611. 
GASPAR, P., BERGER, B., ALVAREZ, C., VIGNY, A. & HENRY, J. P. 1985. 
Catecholaminergic innervation of the septal area in man - immunocytochemical 
study using TH and DBH antibodies. Journal of Comparative Neurology, 241, 
12-33. 
GASPAR, P., BERGER, B., FEBVRET, A., VIGNY, A., KRIEGER-POULET, M. & 
BORRI-VOLTATTORNI, C. 1987. Tyrosine hydroxylase-immunoreactive 
neurons in the human cerebral cortex: a novel catecholaminergic group? 
Neuroscience Letters, 80, 257-62. 
GATES, M. A., COUPE, V. M., TORRES, E. M., FRICKER-GATES, R. A. & 
DUNNETT, S. B. 2004. Spatially and temporally restricted chemoattractive and 
chemorepulsive cues direct the formation of the nigro-striatal circuit. European 
Journal of Neuroscience, 19, 831-844. 
GATES, M. A., TORRES, E. M., WHITE, A., FRICKER-GATES, R. A. & 
DUNNETT, S. B. 2006. Re-examining the ontogeny of substantia nigra 
dopamine neurons. European Journal of Neuroscience, 23, 1384-1390. 
GELB, D. J., OLIVER, E. & GILMAN, S. 1999. Diagnostic criteria for Parkinson 
disease. Archives of Neurology, 56, 33-39. 
GERFEN, C. R., ENGBER, T. M., MAHAN, L. C., SUSEL, Z., CHASE, T. N., 
MONSMA, F. J. & SIBLEY, D. R. 1990. D1 and D2 dopamine receptor 
regulated gene-expression of striatonigral and striatopallidal neurons. Science, 
250, 1429-1432. 
GERFEN, C. R., HERKENHAM, M. & THIBAULT, J. 1987. The neostriatal mosaic. 
II. patch-directed and matrix-directed mesostriatal dopaminergic and non-
dopaminergic systems. The Journal of Neuroscience, 7, 3915-34. 
GERLACH, M., DESSER, H., YOUDIM, M. B. J. & RIEDERER, P. 1996. New 
horizons in molecular mechanisms underlying Parkinson's disease and in our 
138 
 
understanding of the neuroprotective effects of selegiline. Journal of Neural 
Transmission Supplement, 48, 7-21. 
GERLACH, M., RIEDERER, P., PRZUNTEK, H. & YOUDIM, M. B. H. 1991. MPTP 
mechanisms of neurotoxicity and their implications for Parkinsons-disease. 
European Journal of Pharmacology-Molecular Pharmacology Section, 208, 
273-286. 
GERMAN, D. C. & MANAYE, K. F. 1993. Midbrain dopaminergic-neurons (nuclei a8, 
a9, and a10) - 3-dimensional reconstruction in the rat. Journal of Comparative 
Neurology, 331, 297-309. 
GERMAN, D. C., NELSON, E. L., LIANG, C. L., SPECIALE, S. G., SINTON, C. M. 
& SONSALLA, P. K. 1996. The neurotoxin MPTP causes degeneration of 
specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. 
Neurodegeneration, 5, 299-312. 
GIASSON, B. I., DUDA, J. E., MURRAY, I. V. J., CHEN, Q. P., SOUZA, J. M., 
HURTIG, H. I., ISCHIROPOULOS, H., TROJANOWSKI, J. Q. & LEE, V. M. 
Y. 2000. Oxidative damage linked to neurodegeneration by selective alpha-
synuclein nitration in synucleinopathy lesions. Science, 290, 985-989. 
GIASSON, B. I., DUDA, J. E., QUINN, S. M., ZHANG, B., TROJANOWSKI, J. Q. & 
LEE, V. M. Y. 2002. Neuronal alpha-synucleinopathy with severe movement 
disorder in mice expressing A53T human alpha-synuclein. Neuron, 34, 521-533. 
GIBB, W. R. G. & LEES, A. J. 1989. The significance of the Lewy Body in the 
diagnosis of idiopathic Parkinsons-disease. Neuropathology and Applied 
Neurobiology, 15, 27-44. 
GIBB, W. R. G. & LEES, A. J. 1991. Anatomy, pigmentation, ventral and dorsal 
subpopulations of the substantia-nigra, and differential cell-death in Parkinsons-
disease. Journal of Neurology Neurosurgery and Psychiatry, 54, 388-396. 
GILADI, N., MCDERMOTT, M. P., FAHN, S., PRZEDBORSKI, S., JANKOVIC, J., 
STERN, M., TANNER, C. & PARKINSON STUDY, G. 2001. Freezing of gait 
in PD - Prospective assessment in the DATATOP cohort. Neurology, 56, 1712-
1721. 
GLINKA, Y., GASSEN, M. & YOUDIM, M. B. H. 1997. Mechanism of 6-
hydroxydopamine neurotoxicity. Journal of Neural Transmission-Supplement, 
55-66. 
GOETZ, C. G., NUTT, J. G. & STEBBINS, G. T. 2008. The Unified Dyskinesia Rating 
Scale: Presentation and Clinimetric Profile. Movement Disorders, 23, 2398-
2403. 
GOETZ, C. G., STEBBINS, G. T., KLAWANS, H. L., KOLLER, W. C., GROSSMAN, 
R. G., BAKAY, R. A. E. & PENN, R. D. 1991. United-Parkinson-Foundation 
neurotransplantation registry on adrenal-medullary transplants - presurgical, and 
1-year and 2-year follow-up. Neurology, 41, 1719-1722. 
GOOD, P. F., HSU, A., WERNER, P., PERL, D. P. & OLANOW, C. W. 1998. Protein 
nitration in Parkinson's disease. Journal of Neuropathology and Experimental 
Neurology, 57, 338-342. 
GOSSEL, M., SCHMIDT, W. J., LOSCHER, W., ZAJACZKOWSKI, W. & DANYSZ, 
W. 1995. Effect of coadministration of glutamate-receptor antagonists and 
dopaminergic agonists on locomotion in monoamine-depleted rats. Journal of 
Neural Transmission-Parkinsons Disease and Dementia Section, 10, 27-39. 
GRAFF-RADFORD, J., FOOTE, K. D., RODRIGUEZ, R. L., FERNANDEZ, H. H., 
HAUSER, R. A., SUDHYADHOM, A., ROSADO, C. A., SANCHEZ, J. C. & 
OKUN, M. S. 2006. Deep brain stimulation of the internal segment of the globus 
pallidus in delayed runaway dyskinesia. Arch Neurol, 63, 1181-4. 
139 
 
GRANT, R. J. & CLARKE, P. B. S. 2002. Susceptibility of ascending dopamine 
projections to 6-hydroxydopamine in rats: Effect of hypothermia. Neuroscience, 
115, 1281-1294. 
GREALISH, S., JONSSON, M. E., LI, M., KIRIK, D., BJORKLUND, A. & 
THOMPSON, L. H. 2010. The A9 dopamine neuron component in grafts of 
ventral mesencephalon is an important determinant for recovery of motor 
function in a rat model of Parkinson's disease. Brain, 133, 482-495. 
GREENE, J. G., DINGLEDINE, R. & GREENAMYRE, J. T. 2005. Gene expression 
profiling of rat midbrain dopamine neurons: implications for selective 
vulnerability in parkinsonism. Neurobiology of Disease, 18, 19-31. 
GREFFARD, S., VERNY, M., BONNET, A.-M., SEILHEAN, D., HAUW, J.-J. & 
DUYCKAERTS, C. 2010. A stable proportion of Lewy body bearing neurons in 
the substantia nigra suggests a model in which the Lewy body causes neuronal 
death. Neurobiology of Aging, 31, 99-103. 
GRIMM, J., MUELLER, A., HEFTI, F. & ROSENTHAL, A. 2004. Molecular basis for 
catecholaminergic neuron diversity. Proceedings of the National Academy of 
Sciences of the United States of America, 101, 13891-13896. 
HABER, S. N. 2003. The primate basal ganglia: parallel and integrative networks. 
Journal of Chemical Neuroanatomy, 26, 317-330. 
HAGELL, P., PICCINI, P., BJORKLUND, A., BRUNDIN, P., REHNCRONA, S., 
WIDNER, H., CRABB, L., PAVESE, N., OERTEL, W. H., QUINN, N., 
BROOKS, D. J. & LINDVALL, O. 2002. Dyskinesias following neural 
transplantation in Parkinson's disease. Nature Neuroscience, 5, 627-628. 
HAGELL, P., SCHRAG, A., PICCINI, P., JAHANSHAHI, M., BROWN, R., 
REHNCRONA, S., WIDNER, H., BRUNDIN, P., ROTHWELL, J. C., ODIN, 
P., WENNING, G. K., MORRISH, P., GUSTAVII, B., BJORKLUND, A., 
BROOKS, D. J., MARSDEN, C. D., QUINN, N. P. & LINDVALL, O. 1999. 
Sequential bilateral transplantation in Parkinson's disease - Effects of the second 
graft. Brain, 122, 1121-1132. 
HAHN, M., TIMMER, M. & NIKKHAH, G. 2009. Survival and Early Functional 
Integration of Dopaminergic Progenitor Cells Following Transplantation in a 
Rat Model of Parkinson's Disease. Journal of Neuroscience Research, 87, 2006-
2019. 
HALLIDAY, G., TRINIDAD HERRERO, M., MURPHY, K., MCCANN, H., ROS-
BERNAL, F., BARCIA, C., MORI, H., BLESA, F. J. & OBESO, J. A. 2009. No 
Lewy Pathology in Monkeys with Over 10 Years of Severe MPTP 
Parkinsonism. Movement Disorders, 24, 1519-1523. 
HAMILTON, D. 2012. Clinical and academic transplantation in Paris. A History of 
Organ Transplantation. 1st edition ed.: University of Pittsburgh Pre. 
HAYES, L., ZHANG, Z., ALBERT, P., ZERVAS, M. & AHN, S. 2011. Timing of 
Sonic Hedgehog and Gli1 Expression Segregates Midbrain Dopamine Neurons. 
Journal of Comparative Neurology, 519, 3001-3018. 
HAYES, N. L. & NOWAKOWSKI, R. S. 2000. Exploiting the dynamics of S-phase 
tracers in developing brain: Interkinetic nuclear migration for cells entering 
versus leaving the S-phase. Developmental Neuroscience, 22, 44-55. 
HAYES, N. L. & NOWAKOWSKI, R. S. 2002. High doses of bromodeoxyuridine 
increase number of labeled cells in adult mouse dentate gyrus by decreasing 
tracer loading time. Society for Neuroscience Abstract Viewer and Itinerary 
Planner, 2002, Abstract No. 126.3-Abstract No. 126.3. 
HEIKKILA, R. E., SHAPIRO, B. S. & DUVOISIN, R. C. 1981. The relationship 
between loss of dopamine nerve-terminals, striatal H-3 spiroperidol binding and 
140 
 
rotational behavior in unilaterally 6-hydroxydopamine-lesioned rats. Brain 
Research, 211, 285-292. 
HEIKKILA, R. E. & SONSALLA, P. K. 1992. The MPTP-treated mouse as a model of 
parkinsonism - how good is it. Neurochemistry International, 20, S299-S303. 
HELY, M. A., MORRIS, J. G. L., REID, W. G. J. & TRAFFICANTE, R. 2005. Sydney 
multicenter study of Parkinson's disease: non-L-dopa-responsive problems 
dominate at 15 years. Movement Disorders, 20, 190-199. 
HENDRY, I. A. 1975. Retrograde trans-synaptic control of development of cholinergic 
terminals in sympathetic-ganglia. Brain Research, 86, 483-487. 
HERTZMAN, C., WIENS, M., BOWERING, D., SNOW, B. & CALNE, D. 1990. 
Parkinsons-disease - a case-control study of occupational and environmental 
risk-factors. American Journal of Industrial Medicine, 17, 349-355. 
HERZOG, J., POGARELL, O., PINSKER, M. O., KUPSCH, A., OERTEL, W. H., 
LINDVALL, O., DEUSCHL, G. & VOLKMANN, J. 2008. Deep brain 
stimulation in Parkinson's disease following fetal nigral transplantation. Mov 
Disord, 23, 1293-6. 
HEUER, A., LELOS, M. J., KELLY, C. M., TORRES, E. M. & DUNNETT, S. B. 
2013a. Dopamine-rich grafts alleviate deficits in contralateral response space 
induced by extensive dopamine depletion in rats. Experimental Neurology, 247, 
485-495. 
HEUER, A., NGOC-NGA, V. & DUNNETT, S. B. 2013b. Behavioural recovery on 
simple and complex tasks by means of cell replacement therapy in unilateral 6-
hydroxydopamine-lesioned mice. European Journal of Neuroscience, 37, 1691-
1704. 
HIRSCH, E. C., GRAYBIEL, A. M., DUYCKAERTS, C. & JAVOYAGID, F. 1987. 
Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease 
and in progressive supranuclear palsy. Proceedings of the National Academy of 
Sciences of the United States of America, 84, 5976-5980. 
HUGHES, A. J., DANIEL, S. E., BLANKSON, S. & LEES, A. J. 1993. A 
clinicopathological study of 100 cases of Parkinsons-disease. Archives of 
Neurology, 50, 140-148. 
HUNG, H. C. & LEE, E. H. Y. 1998. MPTP produces differential oxidative stress and 
antioxidative responses in the nigrostriatal and mesolimbic dopaminergic 
pathways. Free Radical Biology and Medicine, 24, 76-84. 
HURD, Y. L., PRISTUPA, Z. B., HERMAN, M. M., NIZNIK, H. B. & KLEINMAN, J. 
E. 1994. The dopamine transporter and dopamine-D-2 receptor messenger-
RNAs are differentially expressed in limbic-related and motor-related 
subpopulations of human mesencephalic neurons. Neuroscience, 63, 357-362. 
ILINSKY, I. A., KULTASILINSKY, K. & SMITH, K. R. 1982. Organization of basal 
ganglia inputs to the thalamus - a light and electron-microscopic study in the cat. 
Applied Neurophysiology, 45, 230-237. 
INDEN, M., KITAMURA, Y., ABE, M., TAMAKI, A., TAKATA, K. & TANIGUCHI, 
T. 2011. Parkinsonian Rotenone Mouse Model: Reevaluation of Long-Term 
Administration of Rotenone in C57BL/6 Mice. Biological & Pharmaceutical 
Bulletin, 34, 92-96. 
INDEN, M., KITAMURA, Y., TAKEUCHI, H., YANAGIDA, T., TAKATA, K., 
KOBAYASHI, Y., TANIGUCHI, T., YOSHIMOTO, K., KANEKO, M., 
OKUMA, Y., TAIRA, T., ARIGA, H. & SHIMOHAMA, S. 2007. 
Neurodegeneration of mouse nigrostriatal dopaminergic system induced by 
repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a 
chemical chaperone. Journal of Neurochemistry, 101, 1491-1504. 
141 
 
IRAVANI, M. M., SYED, E., JACKSON, M. J., JOHNSTON, L. C., SMITH, L. A. & 
JENNER, P. 2005. A modified MPTP treatment regime produces reproducible 
partial nigrostriatal lesions in common marmosets. European Journal of 
Neuroscience, 21, 841-854. 
JANKOVIC, J. 2008. Parkinson's disease: clinical features and diagnosis. Journal of 
Neurology Neurosurgery and Psychiatry, 79, 368-376. 
JAVITCH, J. A., DAMATO, R. J., STRITTMATTER, S. M. & SNYDER, S. H. 1985. 
Parkinsonism-inducing neurotoxin, n-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine - uptake of the metabolite n-methyl-4-phenylpyridine by 
dopamine neurons explains selective toxicity. Proceedings of the National 
Academy of Sciences of the United States of America, 82, 2173-2177. 
JIANG, H., JACKSONLEWIS, V., MUTHANE, U., DOLLISON, A., FERREIRA, M., 
ESPINOSA, A., PARSONS, B. & PRZEDBORSKI, S. 1993. Adenosine 
receptor antagonists potentiate dopamine receptor agonist-induced rotational 
behavior in 6-hydroxydopamine-lesioned rats. Brain Research, 613, 347-351. 
JOKSIMOVIC, M., YUN, B. A., KITTAPPA, R., ANDEREGG, A. M., WCHANG, 
W., TAKETO, M. M., MCKAY, R. D. G. & AWATRAMANI, R. B. 2009. Wnt 
antagonism of Shh facilitates midbrain floor plate neurogenesis. Nature 
Neuroscience, 12, 125-131. 
JONSSON, M. E., ONO, Y., BJORKLUND, A. & THOMPSON, L. H. 2009. 
Identification of transplantable dopamine neuron precursors at different stages of 
midbrain neurogenesis. Experimental Neurology, 219, 341-354. 
KATZENSCHLAGER, R., HEAD, J., SCHRAG, A., BEN-SHLOMO, Y., EVANS, A., 
LEES, A. J. & PARKINSON'S DIS RES GRP UNITED, K. 2008. Fourteen-year 
final report of the randomized PDRG-UK trial comparing three initial treatments 
in PD. Neurology, 71, 474-480. 
KAUFMAN, M. P., LONGHURST, J. C., RYBICKI, K. J., WALLACH, J. H. & 
MITCHELL, J. H. 1983. Effects of static muscular-contraction on impulse 
activity of group-iii and group-iv afferents in cats. Journal of Applied 
Physiology, 55, 105-112. 
KAY, D. M., FACTOR, S. A., SAMII, A., HIGGINS, D. S., GRIFFITH, A., 
ROBERTS, J. W., LEIS, B. C., NUTT, J. G., MONTIMURRO, J. S., KEEFE, 
R. G., ATKINS, A. J., YEAROUT, D., ZABETIAN, C. P. & PAYAMI, H. 
2008. Genetic Association Between alpha-Synuclein and Idiopathic Parkinson's 
Disease. American Journal of Medical Genetics Part B-Neuropsychiatric 
Genetics, 147B, 1222-1230. 
KELE, J., SIMPLICIO, N., FERRI, A. L. M., MIRA, H., GUILLEMOT, F., ARENAS, 
E. & ANG, S. L. 2006. Neurogenin 2 is required for the development of ventral 
midbrain dopaminergic neurons. Development, 133, 495-505. 
KELLY, C. M., PRECIOUS, S. V., TORRES, E. M., HARRISON, A. W., WILLIAMS, 
D., SCHERF, C., WEYRAUCH, U. M., LANE, E. L., ALLEN, N. D., 
PENKETH, R., AMSO, N. N., KEMP, P. J., DUNNETT, S. B. & ROSSER, A. 
E. 2011. Medical Terminations of Pregnancy: A Viable Source of Tissue for 
Cell Replacement Therapy for Neurodegenerative Disorders. Cell 
Transplantation, 20, 503-513. 
KIM, H.-J., SUGIMORI, M., NAKAFUKU, M. & SVENDSEN, C. N. 2007. Control of 
neurogenesis and tyrosine hydroxylase expression in neural progenitor cells 
through bHLH proteins and Nurr1. Experimental Neurology, 203, 394-405. 
KIRIK, D., GEORGIEVSKA, B., BURGER, C., WINKLER, C., MUZYCZKA, N., 
MANDEL, R. J. & BJORKLUND, A. 2002. Reversal of motor impairments in 
parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-
142 
 
mediated gene transfer. Proceedings of the National Academy of Sciences of the 
United States of America, 99, 4708-4713. 
KISH, S. J., SHANNAK, K. & HORNYKIEWICZ, O. 1988. Uneven pattern of 
dopamine loss in the striatum of patients with idiopathic Parkinsons-disease - 
pathophysiologic and clinical implications. New England Journal of Medicine, 
318, 876-880. 
KITADA, T., ASAKAWA, S., HATTORI, N., MATSUMINE, H., YAMAMURA, Y., 
MINOSHIMA, S., YOKOCHI, M., MIZUNO, Y. & SHIMIZU, N. 1998. 
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. 
Nature, 392, 605-608. 
KOHLER, C., EVERITT, B. J., PEARSON, J. & GOLDSTEIN, M. 1983. 
Immunohistochemical evidence for a new group of catecholamine-containing 
neurons in the basal forebrain of the monkey. Neuroscience Letters, 37, 161-
166. 
KOLB, B., PEDERSEN, B., BALLERMANN, M., GIBB, B. & WHISHAW, I. Q. 
1999. Embryonic and postnatal injections of bromodeoxyuridine produce age-
dependent morphological and behavioral abnormalities. Journal of 
Neuroscience, 19, 2337-2346. 
KORDOWER, J. H., CHU, Y. P., HAUSER, R. A., FREEMAN, T. B. & OLANOW, C. 
W. 2008a. Lewy body-like pathology in long-term embryonic nigral transplants 
in Parkinson's disease. Nature Medicine, 14, 504-506. 
KORDOWER, J. H., CHU, Y. P., HAUSER, R. A., OLANOW, C. W. & FREEMAN, 
T. B. 2008b. Transplanted Dopaminergic Neurons Develop PD Pathologic 
Changes: A Second Case Report. Movement Disorders, 23, 2303-2306. 
KORDOWER, J. H., FREEMAN, T. B., CHEN, E. Y., MUFSON, E. J., SANBERG, P. 
R., HAUSER, R. A., SNOW, B. & OLANOW, C. W. 1998. Fetal nigral grafts 
survive and mediate clinical benefit in a patient with Parkinson's disease. 
Movement Disorders, 13, 383-393. 
KORDOWER, J. H., GOETZ, C. G., FREEMAN, T. B. & OLANOW, C. W. 1997a. 
Dopaminergic transplants in patients with Parkinson's disease: Neuroanatomical 
correlates of clinical recovery. Experimental Neurology, 144, 41-46. 
KORDOWER, J. H., KANAAN, N. M., CHU, Y., BABU, R. S., STANSELL, J., III, 
TERPSTRA, B. T., SORTWELL, C. E., STEECE-COLLIER, K. & COLLIER, 
T. J. 2006. Failure of proteasome inhibitor administration to provide a model of 
Parkinson's disease in rats and monkeys. Annals of Neurology, 60, 264-268. 
KORDOWER, J. H., ROSENSTEIN, J. M., COLLIER, T. J., BURKE, M. A., CHEN, 
E. Y., LI, J. M., MARTEL, L., LEVEY, A. E., MUFSON, E. J., FREEMAN, T. 
B. & OLANOW, C. W. 1996. Functional fetal nigral grafts in a patient with 
Parkinson's disease: Chemoanatomic, ultrastructural, and metabolic studies. 
Journal of Comparative Neurology, 370, 203-230. 
KORDOWER, J. H., STYREN, S., CLARKE, M., DEKOSKY, S. T., OLANOW, C. 
W. & FREEMAN, T. B. 1997b. Fetal grafting for Parkinson's disease: 
expression of immune markers in two patients with functional fetal nigral 
implants. Cell Transplant, 6, 213-9. 
KOTKOVA, P. & WEISS, P. 2013. Psychiatric factors related to sexual functioning in 
patients with Parkinson's disease. Clinical Neurology and Neurosurgery, 115, 
419-424. 
KRACK, P., BENAZZOUZ, A., POLLAK, P., LIMOUSIN, P., PIALLAT, B., 
HOFFMANN, D., XIE, J. & BENABID, A. L. 1998. Treatment of tremor in 
Parkinson's disease by subthalamic nucleus stimulation. Movement Disorders, 
13, 907-914. 
143 
 
KRAMER, M. L. & SCHULZ-SCHAEFFER, W. J. 2007. Presynaptic alpha-synuclein 
aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy 
bodies. Journal of Neuroscience, 27, 1405-1410. 
KRAYENBUHL, H. & YASARGIL, M. G. 1960. Bilateral thalamotomy in 
parkinsonism. Journal of Nervous and Mental Disease, 130, 538-541. 
KRAYENBUHL, H., YASARGIL, M. G. & WYSS, O. A. M. 1961. Bilateral 
thalamotomy and pallidotomy as treatment for bilateral parkinsonism. Journal of 
Neurosurgery, 18, 429-&. 
KRIKS, S., SHIM, J.-W., PIAO, J., GANAT, Y. M., WAKEMAN, D. R., XIE, Z., 
CARRILLO-REID, L., AUYEUNG, G., ANTONACCI, C., BUCH, A., YANG, 
L., BEAL, M. F., SURMEIER, D. J., KORDOWER, J. H., TABAR, V. & 
STUDER, L. 2011. Dopamine neurons derived from human ES cells efficiently 
engraft in animal models of Parkinson's disease. Nature, 480, 547-U177. 
KRISS, J. P. & REVESZ, L. 1962. Distribution and fate of bromodeoxyuridine and 
bromodeoxycytidine in mouse and rat. Cancer Research, 22, 254-&. 
KRUGER, R., KUHN, W., MULLER, T., WOITALLA, D., GRAEBER, M., KOSEL, 
S., PRZUNTEK, H., EPPLEN, J. T., SCHOLS, L. & RIESS, O. 1998. Ala30Pro 
mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nature 
Genetics, 18, 106-108. 
KUAN, W. L., LIN, R., TYERS, P. & BARKER, R. A. 2007. The importance of A9 
dopaminergic neurons in mediating the functional benefits of fetal ventral 
mesencephalon transplants and levodopa-induced dyskinesias. Neurobiology of 
Disease, 25, 594-608. 
KUUSISTO, E., PARKKINEN, L. & ALAFUZOFF, I. 2003. Morphogenesis of Lewy 
bodies: Dissimilar incorporation of alpha-synuclein, ubiquitin, and p62. Journal 
of Neuropathology and Experimental Neurology, 62, 1241-1253. 
LACEY, M. G., MERCURI, N. B. & NORTH, R. A. 1987. Dopamine acts on D2 
receptors to increase potassium conductance in neurons of the rat substantia-
nigra zona compacta. Journal of Physiology-London, 392, 397-416. 
LADER, M. 2008. Antiparkinsonian medication and pathological gambling. Cns Drugs, 
22, 407-416. 
LAMMEL, S., HETZEL, A., HAECKEL, O., JONES, I., LISS, B. & ROEPER, J. 2008. 
Unique properties of mesoprefrontal neurons within a dual mesocorticolimbic 
dopamine system. Neuron, 57, 760-773. 
LANDMESSER, L. 1978. Interactions between neurons and their targets   during invivo 
synaptogenesis. Federation Proceedings, 37. 
LANG, A. E. & LOZANO, A. M. 1998. Parkinson's disease - Second of two parts. New 
England Journal of Medicine, 339, 1130-1143. 
LANGSTON, J. W., BALLARD, P., TETRUD, J. W. & IRWIN, I. 1983. Chronic 
parkinsonism in humans due to a product of meperidine-analog synthesis. 
Science, 219, 979-980. 
LANGSTON, J. W., FORNO, L. S., REBERT, C. S. & IRWIN, I. 1984. Selective 
nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-
tetrahydropyrine (MPTP) in the squirrel-monkey. Brain Research, 292, 390-394. 
LASAK, J. M. & GORECKI, J. P. 2009. The History of Stereotactic Radiosurgery and 
Radiotherapy. Otolaryngologic Clinics of North America, 42, 593-599. 
LEE, K. H., CHANG, S. Y., ROBERTS, D. W. & KIM, U. 2004. Neurotransmitter 
release from high-frequency stimulation of the subthalamic nucleus. Journal of 
Neurosurgery, 101, 511-517. 
LEES, A. J., HARDY, J. & REVESZ, T. 2009. Parkinson's disease. Lancet, 373, 2055-
2066. 
144 
 
LESAGE, S., DURR, A., TAZIR, M., LOHMANN, E., LEUTENEGGER, A. L., 
JANIN, S., POLLAK, P., BRICE, A. & FRENCH PARKINSON'S DIS 
GENETICS, S. 2006. LRRK2 G2019S as a cause of Parkinson's disease in 
North African Arabs. New England Journal of Medicine, 354, 422-423. 
LEVIVIER, M., DETHY, S., RODESCH, F., PESCHANSKI, M., VANDESTEENE, 
A., DAVID, P., WIKLER, D., GOLDMAN, S., CLAES, T., BIVER, F., 
LIESNARD, C., GOLDMAN, M., HILDEBRAND, J. & BROTCHI, J. 1997. 
Intracerebral transplantation of fetal ventral mesencephalon for patients with 
advanced Parkinson's disease - Methodology and 6-month to 1-year follow-up in 
3 patients. Stereotactic and Functional Neurosurgery, 69, 99-111. 
LI, J.-Y., ESPAY, A. J., GUNRAJ, C. A., PAL, P. K., CUNIC, D. I., LANG, A. E. & 
CHEN, R. 2007. Interhemispheric and ipsilateral connections in Parkinson's 
disease: Relation to mirror movements. Movement Disorders, 22, 813-821. 
LI, J. Y., ENGLUND, E., HOLTON, J. L., SOULET, D., HAGELL, P., LEES, A. J., 
LASHLEY, T., QUINN, N. P., REHNCRONA, S., BJORKLUND, A., 
WIDNER, H., REVESZ, T., LINDVALL, O. & BRUNDIN, P. 2008. Lewy 
bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-
graft disease propagation. Nature Medicine, 14, 501-503. 
LI, Y., LIU, W., OO, T. F., WANG, L., TANG, Y., JACKSON-LEWIS, V., ZHOU, C., 
GEGHMAN, K., BOGDANOV, M., PRZEDBORSKI, S., BEAL, M. F., 
BURKE, R. E. & LI, C. 2009. Mutant LRRK2(R1441G) BAC transgenic mice 
recapitulate cardinal features of Parkinson's disease. Nature Neuroscience, 12, 
826-828. 
LIBOW, L. S., FRISINA, P. G., HAROUTUNIAN, V., PERL, D. P. & PUROHIT, D. 
P. 2009. Parkinson's disease dementia - A diminished role for the Lewy body. 
Parkinsonism & Related Disorders, 15, 572-575. 
LIM, S.-Y., EVANS, A. H. & MIYASAKI, J. M. 2008. Impulse Control and Related 
Disorders in Parkinson's Disease Review. Year in Neurology 2008, 1142, 85-
107. 
LIMA, M. M. S., MARTINS, E. F., DELATTRE, A. M., PROENCA, M. B., MORI, M. 
A., CARABELLI, B. & FERRAZ, A. C. 2012. Motor and Non-Motor Features 
of Parkinson's Disease - A Review of Clinical and Experimental Studies. Cns & 
Neurological Disorders-Drug Targets, 11, 439-449. 
LIMOUSIN, P., POLLAK, P., BENAZZOUZ, A., HOFFMANN, D., LEBAS, J. F., 
BROUSSOLLE, E., PERRET, J. E. & BENABID, A. L. 1995. Effect on 
parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. 
Lancet, 345, 91-95. 
LIMOUSIN, P., SPEELMAN, J. D., GIELEN, F. & JANSSENS, M. 1999. Multicentre 
European study of thalamic stimulation in parkinsonian and essential tremor. 
Journal of Neurology Neurosurgery and Psychiatry, 66, 289-296. 
LINDVALL, O. & BJORKLUND, A. 1974. The organization of the ascending 
catecholamine neuron systems in the rat brain as revealed by the glyoxylic acid 
fluorescence method. Acta physiologica Scandinavica. Supplementum, 412, 1-
48. 
LINDVALL, O., BRUNDIN, P., WIDNER, H., REHNCRONA, S., GUSTAVII, B., 
FRACKOWIAK, R., LEENDERS, K. L., SAWLE, G., ROTHWELL, J. C., 
MARSDEN, C. D. & BJORKLUND, A. 1990. Grafts of fetal dopamine neurons 
survive and improve motor function in Parkinsons-disease. Science, 247, 574-
577. 
LINDVALL, O., REHNCRONA, S., BRUNDIN, P., GUSTAVII, B., ASTEDT, B., 
WIDNER, H., LINDHOLM, T., BJORKLUND, A., LEENDERS, K. L., 
ROTHWELL, J. C., FRACKOWIAK, R., MARSDEN, C. D., JOHNELS, B., 
145 
 
STEG, G., FREEDMAN, R., HOFFER, B. J., SEIGER, A., BYGDEMAN, M., 
STROMBERG, I. & OLSON, L. 1989. Human-fetal dopamine neurons grafted 
into the striatum in 2 patients with severe Parkinsons-disease - a detailed 
account of methodology and a 6-month follow-up. Archives of Neurology, 46, 
615-631. 
LINDVALL, O., SAWLE, G., WIDNER, H., ROTHWELL, J. C., BJORKLUND, A., 
BROOKS, D., BRUNDIN, P., FRACKOWIAK, R., MARSDEN, C. D., ODIN, 
P. & REHNCRONA, S. 1994. Evidence for long-term survival and function of 
dopaminergic grafts in progressive Parkinsons-disease. Annals of Neurology, 35, 
172-180. 
LINDVALL, O., WIDNER, H., REHNCRONA, S., BRUNDIN, P., ODIN, P., 
GUSTAVII, B., FRACKOWIAK, R., LEENDERS, K. L., SAWLE, G., 
ROTHWELL, J. C., BJORKLUND, A. & MARSDEN, C. D. 1992. 
Transplantation of fetal dopamine neurons in Parkinsons-disease - one-year 
clinical and neurophysiological observations in 2 patients with putaminal 
implants. Annals of Neurology, 31, 155-165. 
LOPEZ-LOZANO, J. J., BRAVO, G., BRERA, B., MILLAN, I., DARGALLO, J., 
SALMEAN, J., URIA, J. & INSAUSTI, J. 1997. Long-term improvement in 
patients with severe Parkinson's disease after implantation of fetal ventral 
mesencephalic tissue in a cavity of the caudate nucleus: 5-year follow up in 10 
patients. Clinica Puerta de Hierro Neural Transplantation Group. J Neurosurg, 
86, 931-42. 
LOTHARIUS, J. & BRUNDIN, P. 2002. Pathogenesis of Parkinson's disease: 
Dopamine, vesicles and alpha-synuclein. Nature Reviews Neuroscience, 3, 932-
942. 
LOUGHLIN, S. E. & FALLON, J. H. 1984. Substantia nigra and ventral tegmental area 
projections to cortex - topography and collateralization. Neuroscience, 11, 425-
435. 
LOWE, J., BLANCHARD, A., MORRELL, K., LENNOX, G., REYNOLDS, L., 
BILLETT, M., LANDON, M. & MAYER, R. J. 1988. Ubiquitin is a common 
factor in intermediate filament inclusion-bodies of diverse type in man, 
including those of Parkinsons-disease, Picks disease, and Alzheimers-disease, as 
well as rosenthal fibers in cerebellar astrocytomas, cytoplasmic bodies in 
muscle, and mallory bodies in alcoholic liver-disease. Journal of Pathology, 
155, 9-15. 
LUNDBLAD, M., DECRESSAC, M., MATTSSON, B. & BJORKLUND, A. 2012. 
Impaired neurotransmission caused by overexpression of alpha-synuclein in 
nigral dopamine neurons. Proceedings of the National Academy of Sciences of 
the United States of America, 109, 3213-3219. 
LYNDBALTA, E. & HABER, S. N. 1994. The organization of midbrain projections to 
the striatum in the primate - sensorimotor-related striatum versus ventral 
striatum. Neuroscience, 59, 625-640. 
MACHT, M., KAUSSNER, Y., MOELLER, J. C., STIASNY-KOLSTER, K., 
EGGERT, K. M., KRUEGER, H.-P. & ELLGRING, H. 2007. Predictors of 
freezing in Parkinson's disease: A survey of 6,620 patients. Movement 
Disorders, 22, 953-956. 
MADRAZO, I., DRUCKERCOLIN, R., DIAZ, V., MARTINEZMATA, J., TORRES, 
C. & BECERRIL, J. J. 1987. Open microsurgical autograft of adrenal-medulla 
to the right caudate-nucleus in 2 patients with intractable Parkinsons-disease. 
New England Journal of Medicine, 316, 831-834. 
MANCA, D., COSSU, G., MURGIA, D., MOLARI, A., FERRIGNO, P., MARCIA, E. 
& MELIS, M. 2009. Reversible Encephalopathy and Axonal Neuropathy in 
146 
 
Parkinson's Disease During Duodopa Therapy. Movement Disorders, 24, 2293-
2294. 
MANN, D. M. A. & YATES, P. O. 1983. Pathological basis for neurotransmitter 
changes in Parkinsons-disease. Neuropathology and Applied Neurobiology, 9, 3-
19. 
MAO, L. M., LAU, Y. S., PETROSKE, E. & WANG, J. Q. 2001. Profound 
astrogenesis in the striatum of adult mice following nigrostriatal dopaminergic 
lesion by repeated MPTP administration. Developmental Brain Research, 131, 
57-65. 
MARCHAND, R. & POIRIER, L. J. 1983. Isthmic origin of neurons of the rat 
substantia-nigra. Neuroscience, 9, 373-381. 
MARIES, E., KORDOWER, J. H., CHU, Y., COLLIER, T. J., SORTWELL, C. E., 
OLARU, E., SHANNON, K. & STEECE-COLLIER, K. 2006. Focal not 
widespread grafts induce novel dyskinetic behavior in parkinsonian rats. 
Neurobiol Dis, 21, 165-80. 
MARSDEN, C. D. 1994. Problems with long-term levodopa therapy for Parkinsons-
disease. Clinical Neuropharmacology, 17, S32-S44. 
MARTINAT, C., SHENDELMAN, S., JONASON, A., LEETE, T., BEAL, M. F., 
YANG, L. C., FLOSS, T. & ABELIOVICH, A. 2004. Sensitivity to oxidative 
stress in DJ-1-deficient dopamine neurons: An ES-derived cell model of primary 
Parkinsonism. Plos Biology, 2, 1754-1763. 
MARUYAMA, W., TAKAHASHI, T., YOUDIM, M. & NAOI, M. 2002. The anti-
parkinson drug, rasagiline, prevents apoptotic DNA damage induced by 
peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. Journal of 
Neural Transmission, 109, 467-481. 
MASLIAH, E., ROCKENSTEIN, E., VEINBERGS, I., MALLORY, M., 
HASHIMOTO, M., TAKEDA, A., SAGARA, Y., SISK, A. & MUCKE, L. 
2000. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: 
Implications for neurodegenerative disorders. Science, 287, 1265-1269. 
MASLIAH, E., ROCKENSTEIN, E., VEINBERGS, I., SAGARA, Y., MALLORY, M., 
HASHIMOTO, M. & MUCKE, L. 2001. beta-Amyloid peptides enhance alpha-
synuclein accumulation and neuronal deficits in a transgenic mouse model 
linking Alzheimer's disease and Parkinson's disease. Proceedings of the National 
Academy of Sciences of the United States of America, 98, 12245-12250. 
MCCORMACK, A. L., ATIENZA, J. G., LANGSTON, J. W. & DI MONTE, D. A. 
2006. Decreased susceptibility to oxidative stress underlies the resistance of 
specific dopaminergic cell populations to paraquat-induced degeneration. 
Neuroscience, 141, 929-937. 
MCCORMACK, A. L., THIRUCHELVAM, M., MANNING-BOG, A. B., 
THIFFAULT, C., LANGSTON, J. W., CORY-SLECHTA, D. A. & DI 
MONTE, D. A. 2002. Environmental risk factors and Parkinson's disease: 
Selective degeneration of nigral dopaminergic neurons caused by the herbicide 
paraquat. Neurobiology of Disease, 10, 119-127. 
MCDONALD, H. Y. & WOJTOWICZ, J. M. 2005. Dynamics of neurogenesis in the 
dentate gyrus of adult rats. Neuroscience Letters, 385, 70-75. 
MCDONNELL, S. K., SCHAID, D. J., ELBAZ, A., STRAIN, K. J., BOWER, J. H., A-
HLSKOG, J. E., MARAGANORE, D. M. & ROCCA, W. A. 2006. Complex 
segregation analysis of Parkinson's disease: The Mayo Clinic family study. 
Annals of Neurology, 59, 788-795. 
MENDEZ, I., DAGHER, A., HONG, M., GAUDET, P., WEERASINGHE, S., 
MCALISTER, V., KING, D., DESROSIERS, J., DARVESH, S., ACORN, T. & 
ROBERTSON, H. 2002. Simultaneous intrastriatal and intranigral fetal 
147 
 
dopaminergic grafts in patients with Parkinson disease: a pilot study. Report of 
three cases. J Neurosurg, 96, 589-96. 
MENDEZ, I., ELISEVICH, K. & FLUMERFELT, B. 1991. Dopaminergic innervation 
of substance p-containing striatal neurons by fetal nigral grafts - an 
ultrastructural double-labeling immunocytochemical study. Journal of 
Comparative Neurology, 308, 66-78. 
MENDEZ, I., SADI, D. & HONG, M. 1996. Reconstruction of the nigrostriatal 
pathway by simultaneous intrastriatal and intranigral dopaminergic transplants. J 
Neurosci, 16, 7216-27. 
MENDEZ, I., SANCHEZ-PERNAUTE, R., COOPER, O., VINUELA, A., FERRARI, 
D., BJORKLUND, L., DAGHER, A. & ISACSON, O. 2005. Cell type analysis 
of functional fetal dopamine cell suspension transplants in the striatum and 
substantia nigra of patients with Parkinson's disease. Brain, 128, 1498-1510. 
MENDEZ, I., VINUELA, A., ASTRADSSON, A., MUKHIDA, K., HALLETT, P., 
ROBERTSON, H., TIERNEY, T., HOLNESS, R., DAGHER, A., 
TROJANOWSKI, J. Q. & ISACSON, O. 2008. Dopamine neurons implanted 
into people with Parkinson's disease survive without pathology for 14 years. 
Nature Medicine, 14, 507-509. 
MENTZEL, C. L., TENBACK, D. E., TIJSSEN, M. A. J., VISSER-VANDEWALLE, 
V. E. R. M. & VAN HARTEN, P. N. 2012. Efficacy and Safety of Deep Brain 
Stimulation in Patients With Medication-Induced Tardive Dyskinesia and/or 
Dystonia: A Systematic Review. Journal of Clinical Psychiatry, 73, 1434-1438. 
MEYERS, R. 1942. Surgical interruption of pallidofugal fibres: Its effect on the 
syndrome paralysis agitans and technical considerations in its application. New 
York State Journal of Medicine, 42, 317-325. 
MEYERS, R. 1951. Surgical experiments in the therapy of certain 'extrapyramidal' 
diseases: a current evaluation. Acta psychiatrica et neurologica. Supplementum, 
67, 1-42. 
MICALLEF, J., REY, M., EUSEBIO, A., AUDEBERT, C., ROUBY, F., JOUVE, E., 
TARDIEU, S. & BLIN, O. 2009. Antiparkinsonian drug-induced sleepiness: a 
double-blind placebo-controlled study of L-dopa, bromocriptine and 
pramipexole in healthy subjects. British Journal of Clinical Pharmacology, 67, 
333-340. 
MICHELL, A. W., BARKER, R. A., RAHA-CHOWDHURY, R. & RAHA, S. K. 2005. 
A case of late onset sporadic Parkinson's disease with an A53T mutation in 
alpha-synuclein. Journal of Neurology Neurosurgery and Psychiatry, 76, 596-
597. 
MIHM, M. J., SCHANBACHER, B. L., WALLACE, B. L., WALLACE, L. J., 
URETSKY, N. J. & BAUER, J. A. 2001. Free 3-nitrotyrosine causes striatal 
neurodegeneration in vivo. Journal of Neuroscience, 21, art. no.-RC149. 
MINGUEZ-MINGUEZ, S., DEL POZO, J. S. G. & JORDAN, J. 2013. Rasagiline in 
Parkinson's disease: A review based on meta-analysis of clinical data. 
Pharmacological Research, 74, 78-86. 
MOLINA, H., QUINONES-MOLINA, R., MUNOZ, J., ALVAREZ, L., ALAMINOS, 
A., ORTEGA, I., OHYE, C., MACIAS, R., PIEDRA, J., GONZALEZ, C. & ET 
AL. 1994. Neurotransplantation in Parkinson's disease: from open microsurgery 
to bilateral stereotactic approach: first clinical trial using microelectrode 
recording technique. Stereotact Funct Neurosurg, 62, 204-8. 
MOORE, D. J. & DAWSON, T. M. 2008. Value of genetic models in understanding the 
cause and mechanisms of Parkinson's disease. Current Neurology and 
Neuroscience Reports, 8, 288-296. 
148 
 
MORENS, D. M., DAVIS, J. W., GRANDINETTI, A., ROSS, G. W., POPPER, J. S. & 
WHITE, L. R. 1996. Epidemiologic observations on Parkinson's disease: 
Incidence and mortality in a prospective study of middle-aged men. Neurology, 
46, 1044-1050. 
MUKHIDA, K., BAKER, K. A., SADI, D. & MENDEZ, I. 2001. Enhancement of 
sensorimotor behavioral recovery in hemiparkinsonian rats with intrastriatal, 
intranigral, and intrasubthalamic nucleus dopaminergic transplants. J Neurosci, 
21, 3521-30. 
MUKHIDA, K., HONG, M., MILES, G. B., PHILLIPS, T., BAGHBADERANI, B. A., 
MCLEOD, M., KOBAYASHI, N., SEN, A., BEHIE, L. A., BROWNSTONE, 
R. M. & MENDEZ, I. 2008. A multitarget basal ganglia dopaminergic and 
GABAergic transplantation strategy enhances behavioural recovery in 
parkinsonian rats. Brain, 131, 2106-26. 
MULLER, T., VAN LAAR, T., CORNBLATH, D. R., ODIN, P., KLOSTERMANN, 
F., GRANDAS, F. J., EBERSBACH, G., URBAN, P. P., VALLDEORIOLA, F. 
& ANTONINI, A. 2013. Peripheral neuropathy in Parkinson's disease: 
Levodopa exposure and implications for duodenal delivery Universally 
Available. Parkinsonism & Related Disorders, 19, 501-507. 
MUNOZ, A., LI, Q., GARDONI, F., MARCELLO, E., QIN, C., CARLSSON, T., 
KIRIK, D., DI LUCA, M., BJORKLUND, A., BEZARD, E. & CARTA, M. 
2008. Combined 5-HTIA and 5-HTIB receptor agonists for the treatment of L-
DOPA-induced dyskinesia. Brain, 131, 3380-3394. 
MURATA, M. & KANAZAWA, I. 1993. Repeated L-DOPA administration reduces the 
ability of dopamine storage and abolishes the supersensitivity of dopamine-
receptors in the striatum of intact rat. Neuroscience Research, 16, 15-23. 
NAIR-ROBERTS, R. G., CHATELAIN-BADIE, S. D., BENSON, E., WHITE-
COOPER, H., BOLAM, J. P. & UNGLESS, M. A. 2008. Stereological estimates 
of dopaminergic, gabaergic and glutamatergic neurons in the ventral tegmental 
area, substantia nigra and retrorubral field in the rat. Neuroscience, 152, 1024-
1031. 
NARENDRA, D., TANAKA, A., SUEN, D.-F. & YOULE, R. J. 2008. Parkin is 
recruited selectively to impaired mitochondria and promotes their autophagy. 
Journal of Cell Biology, 183, 795-803. 
NARENDRA, D. P., JIN, S. M., TANAKA, A., SUEN, D. F., GAUTIER, C. A., 
SHEN, J., COOKSON, M. R. & YOULE, R. J. 2010. PINK1 Is Selectively 
Stabilized on Impaired Mitochondria to Activate Parkin. Plos Biology, 8. 
NAYLOR, J. L., WIDDOWSON, P. S., SIMPSON, M. G., FARNWORTH, M., ELLIS, 
M. K. & LOCK, E. A. 1995. Further evidence that the blood-brain-barrier 
impedes Paraquat   entry into the brain. Human & Experimental Toxicology, 14, 
587-594. 
NELANDER, J., HEBSGAARD, J. B. & PARMAR, M. 2009. Organization of the 
human embryonic ventral mesencephalon. Gene Expression Patterns, 9, 555-
561. 
NIKKHAH, G., EBERHARD, J., OLSSON, M. & BJORKLUND, A. 1995. 
Preservation of fetal ventral mesencephalic cells by cool storage - in-vitro 
viability and TH-positive neuron survival after microtransplantation to the 
striatum. Brain Research, 687, 22-34. 
NILSSON, O. G., CLARKE, D. J., BRUNDIN, P. & BJORKLUND, A. 1988. 
Comparison of growth and reinnervation properties of cholinergic neurons from 
different brain-regions grafted to the hippocampus. Journal of Comparative 
Neurology, 268. 
149 
 
NUTT, J. G., WOODWARD, W. R., HAMMERSTAD, J. P., CARTER, J. H. & 
ANDERSON, J. L. 1984. The on off phenomenon in Parkinsons-disease - 
relation to levodopa absorption and transport. New England Journal of 
Medicine, 310, 483-488. 
O'KEEFFE, F. E., SCOTT, S. A., TYERS, P., O'KEEFFE, G. W., DALLEY, J. W., 
ZUFFEREY, R. & CALDWELL, M. A. 2008. Induction of A9 dopaminergic 
neurons from neural stem cells improves motor function in an animal model of 
Parkinsons disease. Brain, 131, 630-641. 
OBESO, J. & LANG, A. 2006. Evolution of Parkinson's Disease and Treatment 
Requirements: What New Treatments are needed and the Role of Striatal 
Grafting. In: BRUNDIN, P. & OLANOW, C. (eds.) Restorative Therapies in 
Parkinson's Disease. New York, USA: Springer. 
OLANOW, C. W., GOETZ, C. G., KORDOWER, J. H., STOESSL, A. J., SOSSI, V., 
BRIN, M. F., SHANNON, K. M., NAUERT, G. M., PERL, D. P., GODBOLD, 
J. & FREEMAN, T. B. 2003. A double-blind controlled trial of bilateral fetal 
nigral transplantation in Parkinson's disease. Annals of Neurology, 54, 403-414. 
OLDS, M. E., JACQUES, D. B. & KOPYOV, O. 2006. Relation between rotation in the 
6-OHDA, lesioned rat and dopamine loss in striatal and substantia nigra 
subregions. Synapse, 59, 532-544. 
OLSON, L. & MALMFORS, T. 1970. Growth characteristics of adrenergic nerves in 
the adult rat. Fluorescence histochemical and 3H-noradrenaline uptake studies 
using tissue transplantations to the anterior chamber of the eye. Acta 
physiologica Scandinavica. Supplementum, 348. 
OLSON, L. & SEIGER, A. 1972. Early prenatal ontogeny of central monoamine 
neurons in rat - fluorescence histochemical observations. Zeitschrift Fur 
Anatomie Und Entwicklungsgeschichte, 137, 301-&. 
OUREDNIK, V. & OUREDNIK, J. 2004. Multifaceted dialogue between graft and host 
in neurotransplantation. J Neurosci Res, 76, 193-204. 
PACKARD, D. S., JR., MENZIES, R. A. & SKALKO, R. G. 1973. Incorportaiton of 
thymidine and its analogue, bromodeoxyuridine, into embryos and maternal 
tissues of the mouse. Differentiation; research in biological diversity, 1, 397-
404. 
PAGONABARRAGA, J. & CRUZ RODRIGUEZ-OROZ, M. 2013. Rasagiline in 
monotherapy in patients with early stages of Parkinson's disease and in 
combined and adjunct therapy to levodopa with moderate and advanced stages. 
Revista De Neurologia, 56, 25-34. 
PALFI, S., LEVENTHAL, L., CHU, Y. P., MA, S. Y., EMBORG, M., BAKAY, R., 
DEGLON, N., HANTRAYE, P., AEBISCHER, P. & KORDOWER, J. H. 2002. 
Lentivirally delivered glial cell line-derived neurotrophic factor increases the 
number of striatal dopaminergic neurons in primate models of nigrostriatal 
degeneration. Journal of Neuroscience, 22, 4942-4954. 
PARISH, C. L., CASTELO-BRANCO, G., RAWAL, N., TONNESEN, J., 
SORENSEN, A. T., SALTO, C., KOKAIA, M., LINDVALL, O. & ARENAS, 
E. 2008. Wnt5a-treated midbrain neural stem cells improve dopamine cell 
replacement therapy in parkinsonian mice. Journal of Clinical Investigation, 
118, 149-160. 
PARKINSON, J. 2002. An essay on the shaking palsy (Reprinted). Journal of 
Neuropsychiatry and Clinical Neurosciences, 14, 223-236. 
PARKKINEN, L., SOININEN, H., LAAKSO, M. & ALAFUZOFF, I. 2001. alpha-
Synuclein pathology is highly dependent on the case selection. Neuropathology 
and Applied Neurobiology, 27, 314-325. 
150 
 
PAXINOS, G. & WATSON, C. 2003. The rat brain in stereotaxic coordinates., 
London, Academic Press. 
PEARCE, R. K. B., HEIKKILA, M., LINDEN, I. B. & JENNER, P. 2001. L-dopa 
induces dyskinesia in normal monkeys: behavioural and pharmacokinetic 
observations. Psychopharmacology, 156, 402-409. 
PERACHON, S., SCHWARTZ, J. C. & SOKOLOFF, P. 1999. Functional potencies of 
new antiparkinsonian drugs at recombinant human dopamine D-1, D-2 and D-3 
receptors. European Journal of Pharmacology, 366, 293-300. 
PERLOW, M. J., FREED, W. J., HOFFER, B. J., SEIGER, A., OLSON, L. & WYATT, 
R. J. 1979. Brain grafts reduce motor abnormalities produced by destruction of 
nigrostriatal dopamine system. Science, 204, 643-7. 
PERRIER, A. L., TABAR, V., BARBERI, T., RUBIO, M. E., BRUSES, J., TOPF, N., 
HARRISON, N. L. & STUDER, L. 2004. Derivation of midbrain dopamine 
neurons from human embryonic stem cells. Proceedings of the National 
Academy of Sciences of the United States of America, 101, 12543-12548. 
PESCHANSKI, M., DEFER, G., N'GUYEN, J. P., RICOLFI, F., MONFORT, J. C., 
REMY, P., GENY, C., SAMSON, Y., HANTRAYE, P., JENY, R. & ET AL. 
1994. Bilateral motor improvement and alteration of L-dopa effect in two 
patients with Parkinson's disease following intrastriatal transplantation of foetal 
ventral mesencephalon. Brain, 117 ( Pt 3), 487-99. 
PICCINI, P., BROOKS, D. J., BJORKLUND, A., GUNN, R. N., GRASBY, P. M., 
RIMOLDI, O., BRUNDIN, P., HAGELL, P., REHNCRONA, S., WIDNER, H. 
& LINDVALL, O. 1999. Dopamine release from nigral transplants visualized in 
vivo in a Parkinson's patient. Nat Neurosci, 2, 1137-40. 
PICCINI, P., LINDVALL, O., BJORKLUND, A., BRUNDIN, P., HAGELL, P., 
CERAVOLO, R., OERTEL, W., QUINN, N., SAMUEL, M., REHNCRONA, 
S., WIDNER, H. & BROOKS, D. J. 2000. Delayed recovery of movement-
related cortical function in Parkinson's disease after striatal dopaminergic grafts. 
Ann Neurol, 48, 689-95. 
PINCUS, J. H. & BARRY, K. M. 1987. Plasma-levels of amino-acids correlate with 
motor fluctuations in parkinsonism. Archives of Neurology, 44, 1006-1009. 
PLUCHINO, S., ZANOTTI, L., ROSSI, B., BRAMBILLA, E., OTTOBONI, L., 
SALANI, G., MARTINELLO, M., CATTALINI, A., BERGAMI, A., FURLAN, 
R., COMI, G., CONSTANTIN, G. & MARTINO, G. 2005. Neurosphere-
derived multipotent precursors promote neuroprotection by an 
immunomodulatory mechanism. Nature, 436, 266-71. 
POLYMEROPOULOS, M. H., LAVEDAN, C., LEROY, E., IDE, S. E., DEHEJIA, A., 
DUTRA, A., PIKE, B., ROOT, H., RUBENSTEIN, J., BOYER, R., 
STENROOS, E. S., CHANDRASEKHARAPPA, S., ATHANASSIADOU, A., 
PAPAPETROPOULOS, T., JOHNSON, W. G., LAZZARINI, A. M., 
DUVOISIN, R. C., DIIORIO, G., GOLBE, L. I. & NUSSBAUM, R. L. 1997. 
Mutation in the alpha-synuclein gene identified in families with Parkinson's 
disease. Science, 276, 2045-2047. 
PONSEN, M. M., STOFFERS, D., BOOIJ, J., VAN ECK-SMIT, B. L. F., WOLTERS, 
E. C. & BERENDSE, H. W. 2004. Idiopathic hyposmia as a preclinical sign of 
Parkinson's disease. Annals of Neurology, 56, 173-181. 
PORRITT, M. J., BATCHELOR, P. E., HUGHES, A. J., KALNINS, R., DONNAN, G. 
A. & HOWELLS, D. W. 2000. New dopaminergic neurons in Parkinson's 
disease striatum. Lancet, 356, 44-45. 
PORRITT, M. J., KINGSBURY, A. E., HUGHES, A. J. & HOWELLS, D. W. 2006. 
Striatal dopaminergic neurons are lost with Parkinson's disease progression. 
Movement Disorders, 21, 2208-2211. 
151 
 
POULOPOULOS, M., LEVY, O. A. & ALCALAY, R. N. 2012. The neuropathology of 
genetic Parkinson's disease. Movement Disorders, 27, 831-842. 
PRAMSTALLER, P. P., SCHLOSSMACHER, M. G., JACQUES, T. S., 
SCARAVILLI, F., ESKELSON, C., PEPIVANI, I., HEDRICH, K., ADEL, S., 
GONZALES-MCNEAL, M., HILKER, R., KRAMER, P. L. & KLEIN, C. 
2005. Lewy body Parkinson's disease in a large pedigree with 77 Parkin 
mutation carriers. Annals of Neurology, 58, 411-422. 
PRENSA, L. & PARENT, A. 2001. The nigrostriatal pathway in the rat: A single-axon 
study of the relationship between dorsal and ventral tier nigral neurons and the 
striosome/matrix striatal compartments. Journal of Neuroscience, 21, 7247-
7260. 
PURSIAINEN, V., HAAPANIEMI, T. H., KORPELAINEN, J. T., SOTANIEMI, K. A. 
& MYLLYLA, V. V. 2007. Sweating in parkinsonian patients with wearing-off. 
Movement Disorders, 22, 828-832. 
PUSCHMANN, A., ENGLUND, E., ROSS, O. A., VILARINO-GUELL, C., 
LINCOLN, S. J., KACHERGUS, J. M., COBB, S. A., TORNQVIST, A.-L., 
REHNCRONA, S., WIDNER, H., WSZOLEK, Z. K., FARRER, M. J. & 
NILSSON, C. 2012. First neuropathological description of a patient with 
Parkinson's disease and LRRK2 p.N1437H mutation. Parkinsonism & Related 
Disorders, 18, 332-338. 
QUINN, N. P. 1990. The clinical-application of cell grafting techniques in patients with 
Parkinsons-disease. Neural Transplantation : from Molecular Basis to Clinical 
Applications, 82, 619-625. 
QUINN, N. P. 1998. Classification of fluctuations in patients with Parkinson's disease. 
Neurology, 51, S25-S29. 
RAJPUT, A. H., FENTON, M. E., BIRDI, S., MACAULAY, R., GEORGE, D., 
ROZDILSKY, B., ANG, L. C., SENTHILSELVAN, A. & HORNYKIEWICZ, 
O. 2002. Clinical-pathological study of levodopa complications. Movement 
Disorders, 17, 289-296. 
RAJPUT, A. H., ROZDILSKY, B. & RAJPUT, A. 1991. Accuracy of clinical-diagnosis 
in parkinsonism - a prospective-study. Canadian Journal of Neurological 
Sciences, 18, 275-278. 
RAO, G., FISCH, L., SRINIVASAN, S., D'AMICO, F., OKADA, T., EATON, C. & 
ROBBINS, C. 2003. Does this patient have Parkinson disease? Jama-Journal of 
the American Medical Association, 289, 347-353. 
REDMOND, D. E., VINUELA, A., KORDOWER, J. H. & ISACSON, O. 2008. 
Influence of cell preparation and target location on the behavioral recovery after 
striatal transplantation of fetal dopaminergic neurons in a primate model of 
Parkinson's disease. Neurobiology of Disease, 29, 103-116. 
REINER, A., ALBIN, R. L., ANDERSON, K. D., DAMATO, C. J., PENNEY, J. B. & 
YOUNG, A. B. 1988. Differential loss of striatal projection neurons in 
Huntington disease. Proceedings of the National Academy of Sciences of the 
United States of America, 85, 5733-5737. 
REYES, S., FU, Y., DOUBLE, K., THOMPSON, L., KIRIK, D., PAXINOS, G. & 
HALLIDAY, G. M. 2012. GIRK2 Expression in Dopamine Neurons of the 
Substantia Nigra and Ventral Tegmental Area. Journal of Comparative 
Neurology, 520, 2591-2607. 
RIBEIRO, D., GOYA, R. L., RAVINDRAN, G., VUONO, R., PARISH, C. L., FOLDI, 
C., PIROTH, T., YANG, S. Z., PARMAR, M., NIKKHAH, G., HJERLING-
LEFFLER, J., LINDVALL, O., BARKER, R. A. & ARENAS, E. 2013. 
Efficient expansion and dopaminergic differentiation of human fetal ventral 
152 
 
midbrain neural stem cells by midbrain morphogens. Neurobiology of Disease, 
49, 118-127. 
RILEY, D., LANG, A. E., BLAIR, R. D. G., BIRNBAUM, A. & REID, B. 1989. 
Frozen shoulder and other shoulder disturbances in Parkinsons-disease. Journal 
of Neurology Neurosurgery and Psychiatry, 52, 63-66. 
ROMERO, C. A., BUSTAMANTE, D. A., ZAPATA-TORRES, G., GOINY, M., 
CASSELS, B. & HERRERA-MARSCHITZ, M. 2006. Neurochemical and 
behavioural characterisation of alkoxyamphetamine derivatives in rats. 
Neurotoxicity Research, 10, 11-22. 
ROY, N. S., CLEREN, C., SINGH, S. K., YANG, L., BEAL, M. F. & GOLDMAN, S. 
A. 2006. Functional engraftment of human ES cell-derived dopaminergic 
neurons enriched by coculture with telomerase-immortalized midbrain 
astrocytes. Nature Medicine, 12, 1259-1268. 
SAMARANCH, L., LORENZO-BETANCOR, O., ARBELO, J. M., FERRER, I., 
LORENZO, E., IRIGOYEN, J., PASTOR, M. A., MARRERO, C., ISLA, C., 
HERRERA-HENRIQUEZ, J. & PASTOR, P. 2010. PINK1-linked parkinsonism 
is associated with Lewy body pathology. Brain, 133, 1128-1142. 
SAMII, A., NUTT, J. G. & RANSOM, B. R. 2004. Parkinson's disease. Lancet, 363, 
1783-1793. 
SCHAPIRA, A. H. V. 2011. Monoamine Oxidase B Inhibitors for the Treatment of 
Parkinson's Disease A Review of Symptomatic and Potential Disease-Modifying 
Effects. Cns Drugs, 25, 1061-1071. 
SCHEIN, J. C., HUNTER, D. D. & ROFFLER-TARLOV, S. 1998. Girk2 expression in 
the ventral midbrain, cerebellum, and olfactory bulb and its relationship to the 
murine mutation weaver. Developmental Biology, 204, 432-450. 
SCHENCK, C. H., BOEVE, B. F. & MAHOWALD, M. W. 2013. Delayed emergence 
of a parkinsonian disorder or dementia in 81% of older men initially diagnosed 
with idiopathic rapid eye movement sleep behavior disorder: a 16-year update 
on a previously reported series. Sleep Medicine, 14, 744-748. 
SCHMIDT, R. H., BJORKLUND, A. & STENEVI, U. 1981. Intra-cerebral grafting of 
dissociated CNS tissue suspensions: a new approach for neuronal transplantation 
to deep brain sites. Brain Research, 218, 347-356. 
SCHMIDT, R. H., INGVAR, M., LINDVALL, O., STENEVI, U. & BJORKLUND, A. 
1982. Functional-activity of substantia nigra grafts reinnervating the striatum - 
neurotransmitter metabolism and c-14 2-deoxy-d-glucose autoradiography. 
Journal of Neurochemistry, 38, 737-748. 
SCHNEIDER, J. S., YUWILER, A. & MARKHAM, C. H. 1987. Selective loss of 
subpopulations of ventral mesencephalic dopaminergic-neurons in the monkey 
following exposure to MPTP. Brain Research, 411, 144-150. 
SCHNELL, L. & SCHWAB, M. E. 1990. Axonal regeneration in the rat spinal-cord 
produced by an antibody against myelin-associated neurite growth-inhibitors. 
Nature, 343, 269-272. 
SCHULTZ, W. 2007. Multiple dopamine functions at different time courses. Annual 
Review of Neuroscience, 30, 259-288. 
SCHWAB, M. E. 1990. Myelin-associated inhibitors of neurite growth and regeneration 
in the CNS. Trends in Neurosciences, 13, 452-456. 
SEIGER, A. & OLSON, L. 1973. Late prenatal ontogeny of central monoamine neurons 
in rat - fluorescence histochemical observations. Zeitschrift Fur Anatomie Und 
Entwicklungsgeschichte, 140, 281-318. 
SHERER, T. B., KIM, J. H., BETARBET, R. & GREENAMYRE, J. T. 2003. 
Subcutaneous rotenone exposure causes highly selective dopaminergic 
153 
 
degeneration and alpha-synuclein aggregation. Experimental Neurology, 179, 9-
16. 
SHIN, J.-H., KO, H. S., KANG, H., LEE, Y., LEE, Y.-I., PLETINKOVA, O., 
TROCONSO, J. C., DAWSON, V. L. & DAWSON, T. M. 2011. PARIS 
(ZNF746) Repression of PGC-1 alpha Contributes to Neurodegeneration in 
Parkinson's Disease. Cell, 144, 689-702. 
SHULTS, C. W., HASHIMOTO, R., BRADY, R. M. & GAGE, F. H. 1990. 
Dopaminergic cells align along radial glia in the developing mesencephalon of 
the rat. Neuroscience, 38, 427-436. 
SIEGFRIED, J. & LIPPITZ, B. 1994. Bilateral chronic electrostimulation of 
ventroposterolateral pallidum - a new therapeutic approach for alleviating all 
parkinsonian symptoms. Neurosurgery, 35, 1126-1129. 
SIMONDS, G. R. & FREED, W. J. 1990. Effects of intraventricular substantia-nigra 
allografts as a function of donor age. Brain Research, 530, 12-19. 
SINCLAIR, S. R., FAWCETT, J. W. & DUNNETT, S. B. 1999. Dopamine cells in 
nigral grafts differentiate prior to implantation. European Journal of 
Neuroscience, 11, 4341-4348. 
SMITH, G. P. & YOUNG, R. C. 1974. A new experimental model of hypokinesia. 
Advances in neurology, 5, 427-32. 
SMITS, S. M., BURBACH, J. P. H. & SMIDT, M. P. 2006. Developmental origin and 
fate of meso-diencephalic dopamine neurons. Progress in Neurobiology, 78, 1-
16. 
SOMME, J. H., GOMEZ-ESTEBAN, J. C., MOLANO, A., TIJERO, B., LEZCANO, E. 
& ZARRANZ, J. J. 2011. Initial neuropsychological impairments in patients 
with the E46K mutation of the alpha-synuclein gene (PARK 1). Journal of the 
Neurological Sciences, 310, 86-89. 
SORTWELL, C. E., COLLIER, T. J., CAMARGO, M. D. & PITZER, M. R. 2004. An 
in vitro interval before transplantation of mesencephalic reaggregates does not 
compromise survival or functionality. Experimental Neurology, 187, 58-64. 
SOTELO, C. & ALVARADOMALLART, R. M. 1987. Reconstruction of the defective 
cerebellar circuitry in adult Purkinje cell degeneration mutant mice by Purkinje 
cell replacement through transplantation of solid embryonic implants. 
Neuroscience, 20, 1-22. 
SPECHT, L. A., PICKEL, V. M., JOH, T. H. & REIS, D. J. 1981. Light-microscopic 
immuno-cytochemical localization of tyrosine-hydroxylase in prenatal rat-brain 
.1. Early ontogeny. Journal of Comparative Neurology, 199, 233-253. 
SPENCER, D. D., ROBBINS, R. J., NAFTOLIN, F., MAREK, K. L., VOLLMER, T., 
LERANTH, C., ROTH, R. H., PRICE, L. H., GJEDDE, A., BUNNEY, B. S. & 
ET AL. 1992. Unilateral transplantation of human fetal mesencephalic tissue 
into the caudate nucleus of patients with Parkinson's disease. N Engl J Med, 327, 
1541-8. 
SPILLANTINI, M. G., SCHMIDT, M. L., LEE, V. M. Y., TROJANOWSKI, J. Q., 
JAKES, R. & GOEDERT, M. 1997. alpha-synuclein in Lewy bodies. Nature, 
388, 839-840. 
STEECE-COLLIER, K., COLLIER, T. J., DANIELSON, P. D., KURLAN, R., 
YUREK, D. M. & SLADEK, J. R., JR. 2003. Embryonic mesencephalic grafts 
increase levodopa-induced forelimb hyperkinesia in parkinsonian rats. Mov 
Disord, 18, 1442-54. 
STEECE-COLLIER, K., SODERSTROM, K. E., COLLIER, T. J., SORTWELL, C. E. 
& MARIES-LAD, E. 2009. Effect of levodopa priming on dopamine neuron 
transplant efficacy and induction of abnormal involuntary movements in 
parkinsonian rats. J Comp Neurol, 515, 15-30. 
154 
 
STERN, G. 1989. Did parkinsonism occur before 1817. Journal of Neurology 
Neurosurgery and Psychiatry, 11-12. 
STROMBERG, I., BYGDEMAN, M. & ALMQVIST, P. 1992. Target-specific 
outgrowth from human mesencephalic tissue grafted to cortex or ventricle of 
immunosuppressed rats. Journal of Comparative Neurology, 315, 445-456. 
SVENDSEN, C. N., CALDWELL, M. A., SHEN, J., TERBORG, M. G., ROSSER, A. 
E., TYERS, P., KARMIOL, S. & DUNNETT, S. B. 1997. Long-term survival of 
human central nervous system progenitor cells transplanted into a rat model of 
Parkinson's disease. Experimental Neurology, 148, 135-146. 
SVENDSEN, C. N., TER BORG, M. G., ARMSTRONG, R. J. E., ROSSER, A. E., 
CHANDRAN, S., OSTENFELD, T. & CALDWELL, M. A. 1998. A new 
method for the rapid and long term growth of human neural precursor cells. 
Journal of Neuroscience Methods, 85, 141-152. 
SVENNILSON, E., TORVIK, A., LOWE, R. & LEKSELL, L. 1960. Treatment of 
parkinsonism by stereotactic thermolesions in the pallidal region - a clinical-
evaluation of 81 cases. Acta Psychiatrica Et Neurologica, 35, 358-377. 
TANDE, D., HOGLINGER, G., DEBEIR, T., FREUNDLIEB, N., HIRSCH, E. & 
FRANCOIS, C. 2006. New striatal dopamine neurons in MPTP-treated 
macaques result from a phenotypic shift and not neurogenesis. Brain, 129, 1194-
1200. 
TERPSTRA, B. T., COLLIER, T. J., MARCHIONINI, D. M., LEVINE, N. D., 
PAUMIER, K. L. & SORTWELL, C. E. 2007. Increased cell suspension 
concentration augments the survival rate of grafted tyrosine hydroxylase 
immunoreactive neurons. Journal of Neuroscience Methods, 166, 13-19. 
TERZIOGLU, M. & GALTER, D. 2008. Parkinson's disease: genetic versus toxin-
induced rodent models. Febs Journal, 275, 1384-1391. 
THANVI, B., LO, N. & ROBINSON, T. 2007. Levodopa-induced dyskinesia in 
Parkinson's disease: clinical features, pathogenesis, prevention and treatment. 
Postgraduate Medical Journal, 83, 384-388. 
THIFFAULT, C., LANGSTON, J. W. & DI MONTE, D. A. 2000. Increased striatal 
dopamine turnover following acute administration of rotenone to mice. Brain 
Research, 885, 283-288. 
THIRUCHELVAM, M., BROCKEL, B. J., RICHFIELD, E. K., BAGGS, R. B. & 
CORY-SLECHTA, D. A. 2000. Potentiated and preferential effects of combined 
paraquat and maneb on nigrostriatal dopamine systems: environmental risk 
factors for Parkinson's disease? Brain Research, 873, 225-234. 
THOMAS, B., MANDIR, A. S., WEST, N., LIU, Y., ANDRABI, S. A., STIRLING, 
W., DAWSON, V. L., DAWSON, T. M. & LEE, M. K. 2011. Resistance to 
MPTP-Neurotoxicity in alpha-Synuclein Knockout Mice Is Complemented by 
Human alpha-Synuclein and Associated with Increased beta-Synuclein and Akt 
Activation. Plos One, 6. 
THOMPSON, L., BARRAUD, P., ANDERSSON, E., KIRIK, D. & BJORKLUND, A. 
2005. Identification of dopaminergic neurons of nigral and ventral tegmental 
area subtypes in grafts of fetal ventral mesencephalon based on cell morphology, 
protein expression, and efferent projections. Journal of Neuroscience, 25, 6467-
6477. 
THOMPSON, L. H., ANDERSSON, E., JENSEN, J. B., BARRAUD, P., 
GUILLEMOT, F., PARMAR, M. & BJORKLUND, A. 2006. Neurogenin2 
identifies a transplantable dopamine neuron precursor in the developing ventral 
mesencephalon. Experimental Neurology, 198, 183-198. 
155 
 
TORRES, E. M., DOWD, E. & DUNNETT, S. B. 2008a. Recovery of functional 
deficits following early donor age ventral mesencephalic grafts in a rat model of 
Parkinson's disease. Neuroscience, 154, 631-640. 
TORRES, E. M., LANE, E. L., HEUER, A., SMITH, G. A., MURPHY, E. & 
DUNNETT, S. B. 2011. Increased efficacy of the 6-hydroxydopamine lesion of 
the median forebrain bundle in small rats, by modification of the stereotaxic 
coordinates. Journal of Neuroscience Methods, 200, 29-35. 
TORRES, E. M., MONVILLE, C., GATES, M. A., BAGGA, V. & DUNNETT, S. B. 
2007. Improved survival of young donor age dopamine grafts in a rat model of 
Parkinson's disease. Neuroscience, 146, 1606-1617. 
TORRES, E. M., MONVILLE, C., LOWENSTEIN, P. R., CASTRO, M. G. & 
DUNNETT, S. B. 2005. Delivery of sonic hedgehog or glial derived 
neurotrophic factor to dopamine-rich grafts in a rat model of Parkinson's disease 
using adenoviral vectors - Increased yield of dopamine cells is dependent on 
embryonic donor age. Brain Research Bulletin, 68, 31-41. 
TORRES, E. M., WEYRAUCH, U. M., SUTCLIFFE, R. & DUNNETT, S. B. 2008b. A 
rat embryo staging scale for the generation of donor tissue for neural 
transplantation. Cell Transplantation, 17, 535-542. 
TWELVES, D., PERKINS, K. S. M. & COUNSELL, C. 2003. Systematic review of 
incidence studies of Parkinson's disease. Movement Disorders, 18, 19-31. 
UNGERSTEDT, U. 1968. 6-hydroxy-dopamine induced degeneration of central 
monoamine neurons. European Journal of Pharmacology, 5, 107-110. 
UNGERSTEDT, U. 1971a. Adipsia and aphagia after 6-hydroxydopamine induced 
degeneration of the nigro-striatal dopamine system. Acta physiologica 
Scandinavica. Supplementum, 367, 95-122. 
UNGERSTEDT, U. 1971b. Postsynaptic supersensitivity after 6-hydroxy-dopamine 
induced degeneration of the nigro-striatal dopamine system. Acta physiologica 
Scandinavica. Supplementum, 367, 69-93. 
UNGERSTEDT, U. 1971c. Striatal dopamine release after amphetamine or nerve 
degeneration revealed by rotational behaviour. Acta physiologica Scandinavica. 
Supplementum, 367, 49-68. 
UNGERSTEDT, U. & ARBUTHNOTT, G. W. 1970. Quantitative recording of 
rotational behavior in rats after 6 hydroxy dopamine lesions of the nigrostriatal 
dopamine system. Brain Research, 24, 485-493. 
UNGERSTEDT, U., AVEMO, A., AVEMO, E., LJUNGBERG, T. & RANJE, C. 1973. 
Animal models of parkinsonism. Calne, D.B. (Ed.). Advances in Neurology, Vol. 
3. Progress in the Treatment of Parkinsonism. Proceedings of a Symposium. 
London, England, January 5-6, 1973. Xiv+326p. Illus. Raven Press Publishers: 
New York, N.Y., U.S.A, 257-271. 
VALENTE, E. M., ABOU-SLEIMAN, P. M., CAPUTO, V., MUQIT, M. M. K., 
HARVEY, K., GISPERT, S., ALI, Z., DEL TURCO, D., BENTIVOGLIO, A. 
R., HEALY, D. G., ALBANESE, A., NUSSBAUM, R., GONZALEZ-
MALDONALDO, R., DELLER, T., SALVI, S., CORTELLI, P., GILKS, W. P., 
LATCHMAN, D. S., HARVEY, R. J., DALLAPICCOLA, B., AUBURGER, G. 
& WOOD, N. W. 2004. Hereditary early-onset Parkinson's disease caused by 
mutations in PINK1. Science, 304, 1158-1160. 
VAN DEN HEUVEL, D. M. A. & PASTERKAMP, R. J. 2008. Getting connected in 
the dopamine system. Progress in Neurobiology, 85, 75-93. 
VERNEY, C., ZECEVIC, N. & PUELLES, L. 2001. Structure of longitudinal brain 
zones that provide the origin for the substantia nigra and ventral tegmental area 
in human embryos, as revealed by cytoarchitecture and tyrosine hydroxylase, 
156 
 
calretinin, calbindin, and GABA immunoreactions. Journal of Comparative 
Neurology, 429, 22-44. 
VEZOLI, J., FIFEL, K., LEVIEL, V., DEHAY, C., KENNEDY, H., COOPER, H. M., 
GRONFIER, C. & PROCYK, E. 2011. Early Presymptomatic and Long-Term 
Changes of Rest Activity Cycles and Cognitive Behavior in a MPTP-Monkey 
Model of Parkinson's Disease. Plos One, 6. 
VILA, M., JACKSON-LEWIS, V., VUKOSAVIC, S., DJALDETTI, R., 
LIBERATORE, G., OFFEN, D., KORSMEYER, S. J. & PRZEDBORSKI, S. 
2001. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. 
Proceedings of the National Academy of Sciences of the United States of 
America, 98, 2837-2842. 
VILARINO-GUEELL, C., WIDER, C., ROSS, O. A., DACHSEL, J. C., 
KACHERGUS, J. M., LINCOLN, S. J., SOTO-ORTOLAZA, A. I., COBB, S. 
A., WILHOITE, G. J., BACON, J. A., BEHROUZ, B., MELROSE, H. L., 
HENTATI, E., PUSCHMANN, A., EVANS, D. M., CONIBEAR, E., 
WASSERMAN, W. W., AASLY, J. O., BURKHARD, P. R., DJALDETTI, R., 
GHIKA, J., HENTATI, F., KRYGOWSKA-WAJS, A., LYNCH, T., 
MELAMED, E., RAJPUT, A., RAJPUT, A. H., SOLIDA, A., WU, R.-M., 
UITTI, R. J., WSZOLEK, Z. K., VINGERHOETS, F. & FARRER, M. J. 2011. 
VPS35 Mutations in Parkinson Disease. American Journal of Human Genetics, 
89, 162-167. 
WADE, L. A. & KATZMAN, R. 1975. Synthetic amino-acids and nature of L-DOPA 
transport at blood-brain-barrier. Journal of Neurochemistry, 25, 837-842. 
WATERS, C. M., PECK, R., ROSSOR, M., REYNOLDS, G. P. & HUNT, S. P. 1988. 
Immunocytochemical studies on the basal ganglia and substantia nigra in 
Parkinsons-disease and Huntingtons-chorea. Neuroscience, 25, 419-438. 
WENNING, G. K., ODIN, P., MORRISH, P., REHNCRONA, S., WIDNER, H., 
BRUNDIN, P., ROTHWELL, J. C., BROWN, R., GUSTAVII, B., HAGELL, 
P., JAHANSHAHI, M., SAWLE, G., BJORKLUND, A., BROOKS, D. J., 
MARSDEN, C. D., QUINN, N. P. & LINDVALL, O. 1997. Short- and long-
term survival and function of unilateral intrastriatal dopaminergic grafts in 
Parkinson's disease. Annals of Neurology, 42, 95-107. 
WENNING, G. K., SHEPHARD, B., HAWKES, C., PETRUCKEVITCH, A., LEES, A. 
& QUINN, N. 1995. Olfactory function in atypical parkinsonian syndromes. 
Acta Neurologica Scandinavica, 91, 247-250. 
WEYRAUCH, U. M. 2009. Cell transplantation in an animal model of Parkinson's 
disease: the influence of donor age on graft survival. PhD, Cardiff University. 
WEYRAUCH, U. M., TORRES, E. M., BAIRD, A. L. & DUNNETT, S. B. 2009. A 
Simple Breeding Protocol for the Procurement of Accurately Staged Rat Donor 
Embryos for Neural Transplantation. Cell Transplantation, 18, 471-476. 
WILLIAMS, D. R. & LEES, A. J. 2005. Visual hallucinations in the diagnosis of 
idiopathic Parkinson's disease: a retrospective autopsy study. Lancet Neurology, 
4, 605-610. 
WILLIAMS, D. R., WATT, H. C. & LEES, A. J. 2006. Predictors of falls and fractures 
in bradykinetic rigid syndromes: a retrospective study. Journal of Neurology 
Neurosurgery and Psychiatry, 77, 468-473. 
WILLIAMS, S. M. & GOLDMAN-RAKIC, P. S. 1998. Widespread origin of the 
primate mesofrontal dopamine system. Cerebral Cortex, 8, 321-345. 
WINDLE, W. F. & CAMMERMEYER, J. 1958. Functional and structural observations 
on chronically reserpinized monkeys. Science, 127, 1503-1503. 
157 
 
WINKLER, C., BENTLAGE, C., NIKKHAH, G., SAMII, M. & BJORKLUND, A. 
1999. Intranigral transplants of GABA-rich striatal tissue induce behavioral 
recovery in the rat Parkinson model and promote the effects obtained by 
intrastriatal dopaminergic transplants. Exp Neurol, 155, 165-86. 
WOJTOWICZ, J. M. & KEE, N. 2006. BrdU assay for neurogenesis in rodents. Nature 
Protocols, 1, 1399-1405. 
WOOTEN, G. F., CURRIE, L. J., BOVBJERG, V. E., LEE, J. K. & PATRIE, J. 2004. 
Are men at greater risk for Parkinson's disease than women? Journal of 
Neurology Neurosurgery and Psychiatry, 75, 637-639. 
WORTH, P. F. 2013. How to treat Parkinson's disease in 2013. Clinical Medicine, 13, 
93-96. 
WU, Y. N. & JOHNSON, S. W. 2011. Dopamine oxidation facilitates rotenone-
dependent potentiation of n-methyl-d-aspartate currents in rat substantia nigra 
dopamine neurons. Neuroscience, 195, 138-144. 
WUERTHELE, S. M., FREED, W. J., OLSON, L., MORIHISA, J., SPOOR, L., 
WYATT, R. J. & HOFFER, B. J. 1981. Effect of dopamine agonists and 
antagonists on the electrical-activity of substantia nigra neurons transplanted 
into the lateral ventricle of the rat. Experimental Brain Research, 44, 1-10. 
YAMADA, K., SEMBA, R., DING, X. H., MA, N. & NAGAHAMA, M. 2005. 
Discrimination of cell nuclei in early S-phase, mid-to-late S-phase, and G(2)/M-
phase by sequential administration of 5-bromo-2'-deoxyuridine and 5-chloro-2'-
deoxyuridine. Journal of Histochemistry & Cytochemistry, 53, 1365-1370. 
YAZDANI, U., GERMAN, D. C., LIANG, C. L., MANZINO, L., SONSALLA, P. K. 
& ZEEVALK, G. D. 2006. Rat model of Parkinson's disease: Chronic central 
delivery of 1-methyl-4-phenylpyridinium (MPP+). Experimental Neurology, 
200, 172-183. 
YORITAKA, A., HATTORI, N., UCHIDA, K., TANAKA, M., STADTMAN, E. R. & 
MIZUNO, Y. 1996. Immunohistochemical detection of 4-hydroxynonenal 
protein adducts in Parkinson disease. Proceedings of the National Academy of 
Sciences of the United States of America, 93, 2696-2701. 
YU, Z. W., XU, X. H., XIANG, Z. H., ZHOU, J. F., ZHANG, Z. H., HU, C. & HE, C. 
2010. Nitrated alpha-Synuclein Induces the Loss of Dopaminergic Neurons in 
the Substantia Nigra of Rats. Plos One, 5, 17. 
ZARRANZ, J. J., ALEGRE, J., GOMEZ-ESTEBAN, J. C., LEZCANO, E., ROS, R., 
AMPUERO, I., VIDAL, L., HOENICKA, J., RODRIGUEZ, O., ATARES, B., 
LLORENS, V., TORTOSA, E. G., DEL SER, T., MUNOZ, D. G. & DE 
YEBENES, J. G. 2004. The new mutation, E46K, of alpha-synuclein causes 
Parkinson and Lewy body dementia. Annals of Neurology, 55, 164-173. 
ZIJLMANS, J. C. M., DANIEL, S. E., HUGHES, A. J., REVESZ, T. & LEES, A. J. 
2004. Clinicopathological including investigation of vascular parkinsonism, 
including clinical criteria for diagnosis. Movement Disorders, 19, 630-640. 
ZIMPRICH, A., BENET-PAGES, A., STRUHAL, W., GRAF, E., ECK, S. H., 
OFFMAN, M. N., HAUBENBERGER, D., SPIELBERGER, S., SCHULTE, E. 
C., LICHTNER, P., ROSSLE, S. C., KLOPP, N., WOLF, E., SEPPI, K., 
PIRKER, W., PRESSLAUER, S., MOLLENHAUER, B., 
KATZENSCHLAGER, R., FOKI, T., HOTZY, C., REINTHALER, E., 
HARUTYUNYAN, A., KRALOVICS, R., PETERS, A., ZIMPRICH, F., 
BRUECKE, T., POEWE, W., AUFF, E., TRENKWALDER, C., ROST, B., 
RANSMAYR, G., WINKELMANN, J., MEITINGER, T. & STROM, T. M. 
2011. A Mutation in VPS35, Encoding a Subunit of the Retromer Complex, 
Causes Late-Onset Parkinson Disease. American Journal of Human Genetics, 
89, 168-175. 
158 
 
ZIMPRICH, A., BISKUP, S., LEITNER, P., LICHTNER, P., FARRER, M., 
LINCOLN, S., KACHERGUS, J., HULIHAN, M., UITTI, R. J., CALNE, D. B., 
STOESSL, A. J., PFEIFFER, R. F., PATENGE, N., CARBAJAL, I. C., 
VIEREGGE, P., ASMUS, F., MULLER-MYHSOK, B., DICKSON, D. W., 
MEITINGER, T., STROM, T. M., WSZOLEK, Z. K. & GASSER, T. 2004. 
Mutations in LRRK2 cause autosomal-dominant Parkinsonism with 
pleomorphic pathology. Neuron, 44, 601-607. 
 
 
 
